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Abstract
Multiplex tests to identify gastrointestinal bacteria,
viruses and parasites in people with suspected infectious
gastroenteritis: a systematic review and economic analysis
Karoline Freeman,1 Hema Mistry,1 Alexander Tsertsvadze,1
Pam Royle,1 Noel McCarthy,1 Sian Taylor-Phillips,1 Rohini Manuel2
and James Mason1*
1Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
2Public Health England, London, UK
*Corresponding author J.Mason@warwick.ac.uk
Background: Gastroenteritis is a common, transient disorder usually caused by infection and characterised
by the acute onset of diarrhoea. Multiplex gastrointestinal pathogen panel (GPP) tests simultaneously
identify common bacterial, viral and parasitic pathogens using molecular testing. By providing test results
more rapidly than conventional testing methods, GPP tests might positively influence the treatment and
management of patients presenting in hospital or in the community.
Objective: To systematically review the evidence for GPP tests [xTAG® (Luminex, Toronto, ON, Canada),
FilmArray (BioFire Diagnostics, Salt Lake City, UT, USA) and Faecal Pathogens B (AusDiagnostics,
Beaconsfield, NSW, Australia)] and to develop a de novo economic model to compare the cost-
effectiveness of GPP tests with conventional testing in England and Wales.
Data sources: Multiple electronic databases including MEDLINE, EMBASE, Web of Science and the
Cochrane Database were searched from inception to January 2016 (with supplementary searches of other
online resources).
Review methods: Eligible studies included patients with acute diarrhoea; comparing GPP tests with
standard microbiology techniques; and patient, management, test accuracy or cost-effectiveness outcomes.
Quality assessment of eligible studies used tailored Quality Assessment of Diagnostic Accuracy Studies-2,
Consolidated Health Economic Evaluation Reporting Standards and Philips checklists. The meta-analysis
included positive and negative agreement estimated for each pathogen. A de novo decision tree model
compared patients managed with GPP testing or comparable coverage with patients managed using
conventional tests, within the Public Health England pathway. Economic models included hospital and
community management of patients with suspected gastroenteritis. The model estimated costs (in 2014/15
prices) and quality-adjusted life-year losses from a NHS and Personal Social Services perspective.
Results: Twenty-three studies informed the review of clinical evidence (17 xTAG, four FilmArray, two
xTAG and FilmArray, 0 Faecal Pathogens B). No study provided an adequate reference standard with
which to compare the test accuracy of GPP with conventional tests. A meta-analysis (of 10 studies) found
considerable heterogeneity; however, GPP testing produces a greater number of pathogen-positive findings
than conventional testing. It is unclear whether or not these additional ‘positives’ are clinically important.
The review identified no robust evidence to inform consequent clinical management of patients. There is
considerable uncertainty about the cost-effectiveness of GPP panels used to test for suspected infectious
gastroenteritis in hospital and community settings. Uncertainties in the model include length of stay,
assumptions about false-positive findings and the costs of tests. Although there is potential for
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cost-effectiveness in both settings, key modelling assumptions need to be verified and model findings
remain tentative.
Limitations: No test–treat trials were retrieved. The economic model reflects one pattern of care,
which will vary across the NHS.
Conclusions: The systematic review and cost-effectiveness model identify uncertainties about the
adoption of GPP tests within the NHS. GPP testing will generally correctly identify pathogens identified by
conventional testing; however, these tests also generate considerable additional positive results of uncertain
clinical importance.
Future work: An independent reference standard may not exist to evaluate alternative approaches to
testing. A test–treat trial might ascertain whether or not additional GPP ‘positives’ are clinically important or
result in overdiagnoses, whether or not earlier diagnosis leads to earlier discharge in patients and what the
health consequences of earlier intervention are. Future work might also consider the public health impact of
different testing treatments, as test results form the basis for public health surveillance.
Study registration: This study is registered as PROSPERO CRD2016033320.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
D iarrhoea may be caused by pathogens such as bacteria, viruses and parasites. Diarrhoea can be veryinfectious and severe diarrhoea may require hospital treatment. Isolation, hygiene and rehydration
are used to manage patient symptoms, and tests are used to identify pathogens and guide treatment.
Current pathogen testing involves a number of procedures, and findings may take up to 3 days to become
available. Gastrointestinal pathogen panels (GPPs) test for all common pathogens using one procedure,
with results returning in 1 day or less.
Our review considered evidence for the clinical effectiveness and cost-effectiveness of three GPP tests
[xTAG® (Luminex, Toronto, ON, Canada), FilmArray (BioFire Diagnostics) and Faecal Pathogens B assay
(AusDiagnostics, Beaconsfield, NSW, Australia)]. We built an economic model, predicting costs and benefits
for patients in the community or hospital setting, to help inform how to best manage patients. The
findings will help inform the National Institute for Health and Care Excellence when making
recommendations about the use of GPP tests in the NHS in England and Wales.
The clinical effectiveness review found 23 relevant studies. These studies agree that GPP tests identify more
pathogens than current methods. Because we found no valid method to verify the outcomes from the new
tests, we do not know how accurate they are in detecting clinically important disease. We also do not
know whether quicker tests result in improved care or in unnecessary treatment.
The economic model found considerable uncertainty about how costs and benefits would change if GPP
tests were introduced. Further research is needed to resolve whether or not GPP tests improve patient
management and provide value for money.
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Scientific summary
Background
Gastroenteritis is a common, transient disorder usually caused by infection with viruses, bacteria or
parasites and is characterised by the acute onset of diarrhoea with or without vomiting. Symptoms are
mostly self-limiting, but severe diarrhoea can quickly cause dehydration. Patients may be managed in the
community or admitted for observation, symptom management and diagnosis. Hospitalised patients with
suspected infectious diarrhoea may be nursed in isolation until an infection has been ruled out or symptoms
subside, but treatment is generally not recommended, except in certain situations (e.g. typhoid fever,
Clostridium difficile infection or immunocompromised patients).
Identifying the infectious agent may aid decision-making in terms of treatment, isolation, management in
the community or hospital, and further investigations for non-infectious causes of diarrhoea. Standard
laboratory methods include cultures for bacteria, nucleic acid amplification for viruses and microscopy or
enzyme immunoassays for parasites. Tests have turnaround times of up to 3 days and, in practice, the
number of pathogens tested for is often restricted.
Gastrointestinal pathogen panel (GPP) tests exploit multiplex nucleic acid amplification methodology,
testing for a wide range of bacteria, viruses and parasites in a single run, potentially increasing the
throughput and volume of information from one test run and decreasing reporting times to ≤ 1 day.
Decision question
What is the clinical effectiveness and cost-effectiveness of the GPP panels xTAG® Gastrointestinal Pathogen
Panel (Luminex, Toronto, ON, Canada), FilmArray Gastrointestinal Panel (BioFire Diagnostics, Salt Lake City,
UT, USA) and Faecal Pathogens B (AusDiagnostics, Beaconsfield, NSW, Australia) in the identification of
gastrointestinal bacteria, viruses and parasites in patients with suspected gastroenteritis presenting in
primary or secondary care compared with conventional microbiological methods outlined in the Public
Health England (PHE) algorithm?
Objective
To systematically review the evidence for the clinical effectiveness of the GPP tests (xTAG, FilmArray and
Faecal Pathogens B), systematically review existing economic evaluations and develop a de novo economic
model to assess the cost-effectiveness of GPP tests compared with the current standard of care in England
and Wales.
Methods for clinical effectiveness and cost-effectiveness reviews
We searched MEDLINE, EMBASE, Web of Science and the Cochrane Database of Systematic Reviews from
inception to November/December 2015 for clinical effectiveness and to January 2016 for cost-effectiveness.
Supplementary searches of other online resources were run to check for other published and unpublished
studies. Weekly autoalerts for emerging evidence were run in Ovid MEDLINE, Ovid EMBASE and PubMed
until 30 April 2016. Reference lists of included studies and information provided by the manufacturers
of the intervention tests were checked for additional eligible studies.
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Two reviewers independently screened and assessed titles and abstracts of all records for inclusion using
the following criteria:
l population – patients with acute diarrhoea with or without vomiting, thought to be a result of infective
gastroenteritis, with test referrals from the hospital and community
l interventions – xTAG, FilmArray or Faecal Pathogens B
l comparator – standard microbiology techniques, outlined in the PHE syndromic algorithm for routine
testing in cases of gastroenteritis and diarrhoea
l outcomes – any patient-/management-related outcome, test agreement, cost-effectiveness estimates
l study design – test–treat trials, clinical diagnostic test accuracy studies, studies comparing discrepant
results between the index and comparator tests using a fair umpire test, studies of agreement and
disagreement, studies of head-to-head comparisons of different index tests, full economic evaluations
l health-care setting – clinical laboratory receiving samples from primary and secondary care.
Quality assessment of eligible studies was undertaken using recognised checklists (tailored Quality Assessment
of Diagnostic Accuracy Studies-2, Consolidated Health Economic Evaluation Reporting Standards and Philips).
We used the original 2 × 2 table data reported by studies without updating results from discrepant
analyses. In the absence of a reference standard, we calculated levels of positive and negative agreements
for each pathogen when benchmarked against either the comparator or GPP test, to determine the
range of feasible outcomes of test agreement. Test agreement estimates were meta-analysed using a
random-effects meta-analysis of proportions for each pathogen at the sample level.
A de novo decision tree model was built in Microsoft Excel® (version 16, Microsoft Corporation, Redmond,
WA, USA) to assess the cost-effectiveness of GPP testing compared with conventional care. The base-case
economic model included hospitalised adult patients with suspected gastroenteritis. The base-case model
was adapted to look at various subgroups: young children, people in the community, immunocompromised
patients and people with a recent history of travel. The data for the model included prevalence information
from the systematic clinical effectiveness review, published literature and expert opinion. The model
estimated the mean total costs and mean total quality-adjusted life-year (QALY) losses for each GPP test
compared with conventional care for the initial index episode, and adopted a NHS and Personal Social
Services perspective. Costs were in 2014/15 prices. Outcomes are reported as incremental cost-effectiveness
ratios expressed in terms of cost per QALY gained. The model was run deterministically and probabilistically
with 1000 bootstrapped iterations.
Results
Clinical effectiveness
The search identified 2215 unique records, 23 of which were included in the review. A total of 10 studies
contributed 2 × 2 data to the meta-analysis. Studies were heterogeneous in terms of participants (hospital
vs. community, risk, comorbidities), country of origin (developing vs. developed), conventional methods
used, and number and type of pathogens considered. The review identified 17 studies that evaluated
xTAG and four studies that evaluated FilmArray. Two studies compared both tests, but no study that
assessed the Faecal Pathogens B assay was identified. The methodological quality of the included studies
was poor. None of the studies used a reference standard against which the index tests and conventional
methods could be reliably evaluated. Instead, in most studies, the index tests were compared with the
conventional methods. Discrepant results between the index test and conventional testing were verified at
the pathogen level in only 4 out of the 23 studies, although confirmatory tests were not adequately
independent of index/routine tests. In many cases, the routine tests were not performed for all pathogens
specified in the GPP test. There were concerns about the applicability and relevance of comparator and
verification tests used in the majority of studies.
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If conventional methods are an accurate determinant of clinically important disease, then meta-analytic
results (benchmarked against conventional testing) suggest that GPP testing is a reliable test and could
replace current microbiological methods, although there would be an increase in false-positive reporting
with potential overdiagnosis and unnecessary treatment. However, if GPP testing is considered accurate
(in the sense that current testing practices are missing clinically important pathology), then it would identify
missed infections and could potentially result in more appropriate treatment.
Studies generally included mixed populations and aggregated findings. No subgroup analysis could
be undertaken.
A small number of studies attempted to verify samples that did not agree when tested with GPPs and
conventional methods. Verification methods were not independent of polymerase chain reaction methods and,
broadly, would be expected to resolve discordant results in favour of GPP assays. As anticipated, discordant
analyses of GPP-positive/conventional testing-negative samples generally favoured the GPP. No studies
investigated discordant results using a ‘fair umpire’ test (imperfect but unbiased), such as exposure or
effectiveness of different treatments.
In head-to-head comparison studies of different GPP tests, no concordance analyses were undertaken
regarding whether or not tests identify the same pathogens in the same samples; therefore, no reliable
assessment of the comparative performance of the different GPP tests was possible.
Studies reported the following secondary outcomes: GPP run failure (n = 8), multiple infections (n = 23),
patient isolation (n = 2), turnaround times (n = 8), costs (n = 3) and other outcomes (n = 4). No study
reported on change in management by test outcome, health-related quality of life, morbidity or mortality.
Cost-effectiveness
The systematic review of cost-effectiveness studies identified only one study considered to be a full
economic evaluation comparing the xTAG GPP with conventional care in people with suspected infectious
gastroenteritis. There were some notable limitations to the study, including use of estimated changes in
isolation as a result of GPP testing (rather than observed changes), and no explicit valuation of patient
outcomes.
For the base model (adult hospitalised patients) and base-case assumptions, there was considerable
uncertainty about the cost-effectiveness of GPP tests. The pattern was similar for the other two hospital-based
models involving young children and immunocompromised patients. These models found that varying
pathogen prevalence does not significantly affect the cost-effectiveness of testing. Important uncertainties
include length of stay and parameters that might influence this, such as false-positive findings. For both the
general community model and the more specific recent travellers model, xTAG GPP appeared to be
cost-effective, whereas FilmArray did not. In community models, without the potential for changes in hospital
length of stay, cost-effectiveness is driven by the cost of the tests themselves and assumptions made when
estimating these costs.
Discussion and conclusion
An evidential finding of the review is that GPP testing produces a greater number of pathogen-positive
findings than conventional testing, but the clinical importance and consequence of these additional
positive findings is uncertain. Evidence retrieved approximates to a mixed population of acute and
hospitalised patients, as the studies do not adequately report outcomes by setting or subgroup. The
available evidence is heterogeneous in populations studied, design, methods and analysis. The impact of
GPP testing on patient management and outcomes, compared with conventional testing, has not been
assessed, meaning that the economic modelling involves some key uncertainties and findings should be
considered tentative.
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Currently, the clinical importance of the additional pathogens identified by GPP testing is uncertain.
Discrepancies between GPP tests and conventional methods may result not only from differences in
accuracy, but also from differences in their targets. Without validation using a reliable reference standard,
the status of additional GPP positives is uncertain; however, there remains a concern about the potential of
GPP testing to identify non-viable pathogens.
A further uncertainty is the value of more rapid testing, achieved to a varying extent by each GPP system.
In the vast majority of cases, hydration, hygiene and watchful waiting are required. Most cases of
gastroenteritis are self-limiting and treatment is usually not indicated.
Strengths and limitations
Strengths of the work include a robust and comprehensive systematic review (literature search, data extraction
and analysis) strategy and the building of a de novo decision tree model to assess cost-effectiveness.
No adequate test–treat trials or diagnostic studies using a reference standard were retrieved, and no
studies conducted adequate discrepant analysis or applied a fair umpire approach. In the absence of
adequate studies, positive and negative agreements were estimated alternating conventional and GPP
testing as the benchmark as an aid to explore differences in findings. Agreement measures are not
measures of test performance in a conventional sense, and only adequately designed research will resolve
uncertainties about the introduction of GPP testing.
Although the economic model represented the clinical care pathway in the NHS, practice and management
will vary from site to site. The economic model reflects one pattern of care for which patients are broadly
tested in line with PHE guidance, although this practice is not universally followed. Different practices,
such as sequential testing, would give rise to different patterns of cost and benefit.
Implications for health care
This review has evaluated GPP systems according to their current specification, but it is anticipated that the
coverage of these systems will continue to evolve in response to changing pathogen prevalence; hence,
the evaluation problem is a dynamic one. NHS organisation of pathogen testing may evolve in the coming
decade and GPP testing technology may further develop, creating challenges for evidence requirements
and timing of adoption decisions.
Research priorities
A randomised test–treat trial may be the best option, with patients randomised to conventional and GPP
testing, and clinical effectiveness and cost-effectiveness outcomes used to determine the value of GPP
testing. Such a trial might include adequate stratification of different populations (e.g. community
managed, community acquired and hospital managed, hospital acquired, children, travellers and
immunocompromised patients).
Study registration
This study is registered as PROPSPERO CRD42016033320.
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Chapter 1 Introduction
Description of the health problem
Gastroenteritis is a common, transient disorder usually caused by infection with viruses, bacteria or
parasites. It is estimated that around 25% of people in the UK have a gastrointestinal infection each year.1
Gastroenteritis is characterised by acute onset of diarrhoea with or without vomiting.2 Depending on the
cause of the infection, the symptoms of gastroenteritis can take from a few hours to a few days to
develop. Most cases resolve without treatment within days, although persistent or severe symptoms may
lead sufferers to contact the health services. Patients may be managed in the community or admitted for
observation, symptom management and diagnosis. Severe diarrhoea can quickly cause dehydration, which
may be life-threatening. The most commonly identified pathogens in England in the Second Infectious
Intestinal Disease in the Community Study were norovirus, sapovirus, Campylobacter and rotavirus.1
Gastroenteritis can also occur in people who are currently taking, or who have recently taken, antibiotics.
This is known as antibiotic-associated diarrhoea, which is frequently caused by Clostridium difficile.3
Diarrhoea may have non-infectious causes, such as inflammatory bowel disease, and it is therefore
sometimes desirable to be able to identify or rule out infectious causes of gastroenteritis in people who
present to health services with diarrhoea or vomiting. Differential diagnoses for gastroenteritis include
non-gastrointestinal infections (e.g. pneumonia, urinary tract infection or human immunodeficiency
virus infection), irritable bowel syndrome, inflammatory bowel disease, coeliac disease, side effects of
medications, endocrinopathy (e.g. diabetes or hyperthyroidism) and secretory tumours.2
Patients who are in hospital and have suspected infectious diarrhoea may be nursed in an isolation bay or
side room until infection has been ruled out or symptoms subside. Patients in isolation are asked not to
enter other areas of the ward or hospital until members of a hospital infection prevention and control
team have advised them otherwise, which can potentially result in a poor patient experience. In addition,
isolation facilities may be limited and experience periods of overdemand; thus, it is not always possible to
isolate all patients. Procedures such as endoscopy may also be cancelled if there is a risk of transmitting
infection. The use of rapid gastrointestinal pathogen panel (GPP) tests might reduce the amount of time
spent in isolation for some patients if the primary reason for isolation is infection risk rather than symptom
management. In addition, for people presenting to primary care services who require faecal microbiology
tests, the more rapid provision of test results may provide earlier information for people who are in regular
contact with young children and older people, helping them to reduce the risk of transmission within their
work and/or home environment. This could bring forward the timing of specific treatment for pathogens
such as giardiasis or typhoid for which antimicrobial treatment is usual, as well as to guide the type of
treatment provided for very ill or vulnerable patients for whom clinical assessment supports antimicrobial
treatment. Early diagnosis may also accelerate exclusion advice to minimise the spread of infection.
The National Institute for Health and Care Excellence (NICE) Diagnostics Advisory Committee is tasked with
providing guidance to the NHS about the use of the integrated multiplex tests for patients with acute
diarrhoea with or without vomiting, thought to be as result of infectious gastroenteritis. To inform the
Diagnostics Advisory Committee, the external assessment group has provided this assessment of the
clinical accuracy and cost-effectiveness of selected multiplex panels as a replacement or adjunct for
standard assessment procedures. The potential value of the multiplex tests is in rapidly determining the
presence and nature of infection, which may be bacterial, viral or parasitic.
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Clear definition of interventions
Three integrated multiplex tests have been evaluated as interventions: xTAG GPP (Luminex, Toronto, ON,
Canada), FilmArray (BioFire Diagnostics, Salt Lake City, UT, USA) and Faecal Pathogens B (AusDiagnostics,
Beaconsfield, NSW, Australia). Clinical judgement is used when interpreting multiplex test findings and
may be further informed by current routine tests or other confirmatory testing. This assessment focuses on
panels combining investigation of bacteria, viruses and parasites and does not consider partial panels that
could be combined to cover all pathogen groups.
xTAG Gastrointestinal Pathogen Panel
The xTAG GPP is a Conformité Européenne (CE)-marked, qualitative, highly multiplexed polymerase chain
reaction (PCR) test for the simultaneous detection and identification of nucleic acids from up to 15
gastroenteritis-causing viruses, parasites and bacteria (Box 1). It can analyse human stool samples that are
fresh, frozen or in a holding medium. It is intended to be used in a laboratory setting.
BOX 1 Pathogens detected by the xTAG GPP assay
Bacteria and bacterial toxins
Campylobacter.
C. difficile, toxin A/B.
Escherichia coli O157.
Enterotoxigenic E. coli LT/ST.
Shiga-like toxin-producing E. coli stx1/stx 2.
Salmonella.
Shigella.
Vibrio cholerae.
Yersinia enterocolitica.
Viruses
Adenovirus 40/41.
Norovirus GI/GII (genogroup).
Rotavirus A.
Parasites
Cryptosporidium.
Entamoeba histolytica.
Giardia.
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The assay uses reverse transcription PCR and the procedure includes five phases.
Using the laboratory’s amplification platform:
1. pre-treatment of the sample
2. nucleic acid extraction and purification using an automated nucleic acid extraction system
3. broad-range PCR using a thermal cycler
4. bead hybridisation and detection using a thermal cycler.
Using the Luminex analyser:
5. data acquisition and analysis [using Luminex 100/200 (Luminex, Toronto, ON, Canada) or MAGPIX
analyser (Luminex, Toronto, ON, Canada)].
A total of 10 µl of purified sample is required for the initial broad-range PCR reaction, which amplifies
nucleic acids that are present in the sample. A total of 5 µl of the broad-range PCR product is then added to
a hybridisation and detection reaction, in which target nucleic acids bind to species-specific tagged beads.
When pathogen nucleic acid is present, fluorescence is emitted by a streptavidin and R-phycoerythrin
conjugate, which is included in the reaction.
Fluorescence intensity is measured by either the Luminex 100/200 or MAGPIX analyser, determining which
bacterial, viral or parasitic deoxyribonucleic acid (DNA) is present in the sample. Positive and negative
controls should be included in each test run. The company recommends that three negative controls
(RNase-free water) and at least one positive control (known positive sample) should be included in each
run. The assay also contains an internal control, which is added to each sample prior to extraction and
indicates whether or not the assay is functioning as intended.
The estimated turnaround time for the xTAG GPP is 5–6 hours, including sample preparation time. This
turnaround time may increase if extraction products are transferred by hand to the PCR thermocycler and
will therefore vary depending on the number of samples. Up to 96 samples (including controls) can be
processed in one run, depending on the capacity of a laboratory’s PCR thermocyclers. The test does not
provide any information on antimicrobial resistance genes or antimicrobial susceptibility.
FilmArray Gastrointestinal Panel
The FilmArray Gastrointestinal Panel is a CE-marked, qualitative, highly multiplexed PCR test that can
simultaneously detect and identify up to 22 pathogens (Box 2) from stool samples in Cary–Blair transport
media. It is intended for use within a clinical laboratory and should be used in conjunction with other
clinical and laboratory findings.
The FilmArray GPP is intended for use with FilmArray and FilmArray 2.0 integrated systems, which include
automated sample preparation. Each FilmArray unit can process one sample per hour and the FilmArray 2.0
system allows FilmArray units to be linked to process up to eight samples per hour depending on how many
modules are purchased. All reagents required for sample preparation, reverse transcription, PCR and detection
are provided freeze-dried in a single-use pouch. Before inserting the reagent pouch into the analyser, the
sample is combined with sample buffer and is injected into the pouch along with a hydration solution.
The system automatically processes a sample through the following stages once a pouch has been inserted:
l nucleic acid purification
l reverse transcription and multiplex PCR
l second-stage ‘nested’ PCR with species-specific primers
l detection with melting curve analysis.
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BOX 2 Pathogens detected by the FilmArray GPP
Bacteria
Campylobacter (jejuni, coli and upsaliensis).
C. difficile (toxin A/B).
Plesiomonas shigelloides.
Salmonella.
Yersinia enterocolitica.
Vibrio (parahaemolyticus, vulnificus and cholerae).
Vibrio cholerae.
Enteroaggregative Escherichia coli.
Enteropathogenic E. coli.
Enterotoxigenic E. coli lt/st.
Shiga-like toxin-producing E. coli stx1/stx2.
E. coli O157.
Shigella/enteroinvasive E. coli.
Viruses
Adenovirus F 40/41.
Astrovirus.
Norovirus GI/GII.
Rotavirus A.
Sapovirus (I, II IV and V).
Parasites
Cryptosporidium.
Cyclospora cayetanensis.
E. histolytica.
Giardia lamblia.
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The system extracts and purifies nucleic acids, which then undergo reverse transcription and are amplified
in the first broad-range PCR reaction. A second nested PCR reaction containing species-specific primers is
run to detect and identify pathogens present in the sample by fluorescence. Each single-use pouch also
contains two internal controls, one ribonucleic acid process control assay and one control assay for the
second-stage PCR. Both controls must be positive for the sample to be reported. Results are reported
automatically using the FilmArray software (version 2, FilmArray, Salt Lake City, UT, USA).
Faecal Pathogens B (16Plex)
The Faecal Pathogens B assay is a CE-marked, highly multiplexed, qualitative PCR test, which can detect
and identify up to 15 pathogens from nucleic acid extracted from fresh faecal samples. The pathogens
detected by the assay are shown in Box 3. The assay is intended to be used in conjunction with the
High-Plex Multiplex Tandem PCR system (AusDiagnostics, Beaconsfield, NSW, Australia) and Easy-Plex
BOX 3 Pathogens detected by the Faecal Pathogens B assay
Bacteria
Salmonella spp.
Shigella spp. and Shigella enteroinvasive Escherichia coli.
Campylobacter spp.
C. difficile.
Shiga toxin 1 and 2.
E. coli O157.
Viruses
Rotavirus A.
Norovirus genogroup I and II.
Adenovirus group F and group G.
Sapovirus.
Astrovirus.
Parasites
Giardia lamblia (18S).
Cryptosporidium (parvus and hominis).
E. histolytica (not dispar).
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results software (version 1.3, AusDiagnostics, Beaconsfield, NSW, Australia). The assay procedure includes
the following processes:
l nucleic acid extraction and purification using the laboratory’s platform
l broad-range PCR (using the High-Plex system)
l real-time PCR with species-specific primers (using the High-Plex system)
l detection with melting curve analysis
In the first PCR step, broad-range primers are used and the product of this reaction is diluted and divided
into a number of real-time PCR reactions, which use nested species-specific primers to detect and identify
any pathogens present in the sample by fluorescence. Results are reported using the Easy-Plex results
software. When multiple pathogens are present in a sample, the software provides a relative quantification
of targets, providing guidance about the relative importance of each detected pathogen. Each tube used
for the broad-range PCR includes an internal positive control (spike) and the company advises that both
positive and negative (water) controls are included in each run. Up to 24 samples can be processed in one
run. The estimated test turnaround time is 3–4 hours. The assay is intended to be used in conjunction with
other clinical and laboratory findings.
Comparative technical overview of the three gastrointestinal
pathogen panels
The differing configurations and capacities of the three panels are summarised in Table 1.
Management of infectious gastroenteritis in hospitals
As previously described (see Clear definition of interventions), patients admitted to hospital with suspected
infectious diarrhoea may be nursed with or without isolation. Use of an isolation bay or side room is
preferable until infection has been ruled out; however, it may not always be possible to isolate patients
when isolation facilities are in full use. When infection prevention control measures are advised for a
patient, some procedures, which may not be classed as urgent (e.g. endoscopy), may be postponed until
the infection has resolved. Gastrointestinal infections may not be the only reason for isolation of patients,
TABLE 1 Overview of features of GPPs considered for assessment
Features of GPPs xTAG (Luminex)
FilmArray
(BioFire Diagnostics)
Faecal Pathogens B
(AusDiagnostics)
Number of pathogens 15 22 15
Pre-treatment time
(minutes)
30–45 2 45–60
Turnaround time (hours) 5 1 3–4
Throughput (samples/run) 96 (including controls) 1 (including controls), up to
8 units per computer
24 (including controls)
Starting material 100 µl of fresh or newly frozen
stool (raw or in holding
medium, e.g. Cary–Blair)
200 µl of Cary–Blair stool Fresh stool
Detection method Bead hybridisation following
PCR
Melting curve following
nested PCR
Melting curve following
nested PCR
System Open (not an integrated system
requiring DNA extraction
before loading for analysis and
post PCR handling)
Closed [fully integrated
system including sample
preparation (DNA extraction),
PCR reactions and detection]
Open (DNA extraction
required before loading
for analysis)
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
which may be required, for example, for other communicable diseases such as respiratory virus infections,
meticillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative bacteria (e.g. extended-
spectrum beta-lactamase producers). Patients carrying, or at risk of carrying, carbapenemase-producing
Enterobacteriaceae are an increasingly important cohort who require single-room isolation.4
Management of infectious gastroenteritis in the community
When infectious gastroenteritis is suspected in the community, people are often advised to absent
themselves from work or, in the case of children, from schools and nursery.5 Advice is also given on
reducing the risk of transmission, particularly when highly transmissible pathogens such as norovirus and
Shigella are suspected. Infectious gastroenteritis can have particular implications for people in certain
professions, such as people who handle food and health-care workers. Food handlers are typically advised
to remain away from work until 48 hours after symptoms have resolved; however, infections with certain
pathogens, including Salmonella typhi or Salmonella paratyphi and Escherichia coli O157, may require
negative microbiology results before the person is able to return to work.6 In some cases, the detection of
suspected food-borne pathogens may result in public health teams initiating an outbreak investigation.
Place of the intervention in the treatment pathway(s)
The main clinical feature of gastrointestinal infection is diarrhoea, but other symptoms can include nausea,
sudden onset of vomiting, blood or mucus in stool, or systemic features such as fever or malaise.2 Public
Health England (PHE) advises that no infection-specific treatment is warranted in most patients.
Management involves strategies to maintain hydration and steps to prevent cross-infection.
In acute cases, diagnostic investigations are needed to confirm that an infection is present or to determine
the causative pathogen. It is recommended that stool samples for microbiological diagnosis are taken in
the following situations:
l There is persistent diarrhoea or malabsorption.
l There is blood, mucus or pus in the stool.
l There is a history of diarrhoea and/or vomiting, and the patient is systemically unwell.
l There is a history of recent hospitalisation.
l There is a history of antibiotic therapy.
When parasitic infections are suspected, it is recommended that three samples are sent 2–3 days apart as
ova, cysts and parasites are shed intermittently.2 In the case of hospital-acquired gastroenteritis and
diarrhoea, laboratories may employ a 3-day rule when deciding whether or not to process stool samples
from inpatients for routine bacterial culture (Salmonella, Shigella, Campylobacter and E. coli O157),
although testing for C. difficile should be done as soon as infective diarrhoea is suspected. The rule
suggests that, in the case of suspected hospital-acquired infection, stool samples should not be sent to
microbiology unless one or more of the following criteria are met:
l diarrhoea develops within 3 days of admission
l in the case of adults with nosocomial diarrhoea, one of the following is present:
¢ pre-existing disease causing permanently altered gut function in a patient aged ≥ 65 years
¢ human immunodeficiency virus infection
¢ neutropenia/immunocompromised
l a nosocomial outbreak (e.g. Salmonella) is suspected
l non-diarrhoeal manifestations of enteric infections are suspected.
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The setting for multiplex testing will include patients from community and hospital settings, with
microbiology laboratories receiving samples from primary and secondary care services. The use of findings
will be in their clinical settings.
Relevant comparators
The comparator will be standard microbiology techniques, outlined in the PHE syndromic algorithm for
routine testing in cases of gastroenteritis and diarrhoea (see Figure 1). People who have a history of recent
travel (to areas other than Western Europe, North America, Australia or New Zealand) may have additional
primary testing for Vibrio and Plesiomonas species by bacterial culture. A two-stage testing approach is
currently recommended for C. difficile, which involves an initial testing step using either a nucleic acid
amplification test or enzyme immunoassay for glutamate hydrogenase. When the initial test is positive, a
sensitive toxin enzyme immunoassay should be performed to detect the presence of the toxins that cause
illness.7 The syndromic algorithm also notes that laboratories may opt to test for norovirus only during
cooler months when peak incidence occurs (November–April). Blood cultures may also be taken if a patient
is systemically unwell.8
The current laboratory pathway for routine screening of stool samples for people with diarrhoea and
vomiting is shown below in Figure 1.8
Multiple types of media may be required for bacterial culture and it may take up to 3 days for incubation
and pathogen detection. The current bacterial culture protocols recommended by PHE for the investigation
of faecal specimens for routine bacterial pathogens9 are shown in Figure 2. The standards also note that
Routine screen
Hospital
Culture
Salmonella sp.
Campylobacter sp.
Shigella sp.
E. coli VTEC (O157)
EIA/microscopy
Cryptosporidium
EIA/NAATs
Clostridium difficile
Primary
testing
Secondary
testing
NAATs
Norovirus
Microscopy
Ova, cysts and 
parasites
Microscopy
Giardia
Community
Culture
Salmonella sp.
Campylobacter sp.
Shigella sp.
E. coli VTEC (O157)
EIA/microscopy
Cryptosporidium
EIA/NAATs
Clostridium difficile
Microscopy
Ova, cysts and 
parasites
Microscopy
Giardia
Additional tests for children < 5 years
EIA/NAATs
Rotavirus
EIA/NAATs
Adenovirus 40 and 41
NAATs
Norovirus
NAATs
Astrovirus
Sapovirus
FIGURE 1 Current laboratory pathway for routine screening of bacterial pathogens for people with diarrhoea and
vomiting. EIA, enzyme immunoassay; NAAT, nucleic acid amplification test. Adapted with permission from PHE.8
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rapid diagnostic tests for the direct identification of bacteria directly from faeces, such as enzyme
immunoassays and PCR, are available. These tests are thought to be highly accurate for Salmonella,
Campylobacter and E. coli O157, but fewer data are available on their effectiveness for detecting
toxin-producing bacteria such as Clostridium perfringens, Bacillus species and S. aureus.9
The need for an adequate reference standard
The standard algorithm (representing routine care) presented is an appropriate comparator for the multiplex
panels. However, it is apparent that standard microbiology techniques, as described in the standard
algorithm, cannot provide a reference standard to evaluate multiplex tests. First-line tests are not 100%
accurate and may require confirmatory PCR assays in the case of diagnostic doubt. A range of PCR tests is
used across the NHS, but these are used neither widely nor consistently. Multiplex tests may identify
substantially higher levels of certain pathogens than standard microbiology. Whether these additional
findings are either correct or clinically important (toxin-producing) needs to be determined by an external
For all diagnostic specimens
(except specific organism
screens)
For all diarrhoeal 
(semiformed or liquid 
faeces) samples, and 
outbreak samples, in 
children < 5 years or 
when advised by a senior
microbiologist/scientist
Prepare all specimens
Mannitol
selenite broth
Subculture to
XLD
Incubate at
35–37°C
Air
16–24 hours
Incubate at
35–37°C
Air
16–24 hours
Read at > 16 hours
Salmonella 
species
refer to ID 24
Modified tryptone
soya broth
Subculture to
CT-SMAC agar
Incubate at
35–37°C
Air
16–24 hours
Incubate at
35–37°C
Air
16–24 hours
Read at > 16 hours
E. coli O157
refer to ID 22
XLD agar
Incubate at
35–37°C
Air
16–24 hours
Read at > 16 hours
Salmonella 
species refer
 to ID 24
Shigella species
refer to ID 20
Campylobacter
selective agar
Incubate at
39–42°C
Microaerobic
> 48 hours
Read at > 40 hours
Campylobacter 
species
refer to ID 23
CT-SAMC agar
Incubate at
35–37°C
Air
16–24 hours
Read at > 16 hours
E. coli O157
refer to ID 22
FIGURE 2 Overview of microbiological laboratory methods for bacterial pathogens according to Public Health
recommendations. Reproduced with permission from PHE.9
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reference standard. Assessment of diagnostic accuracy depends on determining the performance of both
index tests (the GPP panels) and comparator (conventional testing) against a common and adequate
reference standard.
Comparison of pathogen coverage between Public Health
England and gastrointestinal pathogen panels
A comparison of the pathogen coverage of the PHE algorithm and GPP panels is provided in Table 2.
TABLE 2 Overview of pathogens tested by PHE, xTAG, FilmArray and Faecal Pathogens B
Pathogen PHE xTAG FilmArray Faecal Pathogens B
Adenovirus ✗ ✗ ✗ ✗
Astrovirus ✗ – ✗ ✗
C. difficile toxin A/B ✗ ✗ ✗ ✗
Campylobacter ✗ ✗ ✗ ✗
Cryptosporidium ✗ ✗ ✗ ✗
Cyclospora cayetanensis – – ✗ –
E. coli O157 ✗ ✗ ✗ ✗
Enteroaggregative E. coli – – ✗ –
Entamoeba histolytica – ✗ ✗ ✗
Enteropathogenic E. coli – – ✗ –
Enterotoxigenic E. coli – ✗ ✗ ✗
Giardia ✗ ✗ ✗ ✗
Norovirus ✗ ✗ ✗ ✗
Plesiomonas shigelloides ✗ – ✗ –
Rotavirus ✗ ✗ ✗ ✗
Salmonella ✗ ✗ ✗ ✗
Sapovirus ✗ – ✗ ✗
Shigella/enteroinvasive E. coli ✗ ✗ ✗ ✗
Shiga toxin-producing E. coli – ✗ ✗ ✗
Vibrio (parahaemolyticus, vulnificus and cholerae) – – ✗ –
Vibrio cholerae ✗ ✗ ✗ –
Yersinia enterocolitica – ✗ ✗ –
Total 14a 15 22 15
–, not included in test.
a Investigation by microscopy may include further parasites.
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Chapter 2 Definition of the decision problem
Decision question
This report, prepared for the NICE Diagnostics Assessment Programme, examines the clinical effectiveness
and cost-effectiveness of GPPs, which include all three types of pathogen: bacteria, viruses and parasites.
The report will help NICE when making recommendations about how well the tests work and whether
or not the benefits are worth the cost of the tests when used in the NHS in England. The assessment
considers both clinical improvement in patients’ symptoms and the cost of the tests using evidence
identified through systematic reviews and information submitted to NICE during the evaluation process by
the companies providing the GPP tests.
The decision question for this project is: what is the clinical effectiveness and cost-effectiveness of the
xTAG, FilmArray and Faecal Pathogens B GPPs in the identification of gastrointestinal bacteria, viruses and
parasites in patients with suspected gastroenteritis presenting in primary or secondary care, compared with
conventional microbiological methods outlined in the PHE standard?8
Overall aim of the assessment
The overall aim of this report is to present evidence on the clinical effectiveness and cost-effectiveness of
the xTAG, FilmArray and Faecal Pathogens B GPPs in the identification of gastrointestinal bacteria, viruses
and parasites compared with conventional microbiological methods.
Objectives
To systematically review the evidence for the clinical effectiveness of the GPP tests (xTAG, FilmArray and
Faecal Pathogens B), systematically review existing economic evaluations and develop a de novo economic
model to assess the cost-effectiveness of GPP tests compared with the standard of care in England
and Wales.
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Chapter 3 Clinical effectiveness review
Methods
Identification and selection of studies
Search strategies for clinical effectiveness
The search strategy for the clinical effectiveness review is detailed in Appendix 1. Briefly, the search
strategy included:
l databases: Ovid MEDLINE 1946 to November week 3 2015; Ovid MEDLINE In-Process & Other
Non-Indexed Citations 31 December 2015; Ovid EMBASE 1980 to 2015 week 52; Web of Science
1980 to 31 December 2015; Cochrane Database of Systematic Reviews issue 5 of 12, May 2016 –
all sections. Weekly auto-alerts for emerging evidence were run in Ovid MEDLINE, Ovid EMBASE and
PubMed from 1 January 2016 to 30 April 2016
l reference lists of all reviews and included studies
l websites of NICE, PHE, Food and Drug Administration (FDA) and the manufacturers of the multiplex
PCR tests
l ongoing studies of the following sources: National Institutes of Health ClinicalTrials.gov, Current
Controlled Trials, World Health Organization International Clinical Trials Registry Platform and UK
Clinical Trials Gateway.
Inclusion and exclusion of relevant studies
Inclusion criteria
Studies that satisfied the criteria outlined in Table 3 were included.
Exclusion criteria
Studies that satisfied the criteria outlined in Table 4 were excluded.
Spiked samples are most commonly samples from healthy volunteers to which pathogens have been
added; therefore, the type and concentration of pathogen is known and the samples do not represent true
clinical samples.
Using the information provided by the manufacturers
The information provided by Luminex, BioFire Diagnostics and AusDiagnostics (see Appendix 2 for an
itemised list of documents received) was screened for three purposes:
1. to identify potential additional studies not identified by our searches
2. to identify unpublished test accuracy and clinical effectiveness data
3. to obtain information on the technical description of the three intervention assays.
Study selection strategy
All publications identified in searches from all sources were collated in EndNote (X7, Thomson Reuters,
CA, USA) and de-duplicated. Two reviewers independently screened the titles and abstracts of all records
identified by the searches and discrepancies were resolved through discussion. Full copies of all studies
deemed potentially relevant were obtained and two reviewers independently assessed these for inclusion;
any disagreements were resolved by consensus or discussion with a third reviewer. Records rejected at
full-text stage and reasons for exclusion were documented. Three authors were contacted to confirm that
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TABLE 3 Inclusion criteria
Criterion Detail
Population Patients with acute diarrhoea with or without vomiting, thought to be a result of infective
gastroenteritis, with test referrals from hospital and community. Subgroups evaluated include
people in the community, people in hospital, children aged < 5 years, people with recent foreign
travel and people who are immunocompromised
Intervention xTAG, FilmArray or Faecal Pathogens B GPPs
Comparator Standard microbiology techniques, outlined in the PHE syndromic algorithm for routine testing in
cases of gastroenteritis and diarrhoea8
Outcome Outcomes of test performance – primary:
l diagnostic accuracy
l agreement
l discordant results with standard microbiology tests
Outcomes of test performance – secondary:
l run failure rates
l multiple infections
l time to test result
l changes to treatment and management plans
l changes to infection and prevention control decisions
l length of stay in isolation rooms
l length of hospital stay
l duration of barrier or cohort nursing
Clinical outcomes:
l morbidity (from the underlying condition and treatment side effects)
l mortality
Patient-reported outcomes:
l health-related quality of life
Costs
Study design Test–treat trials comparing clinically relevant outcomes (e.g. morbidity, mortality, length of stay and
length of isolation) for patients randomised to either conventional testing or GPP
Clinical diagnostic test accuracy studies that compare the index tests (GPP) and the comparator
(conventional methods) to an adequate reference standard (if an adequate reference standard
exists or is reported)
Studies that compare discrepant results between the index tests (GPP) and the comparator
(conventional methods) using an unbiased umpire test (if an adequate reference standard does not
exist or is not reported)
Studies of agreement and disagreement between the index tests (GPP) and the comparator
(conventional methods) without using an unbiased umpire test (neither an adequate reference
standard nor an unbiased umpire test exists or is reported)
Studies of head-to-head comparisons of different index tests (GPP) reporting agreement of tests
Health-care setting Clinical laboratory receiving samples from primary and secondary care
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the included study population was eligible. Eligible studies identified after 23 March 2016 were not
included in the analysis but contributed to the discussion of the clinical effectiveness.
Data extraction strategy
Data were extracted by one reviewer using a piloted data extraction form. Completed data extraction
forms are available from the authors. A second reviewer checked the extracted data. Any disagreements
were resolved by consensus or discussion with a third reviewer. A sample data extraction form used in this
review is available in Appendix 3.
Test results for GPP and comparator tests were extracted into 2 × 2 contingency tables following the
format shown in Table 5. Ideally, studies provided a comparison for each sample of the full PHE algorithm
and an index panel test. For studies in which each sample might receive only a selection of conventional
methods (according to physician’s choice), the denominator was adjusted accordingly for each pathogen.
Only samples that received (for each pathogen) both the index test and conventional methods were
included in the 2 × 2 table. The four cells of the 2 × 2 table are subsequently referred to as a(+/+), b(−/+),
c(+/−) and d(−/−).
Quality assessment strategy
Quality assessment of eligible studies was undertaken with a highly tailored Quality Assessment of
Diagnostic Accuracy Studies-2 (QUADAS-2) tool.10 A single reviewer determined the methodological quality
of included studies and a second reviewer checked findings. Any disagreements were resolved by consensus
or arbitration.
Quality assessment aimed to assess the risk of bias and applicability concerns of included studies on the
pathogen level, where the GPP method was the index test, conventional methods were the comparator
and any efforts to verify discordant results were assessed under the reference standard domain. The
studies did not fit the conventional test accuracy study format, as there is no reference standard, and each
pathogen investigated had to be considered individually in terms of test accuracy. Modifications to tailor
the QUADAS-2 form to the research question in terms of the risk-of-bias assessment are detailed next
(see Appendix 4 for the tailored QUADAS-2 form and guidance notes).
TABLE 4 Exclusion criteria
Criterion Detail
Population ‘Spiked’ samples, swab testing or non-representative populations
Intervention Other modular or partial multiplex tests, index tests during outbreaks or for the routine management of
chronic conditions
Study design Reviews, biological studies, case reports, editorials and opinions, poster presentations without
supporting abstracts, non-English-language reports, meeting abstracts without sufficient detail on test
performance for 2 × 2 data table extraction per pathogen
TABLE 5 Test contingency table
Test Comparator + Comparator –
GPP + +/+ –/+
GPP – +/– –/–
–, pathogen absent; +, pathogen present.
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Patient selection domain
Addition of one signalling question: was only one sample per episode of diarrhoea included in the study?
It is important that studies do not include more than one sample per patient per episode of diarrhoea to
avoid double counting. Many studies reported samples rather than patients, or studies reported greater
numbers of samples included than numbers of patients, where it would be important to ascertain that
samples are representative of one episode of diarrhoea. We assumed that a period of 1 month between
samples was required to define separate episodes of diarrhoea.
Index test domain
The addition of one signalling question: was the index test undertaken as recommended by the manufacturer?
Bias may occur if the study deviates from the manufacturers’ recommendations in the conduct and
interpretation of the GPP tests. Manufacturers provide clear package inserts for the handling of samples
and equipment. Deviation in terms of type of sample (fresh, frozen, pure, in Cary–Blair medium), amount
of sample and handling of sample if not tested immediately may result in systematic differences in the
performance of the test.
Comparator domain
The addition of a domain for the comparator.
The eligible studies compared GPP testing with a comparator that consisted, broadly speaking, of a range
of conventional microbiological tests that cannot be classed as the reference standard because GPP testing
may be superior to conventional methods. Therefore, the comparator was assessed in addition to the index
test and the reference standard. Similar signalling questions in terms of blinding and thresholds were
considered for the comparator. In addition, one signalling question was added: was culture performed on
fresh (not previously frozen) samples? Culture from frozen samples appear to be less reliable than culture
from fresh samples, which will result in greater discrepancies between conventional and GPP methods for
pathogens that are confirmed by culture.11,12
Reference standard domain
The addition of one signalling question: was the reference standard independent and unbiased?
As there is no independent and reliable reference standard for the assessment, we looked for an independent
and unbiased umpire test to be used in the studies to assess discordant results between index test and
conventional methods [e.g. exposure, treatment effect (pathogen-specific treatment) or self-reported
symptoms, previous antibiotic treatment, over-the-counter medicine].
Flow and timing domain
The adjustment of one signalling question: did all discordant samples receive a reference standard?
For a fair umpire test to be a valid verification method, all discordant results rather than a proportion
should be tested.
The addition of one signalling question: did all samples receive the comparator methods for all pathogens
considered in the study?
The risk of bias is high if patients received conventional tests only on the basis of prior assessments by
physicians and according to symptoms.
Methods of analysis/synthesis
Following 2 × 2 data extraction, several approaches to data analysis were considered. In order to justify the
approach, the limitations of the available data are explained, rendering more robust methods inappropriate.
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Summary of strategies for analysis
Test–treat trials
The most pertinent study design would be a test–treat trial comparing clinically relevant outcomes such as
morbidity, mortality, length of stay and length of isolation for patients randomised to either conventional
testing or GPP. In the absence of an appropriate reference standard, and as the primary interest is the
effect on clinically relevant outcomes, this would be the most informative study design. However, no
test–treat trials investigating this question in the relevant population were identified.
Conventional test accuracy paradigm: calculation of sensitivity and specificity
Following the conventional diagnostic test accuracy paradigm, the ideal scenario would be to derive
sensitivity and specificity as a measure of test performance of GPP testing. This would require testing all
samples with a reference standard. The reference standard would need to be a highly accurate (and ideally
independent) test, recognised as the best available. It is known that PCR can detect pathogen DNA at very
low levels, including from non-viable organisms. Neither PCR nor culture can be used as a reference
standard because we do not know which is more accurate and because it might introduce significant bias
to define one or other test as the reference standard. There are no other appropriate tests to act as
reference standard, therefore sensitivity and specificity cannot be calculated.13
Discrepant analysis
Discrepant analysis14 involves retesting discordant results between the index test (GPP) and comparator test
(conventional testing), using a resolving test with better discriminatory properties, to update the final 2 × 2
table. Sometimes this approach has been used in studies to calculate sensitivity and specificity of the tests
using the assumption that when both tests agree (without resolving test) then they are both correct. This
may produce inflated estimates of sensitivity and specificity. This was not an appropriate approach for this
review15 because of the potential bias introduced and the lack of a suitable resolving test.
Fair umpire test
The fourth approach considered was not based on the conventional diagnostic test accuracy paradigm,
in the absence of a reference standard. In this scenario, in addition to the 2 × 2 data of association between
the GPP test and conventional methods, verification results for discordant outcomes using an unbiased,
independent (but possibly imperfect) umpire test are considered, for example exposure levels to the pathogen
of interest. The characteristics of discordant results in cell b of a 2 × 2 table (GPP positive, conventional test
negative) are compared with those in cell c (GPP negative, conventional test positive). The characteristics to
be compared must have a better than chance association with the condition or outcome of interest and,
crucially, be unbiased towards one test or another. This can provide unbiased information on which is the
most accurate test, but cannot be used to calculate sensitivity or specificity.13 In anticipation of this approach,
information on verification and characterisation of discordant results were sought, assessed for independence
from the index test and comparator, and 2 × 2 tables updated with information on discordant outcomes to
allow unbiased assessment of the direction of resolution of discordant results in favour of either the index test
or the comparator.13
This approach yielded no results: discordant results were verified only in a limited number of studies and
only with PCR-based methods. These methods are not independent and unbiased, as PCR assays are not
sufficiently different from GPP tests (i.e. the index test), which are also based on PCR methodology and
should produce biased results in favour of GPP testing. No fair umpire test based using exposure or
outcome variables was identified in any of the included studies.
Test agreement: kappa
Test agreement (Cohen’s kappa) was considered as a single measure of agreement between tests using
the updated 2 × 2 tables. However, Cohen’s kappa is only really useful and interpretable for test–retest
reliability, not for comparing different tests (conventional tests and GPP), when small deviations from a
kappa of 1 could have clinically meaningful implications. Furthermore, Cohen’s kappa is unstable when
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individual cell counts are low in a 2 × 2 table, as they are for many pathogens in this review.16 The use of a
single measure of agreement, such as Cohen’s kappa in this instance, is, therefore, discouraged.17
Methods of analysis
In the absence of any test–treat trials, a suitable reference standard or any fair umpire tests in any included
studies, we followed the FDA recommendations on reporting results from studies evaluating diagnostic
tests.17 In the absence of a reference standard, the guidance discourages the reporting of sensitivity and
specificity and recommends reporting measures of positive and negative test agreement.
We calculated positive agreement (a/a + c) and negative agreement (d/b + d) when benchmarked against
the comparator, and positive agreement (a/a + b) and negative agreement (d/c + d) when benchmarked
against GPP for each pathogen to determine the range of feasible outcomes of test agreement.
The resulting measures of agreement are not measures of performance, as it is not known which test is
correct. Agreement could be poor because one test is more accurate than the other or because they are
both poor. There is no statistical method to determine which scenario is correct. As recommended in the
guidance,17 we used the original 2 × 2 table data without updating results from discrepant analyses
because, when attempted in a minority of studies, the resolving test used was not a reference standard.
Positive and negative agreement benchmarked against conventional methods and positive and negative
agreement benchmarked against GPP were then meta-analysed by pathogen if the denominator was ≥ 20
to achieve agreement estimates and explore heterogeneity.
We undertook a random-effects meta-analysis of proportions using the metaprop command in Stata SE
14.1 (StataCorp LLC, College Station, TX, USA).18 The analysis was exploratory and no adjustment was
made for the interdependence of positive and negative values. Exact binomial methods were used to
estimate 95% confidence intervals (CIs) using the Freeman–Tukey transformation of proportions, and the
I2-statistic of between-study heterogeneity was computed.
The analysis was undertaken for each pathogen at the sample level, assuming independence between
samples within studies and between studies, that is, having one pathogen does not affect the likelihood of
having another pathogen.
Definitions for the review
Definition of the Public Health England algorithm
The PHE algorithm8 consists of primary testing for Salmonella, Campylobacter, Shigella, E. coli O157,
Cryptosporidium and C. difficile with additional tests for children aged < 5 years for rotavirus, adenovirus
40/41 and norovirus. Secondary testing in hospitalised adults is recommended for norovirus and ova, cysts
and parasites including Giardia, whereas people in the community should not be tested for norovirus and
children aged < 5 years should also be tested for astro- and sapovirus. Furthermore, our assessment
included travellers as a subgroup of interest for which additional tests for Vibrio and Plesiomonas species
are considered if they are returning from areas other than Western Europe, North America, Australia or
New Zealand. Physicians following this algorithm use local tests that vary across the UK and may or may
not request all tests detailed in the PHE algorithm, depending on symptoms and suspicion following
patient assessment. In order to compare GPP testing with microbiology techniques, as outlined in the PHE
syndromic algorithm for routine testing, a clear definition of the comparator is needed.
For the purpose of this review, no differentiation is being made between primary and secondary testing or
differences in terms of population testing (children, adults, travellers) and seasonality (including norovirus
testing in winter months only). For a sufficiently equivalent comparator, all pathogens mentioned in the
syndromic PHE pathway8 for any of the populations of interest were included. A pragmatic judgement was
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required regarding whether or not the number of tested pathogens in the studies is sufficiently similar to
the PHE algorithm [i.e. at least 75% (≥ 11 of the above pathogens) included in study].
In terms of tests, the following was assumed: testing is classed as sufficiently equivalent to the PHE
algorithm if the comparator in the studies includes:
l culture or PCR for bacteria (see final bullet point for C. difficile)
l PCR or enzyme immunoassay for viruses
l microscopy or enzyme immunoassay for parasites
l PCR and/or enzyme immunoassay (plus toxin test) for C. difficile.
It is noteworthy that even if the type of method is equivalent, there are a huge number of different tests
and testing kits currently used within the NHS for the various pathogens. Therefore, we have included
studies using a wide range of conventional microbiology approaches, reflecting variation in health
services practice.
Clinical effectiveness results
Search results
The process of study identification and selection for the clinical effectiveness review is illustrated in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram (Figure 3). The
search identified 3468 records. Following duplicate removal, we screened 2215 unique records, of which
Records after duplicates removed
(n = 2215)
Records screened
(n = 2215)
Records excluded
(n = 2105)
Studies included
(n = 23, reported in 28 articles)
Id
en
ti
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Full-text articles 
assessed for eligibility
(n = 110)
Full-text articles 
excluded, with reasons
(n = 57)
Abstracts on index
tests excludeda
(n = 25)
Records identified through
database searching
(n = 3463)
Additional records identified 
through other sources
(n = 5)
FIGURE 3 The PRISMA flow diagram of study selection for the clinical effectiveness review. a, Without sufficient
detail on test performance for 2 × 2 data table per pathogen.
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110 were taken forward to full-text assessment. A total of 57 studies were subsequently excluded, and a
further 25 abstracts that did not report sufficient data on the validation method, the comparator and/or
the outcomes per pathogens tested also were excluded. The list of excluded full texts and abstracts with
reasons can be found in Appendix 5. We included a total of 23 studies11,12,19–39 that were reported in
28 articles.
The xTAG GPP assay trial for FDA approval tested 14 pathogens and was reported in two FDA
documents,25,40 as well as one review by the company.41 This study is referenced as FDA25 in this report.
Similarly, the trial undertaken by BioFire for the approval of the FilmArray GPP test was reported variously
as FDA report,42 as 510(k) submission to the FDA,43 as part of the instruction manual44 and as a published
study.20 This study is referenced as Buss et al.20 in this report.
The search for ongoing trials identified one ongoing trial for which no outcomes were available for this
review (see Appendix 6). Screening of the information provided by the companies did not identify any
additional published or unpublished studies.
Studies identified after the review deadline
Three studies were identified after the deadline for inclusion of studies and were therefore not included in
the review: Stockmann et al.,45 Eibach et al.46 and De Rauw et al.47
Study characteristics
The 23 studies11,12,19–39 included in the clinical effectiveness review are described in Table 6.
Participants
The included patient population and the setting of studies were insufficiently characterised, possibly as result
of the inclusion of samples rather than patients in the majority of studies. Only one study11 differentiated
between hospital-based samples (from children admitted with suspected viral gastroenteritis and children
presenting to the emergency room) and community-based samples [adult and child travellers whose samples
were submitted by general practitioners (GPs)]; the study population consisted of children and travellers only.
Seven studies19,22,26,27,29,35,39 reported the setting sufficiently to allow judgement on the origin of the infection
(hospital vs. community). The majority of studies11,12,20,21,23–25,28,30–34,36–38 reported recruitment of hospitalised
patients, for which a mixed population should be assumed (in terms of origin of infection) as it is unclear
at what point in time during hospitalisation each infection occurred. Only one study was identified as a
community study, set in Côte d’Ivoire.19 Subgroups of interest were reported in 10 studies11,19,20,22,25,26,29,35,36,39
and, of these, one considered travellers only39 and two considered immunocompromised patients only.22,26
Children aged < 5 years were not considered separately in any study, but the proportion of children aged
< 5 years was reported in six studies11,19,20,25,35,36 and ranged from 2% to 40% of the total study population.
These studies did not report outcomes by setting or subgroup at the pathogen level, which is why reported
outcomes should be regarded as applicable to a mixed population. However, one study reported study-level
results for hospital- and community-acquired infections.27
Country of study
Eleven studies11,22,27–30,32,35,37–39 included participants from European countries, including three studies from
the UK.27,30,32 One study was multinational, covering North America and Europe,21 eight studies were
from North America,12,20,25,26,31,33,34,36 two were from Asia23,24 and one was from Africa.19 Therefore, the
applicability of the study population in terms of prevalence of pathogens is questionable in 3 out of the
23 studies (see Quality considerations of included studies).
Index test
Overall, 17 studies11,19,21–25,27–33,37–39 evaluated xTAG and four studies20,34–36 evaluated FilmArray. Two
studies12,26 compared both tests but no study was identified that assessed the Faecal Pathogens B assay.
The majority of studies11,12,19,21,23,24,26–30,32,33,37–39 investigated xTAG for all 15 pathogens, of which two
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studies12,33 specified the research use only version (pre-FDA approval). However, two studies considered
either 1131 (excluding adenovirus, Entamoeba histolytica, Vibrio cholerae and Yersinia) or 1425 pathogens
(excluding Yersinia). Initial FDA approval of xTAG only covered 11 pathogens but was extended to 14
pathogens following an additional submission by Luminex requesting to extend reporting to a further three
pathogens in 2014.40 However, CE marking for xTAG covers all 15 pathogens.48 Therefore, variation of
the number of pathogens included in the studies exists. The assay methods are identical in the different
versions.40 Similarly, an investigational use only version of the FilmArray panel test included a test for
Aeromonas. This pathogen is not included in the FDA-cleared version of the panel test. Therefore, the
majority of FilmArray studies included 23 pathogens12,20,26,34,36 using the investigational use only version
rather than the CE-marked 2235 pathogen panel.
Comparator
A methodological limitation of studies included in this review concerns the varying ways in which comparator
tests are implemented between studies. Relatively few studies have used a mix of microbiological and PCR
methods reflected in the PHE pathway, with an over-reliance on PCR methods and sequencing. A further
difficulty is the inconsistent use of the full comparator method. In most studies the GPP system is compared
with a subset of conventional pathogen tests rather than assessing the full PHE algorithm.
According to our definition of the PHE algorithm (see Definitions for the review), only six studies12,21,26,27,29,36
can be classed as having used a comparator sufficiently similar to the routine screening pathway
recommended by PHE in terms of pathogens included (at least 11) and methods used. None of the studies
tested patients or samples with all conventional tests. Pathogens were tested according to the physician’s
request only. Two studies19,34 considered as few as two pathogens in common with the PHE algorithm,
whereas two restricted conventional testing to only five pathogens28 and four pathogens.30 Rand et al.34
included samples negative for rotavirus and C. difficile only and Beckmann et al.11 tested children only for
viruses and travellers only for parasites with conventional methods. The two main clinical studies by the
companies20,25 used a comparator that was significantly different (PCR and sequencing for the majority of
pathogens) to typical conventional methods, whereas one study from the Netherlands38 also used methods
different from the PHE methods, namely multiplexed PCR for parasites and viruses. Although multiplexing
is emerging in UK laboratories for individual pathogens or types of pathogens, this is not specified in the
PHE algorithm.8 The assessment of the comparator in terms of equivalence to the algorithm was not
possible for one multinational study35 in which conventional methods were described as routine tests
undertaken at local laboratories in 10 different countries.
Outcomes
Ten studies20–27,29,30 reported results of association between the comparator and the GPP test in sufficient
detail by pathogen to allow the construction of 2 × 2 tables by pathogen. These studies are further
characterised in Table 7 and contributed data to the meta-analysis in Pathogen-level positive and negative
agreement.
An attempt to verify at least some of the discrepant results between GPP assay and conventional methods
was undertaken in 15 studies.11,12,20–23,25,29–34,38,39 However, only four studies reported outcomes of
verification by pathogen.20,23,25,30
Study design
Table 7 characterises the design heterogeneity among the studies reported, which should be noted when
considering the pooled study outcomes. Studies retrospectively included samples with confirmed gastroenteritis
and negative controls30 or prospectively included samples from patients with suspected gastroenteritis.20–27,29
Comparator and GPP tests were both undertaken at the study site(s) in seven studies,22–27,29 whereas one study
sent the samples to reference laboratories for conventional testing,30 one study sent the samples to Luminex for
GPP testing21 and one study sent the samples to BioFire for comparator testing.20 Verification was undertaken
on all discrepant samples by four studies,20,23,25,30 on a subset of samples by Claas et al.,21 on positive samples
for enteric viruses and Campylobacter as well as 23 negative samples by Coste et al.,22 and on samples with
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
Buss et al. 2015;20
USA; 4
FilmArray n= 1556 Study set up: culture was set up
as part of routine clinical testing
at four testing sites using their
standard procedure, submitting
physicians may have ordered
testing in addition to stool culture;
however, the results of such routine
testing were not collected or
utilised in this study for comparator
analysis. FilmArray was performed
at study sites
Comparator: bacteria – specimens
were tested using stool culture.
Viruses/parasites/C. difficile
toxins/STEC/ETEC/EPEC/EAEC –
real-time PCR (two independent
well-validated assays for each
analyte different from the FilmArray
GI Panel targets if possible) and
sequence analysis were performed
by BioFire personnel. Comparator
was regarded positive if both tests
were positive; if discrepant, both
PCRs were repeated
All samples received all comparator
tests with two exceptions regarding
interpretation of results: in order
to follow the same algorithm as
FilmArray utilises, EPEC results were
classed as NA if they were STEC
positive and E. coli O157 results
were only considered if the STEC
test was positive
GPP: IUO version therefore
including results for Aeromonas,
all samples tested with FilmArray
at study sites within 4 days of
sampling, samples shipped frozen
on a weekly basis
Verification: discordant samples
tested blinded by BioFire, PCR and
sequencing using different targets
to comparator method and
FilmArray, or using enhanced
methods (additional PCR cycles and
replicate samples) or using bench
top version of FilmArray (FilmArray
primers in conventional real-time
PCR)
Positive per cent
agreement and
negative per cent
agreement instead of
sensitivity and
specificity to indicate
that a non-gold-
standard assay (e.g.
PCR) was used for the
comparator analysis
Hospitalised: 164
(10.5%)
ER: 42 (2.7%)
Outpatients: 1350
(86.8%)
Adults aged
> 21 years: 584 (38%)
Children aged
0–5 years: 539 (35%)
Children and young
people aged
6–21 years: 433 (27%)
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
Claas et al. 2013;21
the Netherlands,
USA, Canada,
UK; 4
xTAG n= 901 Study set up: each participating
laboratory analysed specimens
according to the routine diagnostic
algorithm in place at that site
and as ordered by the referring
physician. All samples were shipped
to Luminex for GPP testing
Comparator: as ordered by
referring physician at four study
sites following their routine
diagnostic algorithms. Bacteria –
culture according to standard
procedures at four sites. Bacterial
toxins – EIA (North America).
Parasites – microscopy or EIA
(North America), microscopy
or PCR (Europe). Viruses – PCR
(Europe only)
GPP: xTAG performed by Luminex
Verification: a subset of samples
was assessed by conventional
PCR and bidirectional sequencing
using validated primers targeting
genomic regions distinct from those
of the xTAG GPP, site of testing not
reported
Sensitivity and
specificity
Coste et al.
2013;22 France; 1
xTAG 54 samples of 49 adult
kidney transplant
recipients
Study set up: stool samples were
taken from each study participant
at the time of the severe diarrhoea
episode, parasitological tests were
performed again on a second
sample taken 72 hours after
inclusion to deal with the shedding
of intestinal protozoa. Routine
microbiology testing at study site,
samples stored and retrospectively
tested by seven GPP assays at the
study site
Comparator: bacteria – culture.
C. difficile – EIA and culture.
Parasites – microscopy. Viruses –
rapid antigen detection tests.
Assumed that all patients received
all mentioned conventional tests
GPP: xTAG on stored frozen
samples at study site
Verification: Stool samples positive
for one of the enteric viruses and
for Campylobacter spp. as well as
23 negative samples by GPP were
sent to a national reference centre
for confirmation and typing
Sensitivity, specificity,
positive predictive
value and negative
predictive value for
norovirus and
Campylobacter
Median age: 51 years
Range: 18–78 years
Male: 30/49 (61%)
Median
post-transplantation
term: 6.3 years (range
3 days to 24.2 years)
Immunocompromised:
49/49 (100%)
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
Deng et al. 2015;23
China; 1
xTAG 290 stool specimens of
290 diarrhoeal patients
Study set up: stool specimens
prospectively collected and
submitted to clinical laboratory.
All stool samples were tested for
all 17 pathogens using routine
methods using standard procedures.
All samples received single-plex PCR
and sequencing for C. difficile. All
samples received xTAG
Comparator: Disregarding what the
physician ordered, all samples were
tested for 17 pathogens at a clinical
laboratory. Bacteria – culture
confirmed by gene sequencing,
mass spectrometry or serotyping.
Viruses – immunochromatography.
Norovirus – real-time reverse-
transcription PCR. Parasites –
microscopy. C. difficile not tested
GPP: xTAG performed at study site
on all samples
Verification: samples discordant
between the routine tests and xTAG
were tested by single-plex PCR and
sequencing using primers from
published literature, which were
synthesised by Sangon Biotech
(Shanghai, China) (assumed to be
different from xTAG primers)
Agreement using
kappa coefficient test,
sensitivity and
specificityInpatients: 70/290
(24%)
Outpatients: 220/290
(76%)
Male: 186/290 (64%)
Median age: 25 months
Age range: 11 days to
83 years
Duong et al.
2016;24 Vietnam;
> 3
xTAG 479 patients
hospitalised with
diarrhoeal disease
Study set up: fresh stool was stored
at 4 °C at sites and transported to
the central study microbiology
laboratory within 24 hours. The
specimens were tested using
microbiological culture and real-time
PCR, then stored at –80 °C for xTAG
testing at study laboratory. All
samples were tested for Shigella,
Salmonella and Campylobacter by
culture and PCR, and all were tested
for adenovirus, norovirus and
rotavirus by PCR, culture and PCR
were evaluated separately
Comparator: All samples received all
tests for pathogens considered in
the study. Bacteria – culture and
PCR. Viruses – PCR
GPP: xTAG of all samples at study
laboratory
Verification: no verification
undertaken, sensitivity and specificity
were calculated for culture as gold
standard and for PCR as gold
standard
Sensitivity and
specificity
Adults age: median
50 years (IQR
33–64 years)
Children age:
16.5 months
(IQR 6.7–20 months)
Adult male: 36/92
(39%)
Children male:
221/387 (57%)
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
FDA 2012;25 USA,
Canada; 6
xTAG n= 1534 patients
(including outbreak
samples)
Study set up: prospective clinical
specimens were submitted fresh to
the sites and were processed
according to their routine algorithm
Comparator: conventional methods
were ordered by the referring
physician following routine
methods at sites, but these were
not included in analysis.
Comparator methods for all
prospective samples were
undertaken in central reference
laboratories. In the event that
comparator results were not
available for all targets on a given
specimen, the specimen in question
was excluded from performance
calculations of xTAG
Salmonella, Shigella, E. coli – culture.
Campylobacter – culture and PCR/
sequencing assay for Campylobacter-
positive samples. STEC – broth
enrichment and immunocard assay.
ETEC – four PCR/sequencing assays.
C. difficile – cytotoxicity assay.
Cryptosporidium, Giardia –
microscopy. Norovirus – real-time
PCR and conventional PCR with
bidirectional sequencing. Rotavirus –
EIA and PCR/sequencing assay
GPP: xTAG on all samples at six study
sites. 14 pathogens (excluding
Yersinia)
Verification: discrepant results
between the xTAG GPP and the
reference methods were evaluated
using analytically validated PCR/
sequencing assays (bidirectional
sequencing analysis) using primers
not covered by the xTAG GPP kit
primers or FDA-cleared molecular
assays (i.e. for C. difficile toxin),
central laboratories undertook
verification
Sensitivity and
specificity (positive
and negative per cent
agreements)
Male: 632 (44.9%)
Age: 12–21 years,
n= 51 (3.6%);
21–65 years, n = 879
(62.5%); > 65 years,
n= 426 (30.3%)
Subject status:
outpatients, n= 421
(29.9%); hospitalised
n= 804 (57.1%);
emergency department,
n= 118 (8.4%);
long-term care facility,
n= 18 (1.3%); not
determined, n= 46
(3.3%)
Immune status:
immunocompromised,
n= 493 (35%);
immunocompetent,
n= 758 (54%); not
determined, 156
(11.12%)
Gu et al. 2015;26
USA; 1
xTAG and
FilmArray
436 samples of 199
paediatric oncology
patients
Study set up: after routine clinical
testing, remnant samples were
stored at –80 °C for 30–44 months
before testing with GPP assays. All
samples were tested with xTAG
and FilmArray
Sensitivity and
specificity using
in-house methods as
reference standard
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
Comparator: standard-of-care
testing at study site on clinical
suspicion and subsequent ordering
of routine test (172 samples). In
addition to routine tests, astrovirus,
norovirus and sapovirus PCR were
tested on all samples, and standard
care tests plus multiplex PCRs for
three additional viruses made up
the comparator. Viruses – multiplex
PCR (adenovirus multiplex PCR
detected all serotypes not limited to
enteric adenovirus). Rotavirus – EIA.
Bacteria – culture. C. difficile – PCR.
Parasites – EIA
GPP: all samples received xTAG and
FilmArray at study site
Verification: no verification
undertaken, agreement was
reported either out of 172 patients
having received conventional
methods or out of 199 patients
having received comparator
Halligan et al.
2014;27 UK; 1
xTAG n= 2187 Study set up: clinicians were advised
to investigate all cases of diarrhoea
selecting tests from a menu
including bacteria (Campylobacter,
Salmonella, Shigella and E. coli
O157 with Vibrio and Yersinia
species available upon specific
request), norovirus (samples
received from children aged
≤ 5 years are automatically tested
for rotavirus and faecal adenovirus
in addition), parasites and C. difficile
testing that is either performed on
request or automatically on samples
from patients aged > 65 years.
Conventional testing was performed
7 days per week. Clinicians were
advised not to send samples for
bacterial culture if the onset of
symptoms was > 3 days following
hospital admission. Samples were
stored at 4 °C until testing was
complete. Clinicians were unable
to request a GPP test directly;
instead, whenever a request for
conventional testing was received,
a GPP request was included
Comparator: testing according to
physician’s request at study centre.
Bacteria – culture. C. difficile – EIA
followed by PCR. Viruses – EIA.
Parasites – microscopy
Agreement and
kappa, sensitivity and
specificity were not
calculated because
of the lack of a
comparable reference
standard or resolving
assay
Hospital-associated
cases: 1201/2187
(55%)
Community-associated
cases: 986/2187 (45%)
continued
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TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
GPP: all samples received xTAG at
study centre. Samples were batched
for DNA extraction at 16.00
Monday–Thursday, further analysis
commenced the following morning
with results available at 15.00.
Alternative run on Friday at 10.00
for late evening or Saturday
reporting
Verification: assumption that xTAG
results are correct, no verification
undertaken
Mengelle et al.
2013;29 France; 1
xTAG 440 samples of 329
diarrhoeic patients
Study set up: prospectively
collected stool samples, C. difficile
and E. coli pathovars tested in
all samples from children, but only
in those from certain adults:
post-antibiotherapy diarrhoea and
nosocomial outbreaks for toxigenic
C. difficile or an epidemiological
infection for STEC. Conventional
and GPP undertaken at study site
Comparator: all had at least one
conventional test according
to physician’s judgement.
Bacteria – culture. C. difficile –
immunochromatographic
test. Viruses – rapid
immunochromatographic test.
Parasites – microscopy
GPP: xTAG on all samples at study
site
Verification: samples showing
discrepant adenovirus results were
tested with an in-house real-time
PCR
Proportions of positives
by conventional and
GPP method and
McNemar’s testImmunosuppressed
hospitalised patients:
(1) 102 adult organ
transplant recipients
(mean age 50.6 years,
median 56 years, range
17–75 years); (2) 50
immunocompromised
children (mean age
5 years, median 7 years,
range 0–14 years);
(3) 56 children
attending the neonatal
unit (aged < 1 year);
and (4) 121 children
attending the
emergency unit (mean
age 2.80 years,
median 9 years, range
0–16 years) were
considered to be
outpatients
Pankhurst et al.
2014;30 UK; 1
xTAG n= 839 Study set up: a retrospective study of
fixed numbers of samples positive
for C. difficile, Campylobacter spp.,
Salmonella spp. and norovirus,
plus samples negative for all these
pathogens. All samples collected
were initially sent to the service
microbiology laboratory for faecal
culture and/or C. difficile toxin
testing by hospital-based doctors or
GPs as a result of a suspected enteric
infection. xTAG was undertaken at
the study site on all samples
Sensitivity and
specificity
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discrepant adenovirus results only by Mengelle et al.29 The remaining three studies,24,26,27 which did not
undertake verification, assumed either that the comparator methods are the reference standard to calculate
sensitivity and specificity24,26 or assumed that the GPP assay is correct and did not calculate sensitivity and
specificity because of the lack of a resolving assay.27 The verification results are summarised in Analysis of
discordant results.
Comparator assays varied considerably between studies. Testing included different pathogens and different
assays according to the routine diagnostic algorithms in place at the study sites. Pankhurst et al.30 only
included the most common four pathogens for conventional testing by selecting fixed numbers of samples
positive for C. difficile, Campylobacter, Salmonella and norovirus. The xTAG GPP Luminex trial25 did not
evaluate test samples using traditional conventional methods within routine laboratory analysis, instead
testing all samples at a reference laboratory; the FilmArray BioFire trial20 only considered conventional
culture results as undertaken by a routine laboratory while the presence of other pathogens was tested at
BioFire with various methods and a combination of methods. Gu et al.26 added multiplex PCR testing to
the in-house methods for four viruses that were not routinely tested for, creating a comparator of in-house
TABLE 7 Overview of study characteristics of studies reporting full 2 × 2 table data of test agreement (continued )
Study reference;
location; number
of centres GPP test
Population; sample
size; characteristics Study design
Agreement
outcome reported
Comparator: initial diagnosis of
the target faecal pathogens was
performed in accordance with
PHE guidelines in the service
microbiology laboratory for faecal
culture and/or C. difficile toxin
testing requested by hospital-based
doctors or GPs. All 839 patients had
results for all four pathogens
GPP: all samples were tested for all
15 pathogens, but only comparison
conventional testing for four most
common: C. difficile, Campylobacter
spp., Salmonella spp. and norovirus,
different laboratory to conventional
testing. C. difficile – EIA testing for
toxins A and B with subsequent
serological and sensitivity testing.
Salmonella and Campylobacter –
culture. Norovirus: not reported
Verification: unexpectedly positive or
negative for target organisms were
retested in duplicate using qPCR
assays, same laboratory, not blinded
samples. Positive on standard
reference microbiology but negative
on xTAG and confirmed negative on
qPCR were considered negative, and
samples negative on standard
reference microbiology but positive
on xTAG and confirmed positive on
qPCR were considered positive
EAEC, enteroaggregative E. coli; EIA, enzyme immunoassay; EPEC, enteropathogenic E. coli; ER, emergency room;
ETEC, enterotoxigenic E. coli; GI, gastrointestinal; GP, general practitioner; IC, immunocompromised; IQR, interquartile range;
IUO, investigational use only; NA, not applicable; qPCR, quantitative polymerase chain reaction; STEC, shiga toxin-producing E. coli.
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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methods consisting of conventional and multiplex PCR assays. In three studies21,27,29 participants received
conventional testing according to the physician’s request not to provide results for all pathogens, for all
included patients. Only Deng et al.23 and Coste et al.22 tested all patients with conventional methods,
irrespective of whether or not they were requested by the physician. Two studies tested all samples with
comparator methods, but these were not equivalent to conventional methods of the PHE algorithm.20,25 In
three studies,22,24,30 samples had received all conventional methods, but the studies only looked at a limited
number of pathogens, and Gu et al.26 constructed a comparator for which conventional methods were
undertaken according to the physician’s judgement, but additional testing for astrovirus, norovirus and
sapovirus was undertaken for all samples.
Use of GPP testing showed less variation across studies; 2 × 2 data were available from nine studies21–27,29,30
for xTAG and from two studies20,26 for FilmArray. Of interest is the batching method reported by Halligan
et al.,27 who batched samples for DNA extraction at 16.00 Monday–Thursday and subsequent analysis of
samples the following morning with results available at 15.00. Alternative runs took place on Friday at
10.00 for late evening or Saturday reporting. This is the only study reporting details of batching of samples.
The majority of studies21–26,30 reported sensitivity and specificity using either GPP or conventional tests as a
reference standard; these estimates were not used within this review, which instead used the 2 × 2 table data
from the studies to estimate the positive and negative agreement between the GPP and conventional tests.
Quality considerations of included studies
Quality assessment for this review required significant adaptations to the QUADAS-2 tool to allow tailoring
to the research question. This is because no adequate reference standard is available for the assessment.
Furthermore, the comparator (the PHE algorithm) needed to be included in the quality assessment, in
effect as a further index test. GPP assays identify more pathogens and may be superior to conventional
microbiological methods; however, it is unlikely that GPP tests identify the same spectrum of information
as conventional methods. Although conventional methods generally identify viable pathogens, the GPP
assays detect the presence of microbial nucleic acids that may result from any non-infective colonisation,
dead pathogen or disease-causing pathogen.
A further challenge for quality appraisal involved assessing study quality at the overall study level while the
outcomes of the test accuracy studies were considered at the pathogen level. GPP testing systems evaluate
a panel of pathogens each with their own test accuracy, threshold, prevalence and clinical importance.
However, analyses at the pathogen level meant that varying inclusion within different versions of GPP
panels (such as ‘investigational use only’ versions) did not present an applicability concern in this
assessment; this only resulted in varying outcomes according to the number of pathogens evaluated.
The ideal study design of a test–treat trial is shown in Table 8. In the absence of a test–treat trial, the test
accuracy study design that we consider feasible for the evaluation of GPP tests is detailed (Table 9). This
study has been assumed to be a minimum requirement for a study of test accuracy to answer the research
question, and the relevant retrieved studies were assessed against this ideal study design.
As there was no independent and reliable reference standard, we sought an independent and unbiased
umpire test, used in the studies to assess discordant results between index test and conventional methods
[e.g. exposure, treatment effect (pathogen-specific treatment) or self-reported symptoms, previous
antibiotic treatment, over-the-counter medication].
Verification of discordant results by retesting, by optimising the index test and conventional methods, or by
undertaking individual PCRs with primers different from the primers used in the GPP assay remain biased,
as PCR assays are not sufficiently different from GPP tests, which are also based on PCR methodology and,
therefore, should provide verification results favouring GPP findings.
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In addition to the ideal study design, we defined a theoretical comparator test based on the PHE
algorithm.8 The definition considered for the quality appraisal is described in Definitions for the review.
Assessment of risk of bias and applicability of study outcomes to the research question
The assessment of risk of bias and applicability for the 23 studies included in the review using the QUADAS-2
tool are summarised in Table 10 and Figure 4.
Risk of bias
In general, the methodological and reporting quality of the included studies was poor. Specifically, none of
the studies used a reference standard against which the index tests and comparators (e.g. routine tests, PHE
algorithm) could be reliably evaluated and compared. Instead, in most studies the index tests were compared
with the routine tests/algorithms. Discrepant results between the two tests (GPP positive and routine test
negative) were verified using confirmatory tests that were not adequately independent of index/routine tests.
In many cases, the routine tests were not performed for all pathogens specified in the GPP and not all samples
received the comparator (routine) tests for all pathogens. Some studies included more than one sample
(or episode) per patient, which may have led to double counting within measures of agreement.
In up to 65% of the studies it was not clear how stool samples (or patients) were selected, and only 9% of
the studies were rated as having a low risk of bias with regard to the patient selection domain (domain 1:
TABLE 9 Study design of the ideal study of test accuracy for GPP tests
Criterion Details
Population Consecutive series of diarrhoeal patients with suspected gastroenteritis who are eligible for
routine laboratory testing
Setting Microbiology laboratory centrally or within a hospital receiving samples from hospital and
community patients
Index test xTAG, FilmArray or Faecal Pathogens B
Comparator Conventional tests according to the PHE standard
Reference standard/fair
umpire
Independent test relative to comparator and index test that may be imperfect but unbiased
(fair umpire) to investigate discordant results
Study design Prospective cohort receiving the comparator and at least one index test with follow-up of
discordant results
Outcome Comparison of characteristics of discordant results in cells b (GPP positive, conventional test
negative) and c (GPP negative, conventional test positive) using a fair umpire test such as
exposure (travellers, hospitalised patients, immunocompromised, small children), treatment
effect (pathogen-specific treatment) or self-reported symptoms, previous antibiotic treatment and
over-the-counter medicine, to allow unbiased assessment of the direction of resolution of
discordant results in favour of either the index test or the comparator
TABLE 8 Desirable test–treat trial design for the assessment of GPP tests
Criterion Details
Population Consecutive series of diarrhoeal patients with suspected gastroenteritis who are eligible for
routine laboratory testing
Setting Microbiology laboratory centrally or within a hospital receiving samples from hospital and
community patients
Index test xTAG, FilmArray or Faecal Pathogens B
Comparator Conventional tests according to the PHE standard
Study design Prospective cohort randomised to either the index test or the comparator
Outcome Morbidity, mortality, management (e.g. length of hospital stay and length of isolation),
treatment
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patient selection). The selection process in the remaining 25% of the studies was rated as being at a high risk
of bias. The use and interpretation of the index test (i.e. GPPs) was associated with a low risk of bias in about
75% of the studies (domain 2: index tests) because these tests were used on all samples independently (the
GPP results were not influenced by the knowledge of routine test results), with a pre-specified threshold, and
were implemented according to recommendations by the manufacturer. In contrast, almost all studies were
rated being at a high risk of bias with regard to the use and interpretation of the comparator (i.e. routine)
tests, mainly as a result of no pre-specified threshold (domain 3: comparator). In 65% of the studies, the use
of verification tests (domain 4: reference standard) was associated with a high risk of bias. No verification
tests were used in 8 (35%) studies (risk of bias not applicable). The between-test intervals and patient/sample
flow for at least 80% of studies were rated as being at a high risk of bias (domain 5: flow and timing), with
only two studies at a low risk of bias.23,30
Applicability of study findings
The applicability of study findings was assessed with regard to four domains: patient selection, index test
(i.e. GPPs), comparator (i.e. routine tests) test and reference standard (i.e. verification tests). In approximately
45% of the studies, the degree of applicability of the included patients was of low concern. The other 45%
of the studies had a high concern for applicability. For the remaining two studies (9%), the applicability
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FIGURE 4 Concerns regarding (a) bias; and (b) applicability in included studies. NA, not applicable.
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of included population could not be determined.31,32 For at least 70% of studies, there was a low concern
for the applicability of the index tests. Only two studies19,32 were rated as having high concern for the
applicability with respect to the index tests (because of deviations from the manufacturer’s instructions:
timing, storage or extraction). The applicability of a comparator was of low concern for six studies
(26.1%)12,21,26,27,29,36 and of high concern for 16 studies (69.6%),11,19,20,22–25,28,30–34,37–39 in which the comparator
methods were not consistent with those specified for the PHE algorithm. The applicability concern for a
reference standard (i.e. verification tests) was high for all 15 studies using such tests.11,12,20–23,25,29–34,38,39 The
remaining eight studies did not use the verification tests (not applicable).19,24,26–28,35–37
Agreement between gastrointestinal pathogen panel tests and conventional methods
Evidence retrieved approximated to a mixed population of acute and hospitalised patients, as the studies did
not adequately report outcomes by setting or subgroup. No subgroup analysis could be undertaken as a result
of a lack of data, more specifically for patients in the community, patients in hospital, children aged < 5 years,
patients with recent foreign travel and patients who are immunocompromised. Sensitivity analyses limited
to UK studies only, or studies judged as equivalent to the PHE algorithm, were not undertaken because,
methodologically, all studies had substantial quality issues. The review identified only three studies from the
UK: Halligan et al.27 provided only conventional testing by clinician request, Perry et al.32 did not report
pathogen-level data and Pankhurst et al.30 considered only four pathogens in the comparison of xTAG versus
conventional methods. Assessing the equivalence of the conventional methods with the PHE algorithm was
pragmatic and did not take into account that the standard is interpreted differently in different laboratories.
These sensitivity analyses were not pre-planned and may lead to overanalysing weak evidence. Accepting
the limitations of the studies, Halligan et al.27 provides the largest UK study, which might be the most
representative of the NHS setting. No one study could be found to adequately characterise the PHE pathway.
Pathogen-level positive and negative agreement
Pathogen-level meta-analysis of positive and negative agreement was undertaken. The 2 × 2 data of
test agreement, by pathogen, for the studies eligible for inclusion in the meta-analysis are reported in
Appendix 7. The meta-analytic outcomes reported in Agreement between xTAG and the comparator and
Agreement between FilmArray and conventional methods are of an exploratory nature, summarising the
available evidence and illustrating patterns in the data as well as heterogeneity. When considering the
results, the following caveats apply.
l The results do not reflect the performance of the tests, but the agreement between the GPP test and
the comparator.
l These findings are typically heterogeneous, probably reflecting both methodological and statistical
heterogeneity and drawing from studies of variable quality.
l Analyses are presented at the pathogen level, requiring independence assumptions both within and
between pathogens (i.e. repeat samples of the same patient are not included and having one
pathogen does not affect the likelihood of having another pathogen).
l The comparator used in studies does not sufficiently align with the conventional methods described in
the PHE algorithm8 in the majority of studies, as described in Definitions for the review.
l Pooled summary estimates (across pathogens) have been included for information; however, these
pooled estimates are not weighted by the prevalence of the different pathogens and include varying
multiple usage of samples for which studies have tested samples with varying components of the
conventional panel of tests, thus violating the independence assumption.
Agreement between xTAG and the comparator
Table 11 reports the positive (a/a + c) and negative (d/b+ d) agreement between xTAG and conventional
methods when conventional methods are the benchmark. When conventional testing provides the benchmark,
virtually all positive cases found by xTAG are confirmed by conventional testing, leading to generally high levels
of positive agreement findings. There are few additional positives identified by xTAG compared with the vast
majority of specimens that are pathogen negative; thus, negative agreement remains high.
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TABLE 11 Positive and negative agreement: xTAG vs. conventional testing (benchmark)
RE LCI UCI
Number of studies
contributing Q p-value I2
Positive agreement
C. difficile 0.959 0.933 0.980 5 5.9 0.207 32%
Campylobacter 0.959 0.924 0.985 6 8.0 0.157 37%
E. coli O157 – – – – – – –
ETEC – – – – – – –
STEC – – – – – – –
Salmonella 0.818 0.666 0.934 5 30.8 0.000 87%
Shigella 0.989 0.949 1.000 3 3.6 0.164 45%
V. cholerae – – – – – – –
Yersinia enterocolitica – – – – – – –
Adenovirus 0.558 0.413 0.699 – – – –
Norovirus 0.927 0.893 0.956 7 10.9 0.093 45%
Rotavirus 0.958 0.920 0.985 3 2.9 0.240 30%
Cryptosporidium 0.914 0.794 0.989 1 – – –
E. histolytica – – – – – – –
Giardia 1.000 0.935 1.000 1 – – –
Negative agreement
C. difficile 0.968 0.933 0.991 7 128.0 0.000 95%
Campylobacter 0.968 0.950 0.982 10 83.7 0.000 89%
E. coli O157 0.995 0.990 0.998 6 10.8 0.055 54%
ETEC 0.988 0.964 1.000 4 23.7 0.000 87%
STEC 0.990 0.984 0.995 4 2.8 0.418 0%
Salmonella 0.940 0.866 0.986 10 726.0 0.000 99%
Shigella 0.985 0.965 0.997 8 120.0 0.000 94%
V. cholerae 1.000 0.998 1.000 4 0.1 0.988 0%
Y. enterocolitica 1.000 1.000 1.000 4 0.4 0.933 0%
Adenovirus 0.990 0.983 0.996 2 – – –
Norovirus 0.969 0.944 0.987 12 239.0 0.000 95%
Rotavirus 0.991 0.979 0.999 8 36.7 0.000 81%
Cryptosporidium 0.989 0.954 1.000 5 77.4 0.000 95%
E. histolytica 0.991 0.979 0.998 5 20.5 0.000 81%
Giardia 0.989 0.970 0.999 7 46.4 0.000 87%
Overall agreement
Positive 0.929 0.898 0.955 33 188.3 0.000 83%
Negative 0.982 0.976 0.988 101 2080.8 0.000 95%
ETEC, enterotoxigenic E. coli; LCI, lower confidence interval; RE, random-effects estimate, measure of agreement; STEC,
shiga toxin-producing E. coli; UCI, upper confidence interval.
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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Overall, more studies contributed to the calculation of negative than positive agreement as only studies
with sufficient numbers (denominator ≥ 20) were included in the analysis. For a number of pathogens,
E. coli O157, enterotoxigenic E. coli, shiga toxin-producing E. coli, V. cholerae, Yersinia enterocolitica and
E. histolytica (rare pathogens or no test requested by physician and marked as empty rows in Tables 6
and 7), limited data were available and, therefore, no positive agreement was estimated. Overall,
agreement is high (positive agreement 0.929 and negative agreement 0.982), with little variation between
pathogens for both positive and negative agreement. Positive agreement for adenovirus was an exception,
as positive agreement was considerably lower at 0.558. This is visualised in the forest plot in Figure 5.
Gu et al.26 reported that an additional 20 samples positive for adenovirus detected by comparator were a
result of the use of multiplex PCR, which detected all serotypes, whereas xTAG only detected adenovirus
40/41, resulting in the poor agreement of tests for this virus. However, it is important to note that for
enteric infections, adenovirus 40/41 is commonly implicated. In situations when a patient may have a
systemic infection affecting, for example, the respiratory or urinary tracts, then all adenovirus serotypes
should be looked for by multiplex PCR. Therefore, it is difficult to come to any firm conclusions about the
positive agreement because of the different parameters (type 40/41 vs. multiplex) that were assessed.
The outlying finding for Salmonella (Pankhurst et al.30), which is caused by a worryingly high number
of missed Salmonella infections by xTAG, is not as easily interpreted. Generally, both tests agreed in
terms of absence of pathogens, masking the relatively small number of disagreements. A forest plot
in Appendix 8 (see Figure 43) shows, however, that there are a few outliers when studies report a
significantly higher number of positives for certain pathogens with xTAG than conventional methods,
specifically Campylobacter and norovirus in a small study of 49 adult kidney transplant recipients22 and
Salmonella in a study in which bacteria were tested by PCR as well as culture.24
Used as a measure of overall heterogeneity of estimates, I2 is moderate (for positive agreement) to high
(for negative agreement) at the pathogen level.
Table 12 shows the positive (a/a + b) and negative (d/c + d) agreement when xTAG is considered the
benchmark. Strikingly, the positive agreement between xTAG and conventional methods is considerably
smaller when xTAG provides the benchmark.
The forest plot in Figure 6 visualises the inconsistency and variation in positive agreement between studies
across all pathogens. When xTAG is the benchmark, the positive cases ‘missed’ by conventional testing
have a considerable impact of the positive agreement findings.
As the positive agreement overall is 0.678 (95% CI 0.580 to 0.770), inverting these figures means that xTAG
finds about 1.5 times more pathology (95% CI 1.3 to 1.7), although this estimate does not reflect the
prevalence of individual pathogens. Negative agreement was consistently very high across studies and
pathogens (see Appendix 8, Figure 44) with the exception of Gu et al.,26 discussed previously. Heterogeneity
is moderate to high when considering I2, and is higher for positive agreement than for negative agreement.
Agreement between FilmArray and conventional methods
Only two studies contributed to the evaluation of FilmArray; therefore, the agreement between FilmArray
and conventional methods is based on one or two studies across the range of pathogens. Table 13 reports
the positive (a/a + b) and negative (d/c + d) agreement between FilmArray and conventional methods
when benchmarked against conventional methods. Positive agreement is very high for all pathogens,
with the same study (Gu et al.26) contributing an outlier value for adenovirus for FilmArray, as was the
case for xTAG (Figure 7). Negative agreement is consistently high for all studies across all pathogens
(see Appendix 8, Figure 45).
When benchmarked against FilmArray, positive agreement between FilmArray and conventional methods
is lower (0.82 vs. 0.95) (Table 14) with greater variability across pathogens (Figure 8), whereas negative
agreement (see Appendix 8, Figure 46) is consistently high, with the exception of Gu et al.26 once again.
Heterogeneity is not reported, as only one or two studies contributed data per pathogen.
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Heterogeneity between groups: p < 0.0001
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FIGURE 5 Positive agreement: xTAG vs. conventional testing (benchmark). G2, genogroup 2; RE, random-effects
estimate. Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed
under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
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TABLE 12 Positive and negative agreement: conventional testing vs. xTAG (benchmark)
RE LCI UCI
Number of studies
contributing Q p-value I2
Positive agreement
C. difficile 0.801 0.594 0.948 5 124.0 0.000 97%
Campylobacter 0.639 0.398 0.849 7 167.0 0.000 96%
E. coli O157 0.750 0.534 0.920 1 – – –
ETEC – – – – – – –
STEC – – – – – – –
Salmonella 0.484 0.278 0.693 8 173.0 0.000 96%
Shigella 0.734 0.381 0.971 3 61.6 0.000 97%
V. cholerae – – – – – – –
Y. enterocolitica – – – – – – –
Adenovirus 0.570 0.425 0.710 2 – – –
Norovirus 0.774 0.584 0.920 8 215.0 0.000 97%
Rotavirus 0.924 0.853 0.975 3 6.5 0.039 69%
Cryptosporidium 0.508 0.407 0.608 2 – – –
E. histolytica – – – – – – –
Giardia 0.337 0.237 0.444 2 – – –
Negative agreement
C. difficile 0.996 0.992 0.999 7 11.1 0.084 46%
Campylobacter 0.998 0.994 1.000 10 37.4 0.000 76%
E. coli O157 1.000 1.000 1.000 6 3.4 0.637 0%
ETEC 0.999 0.996 1.000 4 3.0 0.393 0%
STEC 1.000 0.998 1.000 4 4.9 0.182 38%
Salmonella 0.992 0.980 0.999 10 94.4 0.000 91%
Shigella 1.000 0.999 1.000 8 12.0 0.099 42%
V. cholerae 1.000 0.999 1.000 4 3.5 0.326 13%
Y. enterocolitica 1.000 0.999 1.000 4 0.4 0.933 0%
Astrovirus 0.989 0.971 0.999 7 68.7 0.000 91%
Norovirus 0.995 0.990 0.998 12 34.9 0.000 69%
Rotavirus 0.998 0.992 1.000 8 29.3 0.000 76%
Cryptosporidium 1.000 0.999 1.000 5 2.0 0.743 0%
E. histolytica 1.000 0.999 1.000 5 3.5 0.481 0%
Giardia 1.000 1.000 1.000 7 1.8 0.941 0%
Overall agreement
Positive 0.678 0.580 0.770 41 1340.5 0.000 97%
Negative 0.998 0.997 0.999 101 429.2 0.000 77%
ETEC, enterotoxigenic E. coli; LCI, lower confidence interval; RE, random-effects estimate, measure of agreement;
STEC, shiga toxin-producing E. coli; UCI, upper confidence interval.
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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Heterogeneity between groups: p < 0.001 
Overall (I2 = 97%)
Halligan 201427
Subtotal (I2 = 96%)
Duong 201624 PCR
Adenovirus
Subtotal (I2 = 97%)
Cryptosporidium
Deng 201523 G2
Claas 201321
Deng 201523
Gu 201526
Pankhurst 201430
Duong 201624
Rotavirus
Salmonella
Subtotal (I2 = 97%)
Mengelle 201329
Deng 201523
FDA 201225
Claas 201321
Claas 201321
Halligan 201427
FDA 201225
Halligan 201426
Claas 201321
Claas 201321
Shigella
FDA 201225
Gu 201526
FDA 201225
Duong 201624 PCR
Subtotal (I2 = 69%)
Duong 201624 culture
Mengelle 201329
Duong 201624 PCR
Claas 201321 G2
FDA 201225
Duong 201624 culture
Pankhurst 201430
Norovirus
Claas 201321
Subtotal (I2 = 96%)
FDA 201225
Duong 201624 culture
Giardia
Pankhurst 201430
Deng 201523
Campylobacter
Subtotal
Duong 201624
Pankhurst 201430
Subtotal
Duong 201624 G1
Subtotal (I2 = 97%)
Halligan 201426
C. difficile
Study
0.678 (0.580 to 0.770)
0.455 (0.372 to 0.540)
0.935 (0.863 to 0.976)
0.801 (0.594 to 0.948)
0.925 (0.796 to 0.984)
0.881 (0.811 to 0.932)
0.910 (0.815 to 0.966)
0.763 (0.598 to 0.886)
0.920 (0.873 to 0.953)
0.967 (0.918 to 0.991)
0.774 (0.584 to 0.920)
0.871 (0.770 to 0.939)
0.556 (0.381 to 0.721)
0.185 (0.099 to 0.300)
1.000 (0.891 to 1.000)
0.912 (0.818 to 0.967)
0.924 (0.864 to 0.963)
0.430 (0.355 to 0.508)
0.234 (0.123 to 0.380)
0.667 (0.498 to 0.809)
0.755 (0.617 to 0.862)
0.357 (0.186 to 0.559)
0.846 (0.719 to 0.931)
0.505 (0.435 to 0.574)
0.952 (0.865 to 0.990)
0.924 (0.853 to 0.975)
0.435 (0.310 to 0.567)
0.333 (0.146 to 0.570)
0.396 (0.330 to 0.465)
0.816 (0.710 to 0.895)
0.125 (0.027 to 0.324)
0.440 (0.336 to 0.548)
0.909 (0.843 to 0.954)
0.732 (0.571 to 0.858)
0.639 (0.398 to 0.849)
0.093 (0.026 to 0.221)
0.181 (0.131 to 0.240)
0.911 (0.865 to 0.946)
0.806 (0.625 to 0.925)
0.337 (0.237 to 0.444)
0.821 (0.631 to 0.939)
0.625 (0.406 to 0.812)
0.508 (0.407 to 0.608)
0.750 (0.509 to 0.913)
0.734 (0.381 to 0.971)
0.383 (0.261 to 0.518)
0.484 (0.278 to 0.693)
RE (95% CI)
0.0 0.2 0.4
Proportion
0.6 0.8 1.0
Bacteria
Viruses
Parasites
E. coli O157
Claas 201321 0.750 (0.509 to 0.913)
Claas 201321 0.200 (0.057 to 0.437)
Subtotal (I2 = 98%) 0.570 (0.425 to 0.710)
Duong 201624 G2 0.955 (0.889 to 0.988)
FIGURE 6 Positive agreement: conventional testing vs. xTAG (benchmark). G1, genogroup 1; G2, genogroup 2;
RE, random-effects estimate. Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access
article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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TABLE 13 Positive and negative agreement: FilmArray vs. conventional testing (benchmark)
RE LCI UCI
Number of studies
contributing Q p-value I2
Positive agreement
C. difficile 0.967 0.937 0.989 2 – – –
Campylobacter 0.971 0.881 1.000 1 – – –
E. coli O157 – – – – – – –
EAEC 0.988 0.949 1.000 1 – – –
EPEC 0.991 0.976 0.999 1 – – –
ETEC 1.000 0.923 1.000 1 – – –
Plesiomonas shigelloides – – – – – – –
STEC 1.000 0.949 1.000 1 – – –
Salmonella 1.000 0.945 1.000 1 – – –
Shigella 0.959 0.881 0.999 1 – – –
Vibrio (parahaemolyticus,
vulnificus and cholerae)
– – – – – – –
V. cholerae – – – – – – –
Y. enterocolitica – – – – – – –
Adenovirus 0.722 0.606 0.826 2 – – –
Astrovirus – – – – – – –
Norovirus 0.932 0.866 0.979 2 – – –
Rotavirus – – – – – – –
Sapovirus 1.000 0.963 1.000 1 – – –
Cyclospora cayetanensis – – – – – – –
Cryptosporidium – – – – – – –
E. histolytica – – – – – – –
Giardia 1.000 0.916 1.000 1 – – –
Negative agreement
C. difficile 0.971 0.962 0.979 2 – – –
Campylobacter 0.987 0.981 0.993 2 – – –
E. coli O157 0.968 0.930 0.993 2 – – –
EAEC 0.982 0.974 0.988 1 – – –
EPEC 0.972 0.961 0.980 1 – – –
ETEC 0.994 0.990 0.997 1 – – –
P. shigelloides 0.990 0.985 0.995 1 – – –
STEC 0.997 0.993 0.999 1 – – –
Salmonella 0.998 0.994 1.000 2 – – –
Shigella 1.000 0.998 1.000 2 – – –
Vibrio (parahaemolyticus,
vulnificus and cholerae)
0.999 0.997 1.000 1 – – –
V. cholerae 1.000 0.997 1.000 2 – – –
Y. enterocolitica 1.000 1.000 1.000 2 – – –
Adenovirus 0.993 0.987 0.997 2 – – –
Astrovirus 1.000 0.998 1.000 2 – – –
Norovirus 0.991 0.985 0.995 2 – – –
Rotavirus 0.995 0.990 0.998 2 – – –
Sapovirus 0.994 0.989 0.997 2 – – –
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TABLE 13 Positive and negative agreement: FilmArray vs. conventional testing (benchmark) (continued )
RE LCI UCI
Number of studies
contributing Q p-value I2
C. cayetanensis 1.000 0.999 1.000 1 – – –
Cryptosporidium 1.000 0.997 1.000 2 – – –
E. histolytica 1.000 0.999 1.000 1 – – –
Giardia 1.000 0.997 1.000 2 – – –
Overall agreement
Positive 0.954 0.897 0.991 14 129.4 0.000 89%
Negative 0.996 0.993 0.998 35 295.6 0.000 88%
EAEC, enteroaggregative E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; LCI, lower confidence interval;
RE, random-effects estimate, measure of agreement; STEC, shiga toxin-producing E. coli; UCI, upper confidence interval.
Heterogeneity between groups: p < 0.001
Overall (I2 = 89%)  
Buss 201520
Buss 201520
ETEC
STEC
EAEC
Buss 201520
Giardia
EPEC
Buss 201520
Adenovirus
Buss 201520
Shigella
Buss 201520
Gu 201526
Salmonella
Buss 201520
Buss 201520
Study
Buss 201520
Subtotal
Buss 201520
Norovirus
Buss 201520
Subtotal
Campylobacter
Sapovirus
Buss 201520
Subtotal
Gu 201526
C. difficile
Gu 201526
0.954 (0.897 to 0.991)
0.971 (0.851 to 0.999)
1.000 (0.894 to 1.000)
1.000 (0.888 to 1.000)
0.988 (0.957 to 0.999)
0.959 (0.860 to 0.995)
0.991 (0.973 to 0.998)
0.130 (0.028 to 0.336)
1.000 (0.923 to 1.000)
0.988 (0.935 to 1.000)
RE (95% CI)
1.000 (0.846 to 1.000)
0.722 (0.606 to 0.826)
1.000 (0.832 to 1.000)
0.945 (0.849 to 0.989)
0.932 (0.866 to 0.979)
0.955 (0.845 to 0.994)
0.967 (0.937 to 0.989)
0.812 (0.674 to 0.911)
0.903 (0.742 to 0.980)
0.0 0.2 0.4 0.6 0.8 1.0
Proportion
Bacteria
Viruses
Parasites
FIGURE 7 Positive agreement: FilmArray vs. conventional testing (benchmark). EAEC, enteroaggregative E. coli; EPEC,
enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; RE, random-effects estimate; STEC, shiga toxin-producing E. coli.
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TABLE 14 Positive and negative agreement: conventional testing vs. FilmArray (benchmark)
RE LCI UCI
Number of studies
contributing Q p-value I2
Positive agreement
C. difficile 0.817 0.766 0.864 2 – – –
Campylobacter 0.586 0.456 0.710 1 – – –
E. coli O157 – – – – – – –
EAEC 0.752 0.667 0.829 1 – – –
EPEC 0.902 0.869 0.931 1 – – –
ETEC 0.710 0.536 0.858 1 – – –
Plesiomonas shigelloides – – – – – – –
STEC 0.868 0.739 0.961 1 – – –
Salmonella 0.838 0.699 0.942 1 – – –
Shigella 0.959 0.881 0.999 1 – – –
Vibrio (parahaemolyticus,
vulnificus and cholerae)
– – – – – – –
V. cholerae – – – – – – –
Y. enterocolitica – – – – – – –
Adenovirus 0.764 0.641 0.868 1 – – –
Astrovirus – – – – – – –
Norovirus 0.851 0.771 0.917 2 – – –
Rotavirus – – – – – – –
Sapovirus 0.780 0.664 0.877 1 – – –
Cyclospora cayetanensis – – – – – – –
Cryptosporidium 0.750 0.555 0.906 1 – – –
E. histolytica – – – – – – –
Giardia 0.741 0.557 0.891 1 – – –
Negative agreement
C. difficile 0.998 0.994 1.000 2 – – –
Campylobacter 1.000 0.999 1.000 2 – – –
E. coli O157 1.000 0.989 1.000 2 – – –
EAEC 0.999 0.997 1.000 1 – – –
EPEC 0.997 0.994 1.000 1 – – –
ETEC 1.000 0.999 1.000 1 – – –
P. shigelloides 1.000 0.999 1.000 1 – – –
STEC 1.000 0.999 1.000 1 – – –
Salmonella 1.000 1.000 1.000 2 – – –
Shigella 1.000 0.998 1.000 2 – – –
Vibrio (parahaemolyticus,
vulnificus and cholerae)
1.000 0.999 1.000 1 – – –
V. cholerae 1.000 1.000 1.000 2 – – –
Y. enterocolitica 1.000 1.000 1.000 2 – – –
Adenovirus 0.997 0.993 0.999 2 – – –
Astrovirus 1.000 0.998 1.000 2 – – –
Norovirus 0.998 0.995 1.000 2 – – –
Rotavirus 1.000 1.000 1.000 2 – – –
Sapovirus 1.000 0.999 1.000 2 – – –
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TABLE 14 Positive and negative agreement: conventional testing vs. FilmArray (benchmark) (continued )
RE LCI UCI
Number of studies
contributing Q p-value I2
C. cayetanensis 1.000 0.999 1.000 1 – – –
Cryptosporidium 1.000 1.000 1.000 2 – – –
E. histolytica 1.000 0.999 1.000 1 – – –
Giardia 1.000 1.000 1.000 2 – – –
Overall agreement
Positive 0.820 0.761 0.872 15 72.3 0.000 81%
Negative 1.000 0.999 1.000 36 171.5 0.000 80%
EAEC, enteroaggregative E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; LCI, lower confidence interval;
RE, random-effects estimate, measure of agreement; STEC, shiga toxin-producing E. coli; UCI, upper confidence interval.
Heterogeneity between groups: p < 0.001
Overall (I2 = 81%)
Buss 201520
Buss 201520
Giardia
ETEC
Gu 201526
EPEC
Subtotal
Cryptosporidium
Buss 201520
Salmonella
STEC
Buss 201520
Buss 201520
Buss 201520
Buss 201520
Sapovirus
Norovirus
Buss 201520
Buss 201520
Buss 201520
Adenovirus
EAEC
Buss 201520
Shigella
Subtotal
Gu 201526
Buss 201520
Campylobacter
Buss 201520
C. difficile
Study
0.820 (0.761 to 0.872)
0.764 (0.630 to 0.868)
0.743 (0.624 to 0.840)
1.000 (0.877 to 1.000)
0.851 (0.771 to 0.917)
0.902 (0.866 to 0.931)
0.780 (0.653 to 0.877)
0.741 (0.537 to 0.889)
0.710 (0.520 to 0.858)
0.959 (0.860 to 0.995)
0.586 (0.449 to 0.714)
0.799 (0.737 to 0.852)
0.868 (0.719 to 0.956)
0.752 (0.660 to 0.830)
0.817 (0.766 to 0.864)
0.886 (0.754 to 0.962)
0.750 (0.533 to 0.902)
0.838 (0.680 to 0.938)
RE (95% CI)
0.0 0.2 0.4 0.6 0.8 1.0
Proportion
Bacteria
Viruses
Parasites
FIGURE 8 Positive agreement: conventional testing vs. FilmArray (benchmark). EAEC, enteroaggregative E. coli; EPEC,
enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; RE, random-effects estimate; STEC, shiga toxin-producing E. coli.
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As positive agreement overall is 0.820 (95% CI 0.761 to 0.872), inverting these figures means that
FilmArray finds about 1.2 times more pathology than conventional testing (95% CI 1.1 to 1.3), although
this estimate does not reflect the prevalence of individual pathogens.
Aetiology of additional positive findings
Studies typically reported overall levels of detection of pathogens in addition to providing pathogen-level
analysis (several studies only provided this overall analysis). Additional pathogens could arise in part
because of a greater ‘sensitivity’ to detect specific pathogens, but also because of a greater coverage of
pathogens within the GPP system than in the conventional method. Studies were reviewed to ascertain the
extent of these two sources of additional positive findings, because simply reporting the total number of
pathogens detected may mislead by confounding these issues.
Table 15 summarises the ascertainment of positive results. Studies reported this issue in a varying manner,
but the agreement findings illustrate that GPP testing produces a greater number of pathogen-positive
findings than conventional testing, and the extent to which greater overall pathology arises from the
number of tests within the GPP system or a higher level of pathogen detection is inconclusive.
Even in the studies in which the comparator was largely PCR based, GPP methods identified more pathogens.25
Only three studies reported more additional samples with conventional testing than with GPP.11,26,38 Gu et al.26
reported that 20 of the additional samples with conventional testing were positive for adenovirus by multiplex PCR,
which detected all serotypes, whereas GPP assays detected only adenovirus 40/41. Beckmann et al.11 detected
parasites in travellers using microscopy and detected additional parasites that were not available on the GPP test.
Similarly, in Wessels et al.,38 51 out of 55 additional positives by conventional methods were pathogens not present
on the panel test.
Eight studies characterised the additional GPP positives by judging whether they were primarily a result of
greater ‘sensitivity’ or greater coverage.11,21,22,28,29,32,34,38 Proportions varied across studies and clearly
depended on how well the conventional methods and GPP test agreed in terms of number and type of
pathogens tested for in individual samples.
Using two methods for the comparator, Duong et al.24 reported considerably more additional positives
when GPP was compared with culture rather than PCR. Conducted in Vietnam, this study reported a
coinfection rate of 58%, much higher than other studies (see Frequency and characterisation of multiple
infections), resulting in a number of additional positives.
There is some suggestion from the meta-analyses that additional positive case findings (above conventional
testing) may be greater with xTAG and FilmArray. However, this suggestion does not arise from a direct
comparison: only one or two studies contribute to evidence for FilmArray, there is considerable heterogeneity
between studies and the methods of pooling across pathogens do not reflect pathogen prevalence. Without
validation with a reliable reference standard, it remains unknown whether additional positives are true or
false positives; however, there is concern that at least some of the additional positives by panel testing are
false positives because they identify non-viable pathogens.
Analysis of discordant results
In the absence of a reference standard to verify test results, a small number of studies attempted to verify
samples that did not agree when tested with GPP and conventional methods (Table 16). In four studies,20,23,25,30
discordant samples were verified and results reported by pathogen, whereas one additional study only reported
that verification produced similar results to GPP testing.29 Verification methods were PCR based. Buss et al.20
aimed to analyse discordant samples using PCR and sequencing assays that targeted DNA sequences different
from both the FilmArray panel and the comparator method. Alternatively, if no distinct PCR assay was
available, discordant samples were retested by the original molecular tests using enhanced methods (including
up to 10 additional PCR cycles and up to 10 additional replicate samples) followed by sequencing. If still
discrepant, samples were tested with a bench-top version of the FilmArray panel followed by sequencing.
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Deng et al.23 sourced primers from the published literature for individual pathogens for single-plex PCR and
followed up results by sequencing. Similarly, the xTAG study in the FDA report25 used validated primers that
targeted genomic regions distinct from the xTAG GPP and followed up with bidirectional sequencing analysis
to confirm pathogen identification. Mengelle et al.29 used in-house real-time PCR to verify discordant results,
and Pankhurst et al.30 used single quantitative PCR for which the primers were probably different from xTAG.
Even though the verification methods differed from conventional methods and used different molecular
targets to GPP assays, they are not independent of the PCR methods used for either conventional methods
or GPP assays, and they would be expected to resolve discordant results in favour of PCR-based methods,
such as the GPP assays. Therefore, they are biased towards GPP testing. The findings are described briefly
and are not considered further in the assessment of the GPP assays or economic modelling. Discordant
analysis of GPP positive/conventional testing negative samples was generally in favour of GPP as anticipated;
however, analysis of GPP negative/conventional positive outcomes more often favoured conventional testing
(see Table 11). Discordant analysis failed to resolve all discordant samples and a considerable number of
discordant results remained inconclusive following testing.
No particular pattern for any specific pathogen emerges from the discordant analysis. Finally, no study
attempted independent verification of samples found to be pathogen positive by both methods.
Agreement between gastrointestinal pathogen panel tests in head-to-head
comparisons
There are few comparative data of different GPP tests. Khare et al.12 directly compared FilmArray with
xTAG and concluded that both assays identify more pathogens than conventional methods and both have
pathogens for which they do not appear to perform as well (FilmArray: Aeromonas, enteroaggregative
E. coli and enteropathogenic E. coli; xTAG: Y. enterocolitica and norovirus). Similarly, Gu et al.26 reported
that both assays detected similar numbers of pathogens with differences between the two tests not
reaching significance, considering either all pathogens on either panel (p = 0.34) or pathogens detectable
only with both systems (p = 0.24). Gu et al.26 reported differences in run failure rates when 10 out of
431 samples failed with xTAG, but none failed with FilmArray. A comparison of seven different multiplex
systems provided no further information for the current review as, apart from xTAG, all other systems
provided partial panel tests and the discrepancy in pathogens detected was significant.22
In the absence of concordance analyses in these studies, whether or not tests identify the same pathogens
in the same samples, no reliable assessment has been possible of the comparative performance of the
different GPP tests.
Secondary outcomes
Studies reported the following secondary outcomes: GPP run failure (n = 8),20,25,26,29,31,33,35,38 multiple infections
(n = 23),11,12,19–39 patient isolation (n = 2),27,34 turnaround times (n = 8),12,20,23,26–28,35,37 costs (n = 3)12,27,31 and
other outcomes (n = 4).22,27,31,34 No study reported on change in management by test outcome, health-related
quality of life, morbidity or mortality. Reported secondary outcomes are summarised in this section.
Run failures/invalid test results
Gastrointestinal pathogen panel run failure results were reported in nine studies (Table 17).20,25,26,29,31,33,35,38,39
In six studies,20,26,29,33,35,38 the run failure rate ranged from 0.8%20 to 7.8%.29 Some of the reasons for these
failures were ‘no call’, software error, loss of vacuum pressure in pouches or failed internal control. In one
study,29 there was a repeated pattern of 34 failures (7.8%) for each pathogen, suggesting that these failures
were test related rather than pathogen related. Likewise, reported failure rates were similar for each
pathogen in the FDA report.25 GPP failures appear much greater than for conventional testing when
considering failures reported in the FDA report, which recorded failures only for C. difficile with conventional
testing. Two other studies reported GPP run failure rates of ≥ 14%,25,31 and no explanations or reasons for
these failures were provided. Only one study using two GPP tests (xTAG and FilmArray) reported comparative
failure rates, with FilmArray producing no run failures whereas xTAG returned about 5%.26
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Test failures for conventional tests were reported for one study only,25 in which, for C. difficile toxin, the
test failure rate was 6.8% (95/1407), whereas for the remaining pathogens no failure was recorded
(Table 18).
Frequency and characterisation of multiple infections
Table 19 summarises multiple infections as a proportion of positive GPP samples in the included studies.
Multiple infections observed in the studies varied from 4%28,32 to 58%.24 The studies with the greatest
reported rate of multiple infections were from Vietnam (58%)24 and Côte d’Ivoire (54%).19 Although the
TABLE 17 Gastrointestinal pathogen panel run failures
Study reference
(GPP assay) Test failures for GPP samples, n/N (%) Comments, resolution and retesting
Buss et al. 201520 (FilmArray) 13/1557 (0.8) One initial run aborted by user; three runs
with software errors; nine runs with failed
internal control; retest resulted in 12 valid
results, one sample could not be retested
within 4 days and was excluded
FDA 201225 (xTAG) Campylobacter: 228/1407 (16.2) No reasons for failure were given
C. difficile toxin A/B: 196/1407 (13.9)
Cryptosporidium: 210/1407 (14.9)
E. coli: 238/1407 (16.9)
ETEC: 239/1407 (16.9)
Giardia: 232/1407 (16.5)
Norovirus: 210/1407 (14.9)
Rotavirus: 241/1407 (17.12)
Salmonella: 236/1407 (16.8)
STEC: 237/1407 (16.8)
Shigella: 234/1407 (16.6)
Gu et al. 201526 (xTAG and
FilmArray)
xTAG: 10/199 (5.0) Failed samples underwent repeat testing,
7/10 were resolved
FilmArray: no failures
Mengelle et al. 201329 (xTAG) 34/440 (7.8) for each pathogen
(the repeated pattern of failures
indicates that they were test related
rather than pathogen related)
Uninterpretable because internal control
was negative
Patel et al. 201431
retrospective (xTAG)
19% and 14%, respectively, for two
laboratories
1 : 10 dilution of samples and retesting
resulted in 3% total inhibition rate
Petterson et al. 201633
(XTAG)
Centre 1 (tertiary care): 4/145 (2.7) Repeatedly ‘no call’ samples that were
subsequently excluded from the analysis
Centre 2 (general hospital): 4/191 (2.1)
Spina et al. 201535 (FilmArray) 36/709 (5.1) Software error/loss of vacuum pressure in
pouches
Wessels et al. 201438 (xTAG) 30/393 (7.7) ‘No call’ xTAG 10-fold dilution of samples
reduced ‘no calls’ to 9/393
Zboromyrska et al. 201439
(xTAG)
NR The large number of initially inhibited
results was addressed by adding an
additional step to the GPP assay protocol:
dilution of all extracted samples (1 : 10 in
water) prior to amplification. Four of the
inhibited samples were not resolved
(negative by routine testing). No further
inhibited results were obtained
ETEC, enterotoxigenic E. coli; NR, not reported; STEC, shiga toxin-producing E. coli.
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TABLE 18 Conventional methods test failures
Study reference
(GPP assay)
Test failures for conventional
method samples, n/N (%) Comments, resolution and retesting
FDA 201225 (xTAG) Campylobacter: 0/1407 (0.0) Inhibited results were presented as ‘invalid’ for each
microbial target. No reasons for failure were given
C. difficile toxin A/B: 95/1407 (6.8)
Cryptosporidium: 0/1407 (0.0)
E. coli: 0/1407 (0.0)
ETEC: 0/1407 (0.0)
Giardia: 0/1407 (0.0)
Norovirus: 0/1407 (0.0)
Rotavirus: 0/1407 (0.0)
Salmonella: 0/1407 (0.0)
STEC: 0/1407 (0.0)
Shigella: 0/1407 (0.0)
ETEC, enterotoxigenic E. coli; STEC, shiga toxin-producing E. coli.
TABLE 19 Overview of multiple infections reported in included studies
Study reference, location
(GPP/population)
Number of coinfections per
positive GPP sample, n/N (%)
Three most commonly
involved pathogens
Becker et al. 2015,19 Côte d’Ivoire
(xTAG/community patients)
37/68 (54)a
l 2 pathogens: 15
l ≥ 3 pathogens: 22
NR
Beckmann et al. 2014,11 Switzerland
(xTAG/children and travellers)
8/87 (9) (5 in children, 3 in travellers)
l 2 pathogens: 8
l ≥ 3 pathogens: 0
Rotavirus, ETEC and C. difficile
Buss et al. 2015,20 USA (FilmArray/routine
stool samples for gastrointestinal testing
262/832 (31)
l 2 pathogens: 199
l ≥ 3 pathogens: 63
Plesiomonas shigelloides, ETEC
and adenovirus
Claas et al. 2013,21 the Netherlands, USA,
UK, Canada (xTAG/paediatric and adult
patients)
86/NR
l 2 pathogens: NR
l ≥ 3 pathogens: NR
C. difficile, norovirus and
Campylobacter
Coste et al. 2013,22 France (xTAG/adult
kidney transplant recipients)
7/36 (19)
l 2 pathogens: 7
l ≥ 3 pathogens: 0
Campylobacter, norovirus and
either Giardia, STEC or
rotavirus
Deng et al. 2015,23 China (xTAG/in- and
outpatients, adults and children with
diarrhoea)
35/193 (18)
l 2 pathogens: 29
l ≥ 3 pathogens: 6
NR
Duong et al. 2016,24 Vietnam (xTAG/
hospitalised patients with diarrhoea)
233/404 (58)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
Cryptosporidium, ETEC and
norovirus
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TABLE 19 Overview of multiple infections reported in included studies (continued )
Study reference, location
(GPP/population)
Number of coinfections per
positive GPP sample, n/N (%)
Three most commonly
involved pathogens
FDA 2012,25 USA, Canada (xTAG/mixed
setting, immunocompromised and
immunocompetent patients)
91/486 (19)
l 2 pathogens: 62
l ≥ 3 pathogens: 29
Norovirus, C. difficile and
Salmonella
Gu et al. 2015,26 USA (xTAG/
immunocompromised paediatric patients)
19/99 (19)
l 2 pathogens: 11
l ≥ 3 pathogens: 8
NR
Gu et al. 2015,26 USA (FilmArray/
immunocompromised paediatric patients)
14/94 (15)
l 2 pathogens: 14
l ≥ 3 pathogens: 2
NR
Halligan et al. 2014,27 UK (xTAG/
hospitalised patients with diarrhoea)
41/483 (8)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
C. difficile, rotavirus and
Salmonella
Kahlau et al. 2013,28 Germany (xTAG/
hospitalised patients with diarrhoea)
7/157 (4)
l 2 pathogens: 7
l ≥ 3 pathogens: 0
Norovirus, Salmonella and C.
difficile
Khare et al. 2014,12 USA (FilmArray/
routine stool samples for gastrointestinal
testing
86/318 (27)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
EPEC, Yersinia and norovirus
Khare et al. 2014,12 USA (xTAG/routine
stool samples for gastrointestinal testing)
44/312 (14)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
Norovirus, C. difficile and STEC
Mengelle et al. 2013,29 France (xTAG/
immunosuppressed adults and children,
children attending neonatal unit and
children attending emergency unit)
31/176 (18)
l 2 pathogens: 23
l ≥ 3 pathogens: 8
Rotavirus, norovirus and
Salmonella
Pankhurst et al. 2014,30 UK (xTAG/
hospitalised patients with diarrhoea)
45/561 (8)
l 2 pathogens: 42
l ≥ 3 pathogens: 3
Norovirus, C. difficile and
Campylobacter
Patel et al. 2014,31 USA (xTAG/paediatric
and adult patients; retrospective)
5/77 (6)
l 2 pathogens: 5
l ≥ 3 pathogens: 0
Norovirus, C. difficile and
rotavirus
Patel et al. 2014,31 USA (xTAG/paediatric
and adult patients; prospective)
5/86 (6)
l 2 pathogens: 5
l ≥ 3 pathogens: 0
C. difficile, norovirus and
Shigella
Perry et al. 2014,32 UK stored samples
(xTAG/patients from hospital and
community)
10/248 (4)
l 2 pathogens: 9
l ≥ 3 pathogens:1
C. difficile, norovirus and
rotavirus
Perry et al. 2014,32 UK concurrently tested
samples (xTAG/patients from hospital and
community)
6/155 (4)
l 2 pathogens: 5
l ≥ 3 pathogens: 1
C. difficile, norovirus and
Shigella
continued
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majority of multiple infections were double infections, Becker et al.19 identified three samples with
10 pathogens, and the FDA study25 reported one sample with seven pathogens. Spina et al.35 investigated
stool samples from in- and outpatients and concluded that multiple infections were mainly identified in
children aged < 5 years and outpatients. The three most frequent pathogens involved in multiple infections
varied between studies, with no clear pattern emerging.
Multiple infections in positive samples identified by the comparator were less frequently reported and the
number of pathogens detected was generally lower. Spina et al.35 reported that 5.4% (7/128) of positive
samples were positive for two pathogens using conventional methods, Stockmann et al.36 reported that 3.4%
(6/175) of positive samples were positive for multiple infections with conventional methods and Gu et al.26
reported that 2% (1/47) of samples tested positive for two pathogens using conventional methods. Deng
et al.23 reported a considerably higher rate of 16% (29/178) of multiple infections with conventional methods.
Patient isolation
Patient isolation as an outcome was reported in two studies (Table 20).27,34 In the study by Halligan et al.,27
a higher proportion of community-acquired inpatient cases versus hospital-acquired inpatient cases
were isolated (69.0% vs. 52.1%), but subsequently removed from isolation (60.1% vs. 41.6%; p < 0.01).
TABLE 19 Overview of multiple infections reported in included studies (continued )
Study reference, location
(GPP/population)
Number of coinfections per
positive GPP sample, n/N (%)
Three most commonly
involved pathogens
Petterson et al. 2016,33 USA Centre 2
(general hospital) (xTAG/uninsured primary
care patients)
5/47 (11)
l 2 pathogens: 4
l ≥ 3 pathogens: 1
Norovirus, Giardia and
Campylobacter
Petterson et al. 2016,33 USA Centre 1
(tertiary care) (xTAG/surgical, transplant
and oncology patients)
1/19 (5)
l 2 pathogens: 1
l ≥ 3 pathogens: 0
Norovirus and Giardia
Rand et al. 2015,34 USA (FilmArray/
hospitalised patients with diarrhoea)
NR EPEC, norovirus and EIEC/
Shigella
Spina et al. 2015,35 Europe (FilmArray/
community-acquired gastroenteritis in- or
outpatients)
64/384 (17)
l 2 pathogens: 49
l ≥ 3 pathogens: 15
EPEC, EAEC and
Campylobacter
Stockmann et al. 2015,36 USA (FilmArray/
children and young adults)
77/244 (32)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
NR
Vocale et al. 2015,37 Italy (xTAG/
hospitalised patients)
123/356 (35)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
C. difficile, norovirus and
Cryptosporidium
Wessels et al. 2014,38 the Netherlands
(xTAG/patients with gastrointestinal
complaints)
6/76 (8)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
NR
Zboromyrska et al. 2014,39 Spain
(xTAG/travellers)
20/70 (29)
l 2 pathogens: NR
l ≥ 3 pathogens: NR
Shigella, ETEC and EAEC
EAEC, enteroaggregative E. coli; EIEC, enteroinvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli;
NR, not reported; STEC, shiga toxin-producing E. coli.
a Joint number from GPP and conventional testing.
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
TABLE 20 Patient isolation
Study
reference,
country
Patient isolation, n/N (%)
Time spent in isolationIsolated
Removed
from
isolation Not removed from isolation
Halligan
et al.
2014,27 UK
Of the 409 CA cases, 282
(69.0%) were isolated and
127 (31%) were not
isolated
Of the 622 HA cases, 324
(52.1%) were isolated and
298 (47.9%) were not
isolated
CA cases:
246/409
(60.1)
HA cases:
259/622
(41.6)
CA cases: 36/409 (8.8%)
HA cases: 65/622 (10.5%)
Reason for not removing patients
from isolation after negative GPP
result:
l colonisation or infection with
multidrug-resistant organisms
(e.g. MRSA, VRE) – 41
l immunocompromised requiring
protective isolation – 17
l infection with respiratory viruses
(e.g. influenza, RSV, etc.) – 13
l no other bed available – 12
l patient safety and dignity – 11
l infection with respiratory
tuberculosis – 4
l infection with chickenpox – 2
l private patient – 1
Median isolation time
(number of days) by
pathogen
CA cases:
l C. difficile – 4
l Norovirus – 3
l Adenovirus – 1
l Rotavirus – 2
l Campylobacter – 2
l Salmonella – 4
l Shigella – 3
l E. coli O157 – 4
l Giardia – 2
l E. histolytica – 1
l Cryptosporidium – 2
HA cases:
l C. difficile – 10
l Norovirus – 8
l Adenovirus – 9
l Rotavirus – 13
l Campylobacter – 9
l Salmonella – 0
l Shigella – 4
l E. coli O157 – 6
l Giardia – 8
l E. histolytica – 9.5
l Cryptosporidium – 13.5
Rand et al.
2015,34 USA
GPP+/conventional– (n= 35):
l 21/35 (60.0%) not
isolated; 14/35 (40.0%)
isolated
GPP–/conventional–
(n= 123):
l 21/123 (17.0%)
isolated with other
reasons (e.g. MRSA,
VRE, multidrug-resistant
Gram organisms)
l 25/102 (24.6%)
isolated without any
definable reason
NR GPP–/conventional– (n = 102):
l 25/102 (24.6%) remained in
isolation (no definable reason)
GPP–/conventional– (n= 25):
l 181.22 patient-days
(range 0.3–31.16 days;
mean 7.2 (standard
deviation ± 7.8);
median 3.8;
IQR 1.8–11.0)
CA, community acquired; HA, hospital acquired; IQR, interquartile range; MRSA, meticillin-resistant S. aureus; NR, not
reported; RSV, respiratory syncytial virus; VRE, vancomycin-resistant enterococci.
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The same study found a tendency for the median number of days spent in isolation to be higher for patients
with hospital-acquired infection (range 0–13.5 days) than for those with community-acquired infection
(range 1–4 days). Rand et al.34 reported that isolation could have been averted in the 25 patients (out of the
102) who tested negative on GPP (24.6%). The median isolation time for these patients was 3.8 days
(interquartile range 1.8–11.0 days).
Turnaround times
The turnaround times for GPP testing were reported in seven studies (Table 21),12,20,23,26–28,35 of which two
compared timings with conventional methods.27,28 In two studies12,26 the results tended to demonstrate a
longer turnaround time for xTAG than for FilmArray. However, turnaround times may apply to different
throughputs, with FilmArray able to test up to eight samples (using eight units) at the same time and xTAG
able to run up to 96 samples. One study found that median turnover time was significantly shorter for
xTAG than for conventional methods (1 day vs. 3 days; p < 0.0005).28 One study reported a wide variability
in turnaround test times across different pathogens when using conventional methods.27 This study
reported separately the clinical and laboratory turnaround times for GPP testing, with clinical turnaround
times being much longer (41.8 hours vs. 26.6 hours), but suggested that xTAG pragmatically may provide
a next-day service with test outcomes, only available the following day, having allowed for batching.
TABLE 21 Turnaround times
Study reference, country Turnaround time (in days or hours)
Buss et al. 2015,20 USA FilmArray: about 1 hour per specimen
Deng et al. 2015,23 China xTAG: 5 hours
Gu et al. 2015,26 USA FilmArray: total run time was approximately 1 hour with approximately 5 minutes of
hands-on time
xTAG: total run time was approximately 6.5 hours with approximately 2.5 hours of
hands-on time, including the sample processing and data analysis
Halligan et al. 2014,27 UK Median clinical turnaround times: xTAG: 41.8 hours for afternoon testing, compared
with conventional methods (C. difficile, 17.3 hours; norovirus, 27.3 hours; adenovirus
and rotavirus, 27 hours; bacterial culture, 66.5 hours; parasites, 66.5 hours); time
includes sample collection and transport time
Laboratory turnaround time: xTAG 26.6 hours for afternoon run and 10.4 hours
for morning run. In 205/2187 (9.4%) patients, xTAG was returned the day after
collection and was significantly slower than the afternoon run
Kahlau et al. 2013,28 Germany Median turnover time (xTAG vs. conventional): 1 day (range 0.5–2 days) vs. 3 days;
p= 0.0000021
Khare et al. 2014,12 USA Processing time per run: FilmArray (2 minutes), xTAG (45 minutes)
Time/run: FilmArray (about 1 hour), xTAG (about 3.5 hours)
Throughput: FilmArray (1 specimen per run), xTAG (96 specimens per run)
Separate extraction required: FilmArray (no), xTAG (yes; about 45 minutes)
Spina et al. 2015,35 Austria, Ireland,
Finland, France, Germany, Greece,
Italy, Portugal, Romania and UK
FilmArray: The median number of days between sampling and testing at the central
study laboratory was 11 (IQR: 7 days)
Vocale et al. 2015,37 Italy,
the Netherlands
For conventional methods:
l bacterial isolation and drug resistance/susceptibility test – 72 hours
l microscopy – 24 hours
l amplification of a specific DNA fragment – 24 hours
l detection of a single virulence factor/toxin per test – 72 hours
l detection of a single antigen per test – 72 hours
IQR, interquartile range.
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One study only reported time taken using conventional methods, reflecting the common experience of
conventional testing taking up to 3 days to result and report.37
Costs
Three studies reported test-related costs (Table 22).12,27,31 GPP testing was reported to be more costly than
conventional tests (£150,641 for 2187 samples vs. £63,431 for 4467 samples).27,31 Among GPPs, FilmArray
was reported to be more costly than xTAG (£22,910 vs. £21,460 list price per instrument).12 These costs
reflect different fixed and variable cost assumptions and are reported for information only.
Other outcomes
Other outcomes (e.g. clinical management change, user acceptance, length of stay, technical hands-on
time) were reported for four studies and are summarised in Table 23.22,27,31,34
TABLE 23 Other outcomes
Study reference, country Other outcomes
Coste et al. 2013,22 France Management not changed as a result of GPP testing, but might be potentially
Intestinal endoscopy was performed in nine patients (18%). Endoscopy was performed if
symptoms persisted for > 21 days with negative microbiological analyses and/or
worsening symptoms (rectal haemorrhage, fever)
Immunosuppressive therapy switching or dose reduction was observed in 13/54 episodes
(24%)
Halligan et al. 2014,27 UK User acceptance: fast turnaround, enhanced infection and prevention control action
Conventional tests performed for every GPP test: 2
Patel et al. 2014,31 USA Technician hands-on time (hours): conventional vs. xTAG (10 vs. 2.5)
Time to detection (hours): conventional vs. xTAG (72 vs. 5)
Rand et al. 2015,34 USA Length of stay, mean (SD): after the negative test for C. difficile and/or rotavirus length of
stay in the hospital was 8.0 (± 9.1) days for those with an unsuspected hospital-acquired
pathogen and was not statistically different from the 15.1 (± 22.2) days for those
negative for all agents on the gastrointestinal panel
SD, standard deviation.
TABLE 22 Reported costs of testing
Study reference, country Costs (£)
Halligan et al. 2014,27 UK Total cost for conventional test (n= 4467): 63,431
Total cost for GPP xTAG (n = 2187): 150,641
Khare et al. 2014,12 USA Per instrument:
l FilmArray – 22,910
l xTAG – 21,460
List price reagent cost per specimen:
l FilmArray – 89.90
l xTAG – 46.40–52.20
Patel et al. 2014,31 USA Per identification reagents (conventional vs. xTAG): 29 vs. 46.40
Per specimen identification (conventional vs. xTAG): 145 vs. 36.25
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Interpretation of the clinical effectiveness results and implications for the
cost-effectiveness evaluation
Interpretation of findings
In the absence of an adequate reference standard or alternative methods of assessing test accuracy,
positive and negative agreements have been produced against a benchmark, as recommended by FDA
guidance. If conventional methods are an accurate determinant of important disease, then meta-analytic
results (benchmarked against conventional testing) suggest that GPP testing is reliable and could replace
current microbiological methods, although there would be an increase in false-positive reporting and
potential overtreatment. However, if GPP testing is considered accurate (in the sense that current testing
practices are missing clinically important pathology), then it would identify missed infections and could
potentially result in more appropriate treatment. Currently, the clinical importance of the additional
pathogens identified by GPP testing is uncertain, apart from, for example, enteroaggregative E. coli, which
is not detected by routine culture.
A further uncertainty is the value of more rapid testing, achieved to a varying extent by each GPP system.
In the vast majority of cases, hydration, hygiene and watchful waiting are required. Only for a select few
pathogens is specific treatment recommended [C. difficile, some strains of Salmonella, Shigella, E. coli
(non-shiga toxin-producing E. coli), Campylobacter and Giardia], although not all patients are treated
(see Chapter 5, Treatment). If conventional methods do accurately determine important disease, then the
introduction of GPP testing could potentially result in some earlier overtreatment of unnecessary cases,
which might spontaneously resolve.
Agreement measures are not measures of test performance in a conventional sense, and only adequately
designed research will resolve uncertainties about the introduction of GPP testing. It may not be possible to
design a study with an adequate independent reference standard. Molecular methods may not be the best
option to address the problem, as the presence of pathogen DNA does not necessarily answer the question
of the clinical importance of the identified pathogens. A randomised controlled trial may be the best option,
with patients randomised to conventional and GPP testing, and clinical effectiveness and cost-effectiveness
outcomes used to determine the value of GPP testing. Currently, there is no adequate evidence of the
impact of GPP testing on the management, treatment and outcome of patients as no test-and-treat trials
have been conducted.
The NICE scope identified the PHE algorithm8 as the relevant comparator against which to consider GPP
tests. However, the PHE algorithm was published in 2013 and may require updating to reflect progress in
routine microbiological laboratories. For instance, the new PHE guidance for the interpretation of PCR
assays for gastrointestinal pathogens states that a growing number of PHE and NHS virology laboratories
use PCR assays for detection of viral gastrointestinal pathogens.50 The same guidance recommends PCR as a
first-line diagnostic test for the intestinal parasites Giardia lamblia, Cryptosporidium spp. and E. histolytica.
This is not reflected in the national standard of practice used in this review. Similarly, this review has
evaluated GPP systems according to their current specification, but it is anticipated that the coverage of
these systems will continue to evolve in response to changing pathogen prevalence, hence the evaluation
problem is a dynamic one.
Current evidence should be regarded as applicable to a mixed population of community and hospitalised
patients, as the studies do not adequately report outcomes by setting or subgroup. Only one study from
Switzerland11 reported receiving samples both from GP practices and hospitals (emergency room and
admitted patients). However, the GP samples were from travellers returning from the tropics only and the
hospital samples were paediatric samples with suspected viral gastroenteritis; the study sample may have
low applicability to a routine clinical setting. One study27 reported that community-acquired infections
show a much greater spectrum of pathogens present than patients with hospital-acquired infections. Thus,
a goal for a future trial might include adequate stratification of different populations (e.g. community
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managed, community acquired and hospital managed, hospital acquired, children, travellers and
immunocompromised patients).
A paucity of head-to-head comparative data of different GPP tests limits conclusions. Khare et al.12 directly
compared FilmArray with xTAG, and concluded that both assays identified more pathogens than
conventional methods, but may not perform uniformly well against different pathogens. Gu et al.26
reported that both assays detected similar numbers of pathogens, with differences between the two tests
not reaching significance. Failure rates may vary between GPP systems, and further research is needed to
inform this issue.
Discrepancies between GPP tests and conventional methods may result from differences not only in accuracy
but also in their targets. For example, discrepancies reported by Gu et al.26 for adenovirus may have been
a result of the comparator PCR identifying all adenovirus strains, whereas the GPP system identified only
adenovirus 40 and 41. Similarly, Pankhurst et al.30 reported that xTAG has two targets for C. difficile (genes for
toxins A and B) and includes two primers against norovirus GI and GII strains. However, the single quantitative
PCRs used as comparators in the study targeted only the gene for toxin B or the GII strain. They classed a
positive result on either target with GPP as indicating the presence of the organism. This misalignment problem
may be exacerbated when comparing different GPP systems with their varying coverage.
Implications for health economic model
Uncertainties about how to interpret available evidence for the performance of GPP systems and the
impact they may have on clinical care make any attempt to model the economic consequences of
introducing GPP systems tentative. Consequently, an economic model has been developed to explore these
uncertainties. In the model, conventional testing using the PHE algorithm is considered to be accurate,
providing the benchmark for comparison. The consequence of replacing conventional testing with GPP
systems is explored. Different populations and a range of assumptions are explored regarding the impact
of adopting GPP systems on clinical care. These assumptions have been variously informed by the direct
evidence, epidemiological sources and expert opinion.
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Chapter 4 Cost-effectiveness review
Systematic review of existing cost-effectiveness evidence
Methods
Search strategy
A comprehensive review of the published literature including economic evaluations, economic models,
cost studies and quality-of-life studies was performed. The systematic search included the following
electronic databases on 29 January 2016:
l Ovid MEDLINE – 1946 to January week 3 2016
l Ovid MEDLINE In-Process & Other Non-Indexed Citations: 27 January 2016
l EMBASE: 1974 to January 27 2016
l Web of Science Core Collection.
The search terms included economic and quality-of-life terms combined with gastroenteritis and the
different GPP tests. The search was limited to studies published in the English language and studies
involving humans. The search strategy was developed, based on the clinical effectiveness review and with
health economist input. Details of the search strategies are provided in Appendix 1.
Review strategy
Citations and abstracts from the electronic online databases were exported into a citation software
package (EndNote X7) and duplicate citations were removed. Two reviewers independently reviewed titles
and abstracts to identify potentially relevant papers for inclusion. Any discrepancies were resolved
by discussion.
Inclusion criteria
Studies meeting the following criteria were included in the review:
l study type – fully published economic evaluations (including any economic models)
l population – patients with suspected infectious gastroenteritis
l intervention – integrated multiplex PCR tests, which include xTAG, FilmArray and Faecal Pathogens B
l comparator – standard microbiology techniques as outlined in the PHE pathway for routine testing in
cases of gastroenteritis and diarrhoea
l outcomes – cost–benefit, cost–consequences, cost-effectiveness or cost–utility studies reporting
outcomes as clinical effectiveness measures or utility measures [utility, EuroQol-5 Dimensions (EQ-5D) or
Short Form questionnaire-6 Dimensions score, or quality-adjusted life-years (QALYs)].
Exclusion criteria
Studies meeting the following criteria were excluded from the review:
l non-English-language publications
l studies not in humans
l studies not in gastroenteritis and diarrhoea
l studies that were not full economic evaluations (incremental costs and incremental benefits).
Studies that provided useful information for the economic model, such as resource use, costs, utilities and
transition probabilities, were retained but were not included in this review.
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Data extraction strategy
Data extraction was carried out by one reviewer using standardised data extraction sheets (www.journalslibrary.
nihr.ac.uk/hta/hta19100) and was then checked by a second reviewer. Data extracted included the following
information:
l study details – study title, author names, source of publication, language and publication type
l baseline characteristics – population (and subgroups), intervention, comparators, outcomes, study
design, and setting and location
l methods – study perspective, time horizon, discount rate, measurement of effectiveness, measurement
and valuation of preference-based outcomes, resource use and costs, currency, price date and
conversion, model type, assumptions and analytical methods
l results – study parameters, incremental costs and outcomes, and reporting of uncertainty
l discussion – study findings, limitations, generalisability and conclusions
l other – sources of funding, conflicts of interest and any comments.
Quality assessment strategy
We critically appraised studies classed as full economic evaluations against the framework of quality
assessment for economic evaluation studies developed by the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) group.51 The CHEERS framework comprises six dimensions (i.e. title and
abstract, introduction, methods, results, discussion and other), including a series of questions check whether
or not the criteria have been clearly reported. If the studies included any model-based economic evaluations,
they were further critically appraised using the framework on quality assessment for economic modelling
developed by Philips et al.52 The framework assesses decision-analytic models used in economic evaluations
under the dimensions of structure, data and consistency.
Results
Search results
The literature search identified 377 records through electronic database searches and other sources:
l Ovid MEDLINE – 1946 to January week 3 2016 (n = 132)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations – 27 January 2016 (n = 12)
l EMBASE – 1974 to January 27 2016 (n = 203)
l Web of Science Core Collection (n = 30).
After removing duplicates, 222 records were screened for inclusion. On the basis of title and abstract sift
only, 217 records were excluded. The remaining five records were included for full-text screening.27,53–56
A further four articles were excluded at the full-text stage as these studies did not contain a full economic
evaluation (see Appendix 9).27,53–55
The literature search identified only one study,56 classed as a full economic evaluation, that simulated the
GPP pathway of care and presented a cost–consequence type model (although not explicitly described)
(Figure 9). Two further reports were identified in our search (and also by NICE) but were not included in our
review: Abubakar et al.57 did not look at the same interventions as outlined above in our inclusion criteria
and Pankhurst et al.30 did not provide a cost-effectiveness analysis. However, both studies contained some
useful information for our economic model and so have been summarised in Additional information.
Quality assessment
The quality of the reporting of the economic analysis provided by the Goldenberg et al.56 study was
assessed using the 25-point CHEERS checklist51 and is provided in Appendix 10.
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The study was comprehensively completed, with 17 out of the 25 statements (68.0%) being completed,
three statements (12.0%) partially completed, three statements (12.0%) not completed and two statements
(8.0%) not applying. The quality of the reporting of the cost–consequence model, using the Philips et al.52
checklist, is presented in Table 7. The article was not comprehensively reported, with just 11 out of the
57 statements (19.3%) completed, 7 statements (12.3%) partially completed, 11 statements (19.3%) not
completed, 18 statements (31.6%) not applying and 10 statements unclear (17.5%). The poor quality of
reporting was related to the authors conducting a partial rather than full economic evaluation.
Overview of included studies
Full economic evaluation
Goldenberg et al.56 report an analysis based on a parallel testing study involving 800 patients and comparing
the Luminex xTAG GPP with conventional laboratory testing (which included a combination of selective
culture, microscopy and enzyme immunoassay). In this study, patients essentially received conventional
testing and care according to clinicians’ usual clinical practice over an 8-month period. Conventional testing
was performed 7 days per week and only one GPP test was performed per 5-day period so that GPP testing
may have influenced the care of some patients, notably removal from isolation. Costs were estimated for
800 patients in a London hospital with suspected infectious gastroenteritis (diarrhoea and/or vomiting). The
paper presented pathways for both the conventional (provided) and GPP (simulated) arms. To summarise the
pathways: a patient could either be isolated or not isolated while they were waiting for test results, then
when the test result arrived the infectious gastroenteritis agent might or might not be detected. If the agent
was detected and the patient was infected with a communicable agent, then the patient was isolated and
treated; however, if the agent was detected and was non-communicable, then the patient was treated
without isolation. If the agent was not detected and symptoms persisted, then the patient was retested, and
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FIGURE 9 A PRISMA flow diagram for the economic review.
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alternative causes were investigated; however, if the symptoms resolved then the patient was discharged.
The authors assumed that all GPP tests were 100% accurate.
The findings were presented as a cost–benefit analysis from a NHS perspective. Although not explicitly
stated, the time horizon for the analysis was the duration of the index episode; whether or not patients were
readmitted is not reported. Resource use and costs included laboratory testing and patient isolation costs,
although a comprehensive breakdown of these costs is not provided. Isolation costs for the conventional
pathway were based on actual days observed and for the GPP pathway these days were estimated. Costs
associated with false-positive and false-negative results and treatment costs were not included. Consequently,
total costs presented may underestimate costs incurred within the NHS. The year for which resources were
costed is not explicitly stated, limiting comparison with other studies. As the time frame of the study was
under 1 year, no discounting of costs (and/or benefits) was performed by the authors.
The preferred outcome measure for NICE is the QALY, permitting comparisons with other diseases and
interventions. Reported as a cost–benefit analysis, the value of outcomes (test accuracy, reduction of time
in isolation) was expressed in Great British pounds (GBP). A common limitation of this form of analysis is
that patient health outcomes are intangible and assumed proxied by tangible measures. Compared with
the conventional pathway, the xTAG GPP pathway had a higher detection rate for isolated patients
[37.2% (152/409) compared with 19.8% (81/409)], reduced isolation time from 2202 to 1447 days, but
cost an additional £22,283 for the laboratory tests, resulting in total savings of £66,765. Overall, the total
costs (isolation costs plus laboratory costs) for GPP testing were £44,482 lower than conventional testing.
The authors also conducted sensitivity analyses to deal with uncertainty around key parameters used in the
economic model. One key sensitivity analysis was around the time spent in isolation (time spent varied
from 1 to 3 days), and in each case there was a net saving under the GPP testing pathway. The authors
found that the break-even point associated with implementing the GPP pathway is a reduction of 252
isolation days. The Goldenberg et al.56 study is summarised in Appendix 10.
The key methodological shortcomings of the Goldenberg et al.56 paper were that the study simulated care
following xTAG diagnosis (no real patient care was involved in this group), the xTAG GPP test was
assumed to be 100% accurate, the days in isolation were estimated for the GPP pathway rather than
observed and outcomes were not in the form of QALYs.
Additional information
The two further health technology assessment reports that were identified,30,57 as noted previously,
have been summarised below.
Abubakar et al.57 assessed the cost-effectiveness of rapid diagnostic tests (real-time PCR and enzyme-linked
immunosorbent assay) compared with routine culture using a hypothetical decision tree model. The
authors tested 10,000 faecal samples for enteric pathogens causing food-borne illnesses. A NHS
perspective was adopted for the study and the time horizon was 1 year. Cost data came from hospitals
and manufacturers; for example, microbiological investigations included average costs of capital and
overheads of providing these services, test costs and staff costs. Treatment costs (antibiotic therapy or
hospital bed-days) were excluded. Costs were presented in GBP in 2005 prices. As the study length was
1 year, no discounting was performed. Data from the clinical effectiveness review, which included data on
isolation rates for each pathogen, were used as the measure of effectiveness in the study. Outcomes were
presented as the cost per additional case detected. At baseline, testing one sample for Campylobacter,
Salmonella and E. coli cost £18.85 with PCR, £15.66 with immunoassays and £15.01 by culture methods.
The use of enzyme-linked immunosorbent assay test kits was a marginally less expensive strategy than PCR
testing. In terms of characterising the uncertainty in the model, small changes in diagnostic accuracy and
implementation cost estimates do not vary the findings. However, the most sensitive parameter was the
isolation rate for each pathogen. The key limitations were the availability of the data for the model, no
inconclusive test results were recorded and there were no repeat tests and, in addition, sensitivity and
specificity for the comparator (bacterial culture) were assumed to be 1. The authors concluded that rapid
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testing in combination with routine culture is unlikely to be cost-effective. However, they believed that,
if the cost of rapid technologies falls, it may become more cost-effective. In addition, they noted that, if
multiple pathogens can be simultaneously detected, then these rapid tests may prove to be cost-effective.
Pankhurst et al.30 aimed to assess the diagnostic accuracy of the Masscode gastric multiplex PCR test (Qiagen
Masscode Technology, Hilden, Germany). The study was split into two phases. Phase 1 was a retrospective
study assessing the sensitivity and specificity of the MassCode test against four major pathogens. In addition,
the questionnaire survey examined current practice and the costs of managing infectious diarrhoea. Phase 2
was a prospective, real-time, parallel-group study estimating the cost-effectiveness of the MassCode test
using a decision Markov model. However, because of analytical problems with the MassCode test, the
project was stopped earlier than intended and the planned economic analyses were not carried out.
Summary
The cost-effectiveness search highlighted only one study that was classed as a full economic evaluation
comparing an integrated multiplex PCR test (xTAG) with conventional care to rapidly identify
gastrointestinal pathogens in people with suspected infectious gastroenteritis. However, the study had
some key limitations, principally changes in isolation due to GPP were estimated not observed, and there
was no explicit valuation of patient outcomes. In the next chapter, we build a de novo economic model
comparing these integrated multiplex PCR tests with conventional care for people with suspected
infectious gastroenteritis.
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Chapter 5 Health economic methods and results
Objective
To develop a de novo model to explore the cost-effectiveness of GPP tests compared with standard care in
England and Wales. This chapter describes the structure of the model, the model inputs, the assumptions
made, the different scenarios that have been evaluated, the main results and the results from the
sensitivity analyses.
Developing the model structure
Currently in the UK, patients with acute suspected gastroenteritis persisting for more than several days
undergo routine faecal microbiology tests to investigate the cause of acute diarrhoea with or without
vomiting. A decision tree model was constructed to see if the use of integrated multiplex PCR tests (xTAG,
FilmArray and Faecal Pathogens B) is cost-effective compared with conventional care (the PHE pathway) for
rapidly identifying gastrointestinal pathogens in people with suspected infectious gastroenteritis. In this
section, the structure of the model is described. Conventional testing was chosen pragmatically as the
benchmark for comparison within the model as it represents current practice.
Models developed
To assess the cost-effectiveness of integrated multiplex PCR tests compared with conventional care, a de
novo decision tree model was developed in Microsoft Excel® (version 16, Microsoft Corporation, Redmond,
WA, USA). A decision tree model was the most appropriate choice as gastroenteritis is a self-limiting illness
and usually stops within 2 weeks (i.e. diarrhoea lasts for 5–7 days and stops within 2 weeks and vomiting
lasts for 1–2 days and stops within 3 days).58
The base economic model (model 1) includes hospitalised adult patients with suspected gastroenteritis
(acute hospital admissions). The following subgroups of people with suspected gastroenteritis are explored
in subsequent models: model 2, young children; model 3, people in the community; model 4, people who
are immunocompromised; and model 5, people with a history of recent foreign travel (to areas other than
Western Europe, North America, Australia or New Zealand).
Model 1: hospitalised adult patients with suspected gastroenteritis
The economic model was developed by determining the different clinical pathways for patients with
suspected gastroenteritis. We have used information from the systematic review of clinical effectiveness,
published literature and expert opinion to develop the different clinical pathways. The model structure is
the same for both the GPP and conventional care arms (the main differences between the two arms are
when test results are received and whether or not patients move from isolated to non-isolated care earlier,
are treated earlier or are discharged earlier). Figure 10 shows the overall structure comparing the different
treatment arms, Figure 11 shows the different pathways for patients who are isolated and Figure 12 shows
the different pathways for patients who are not isolated.
The pathway assumes that an adult patient is admitted to (or already in) hospital with suspected
gastroenteritis (diarrhoea and/or vomiting). A decision is made by the medical staff regarding whether the
patient goes to a side room (isolated) or stays on an open bay/ward (not isolated). This decision may
depend on the availability of isolation rooms.
The patient provides a stool sample to test for suspected gastroenteritis. The stool sample is then sent to
the laboratory (or transported in some instances when the laboratory is not on site) for testing. The model
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evaluates the consequences of using a multiplex integrated PCR test (xTAG, FilmArray or Faecal Pathogens B)
or conventional testing. When results are returned, care is determined according to whether a pathogen(s)
has or has not been detected. The presence of a pathogen is determined by conventional testing, as the
benchmark test.
Isolated patients
In the following pathways, ‘treatment’ refers to pathogen-specific treatment over and above general care,
hydration and hygiene management received by all patients. In the case of isolated patients in whom a
pathogen has been detected, there are four options:
1. discharge the patient because symptoms have resolved
2. continue to isolate the patient and provide treatment
3. continue to isolate the patient and do not provide any treatment
4. deisolate the patient and do not provide any treatment.
With the final three options, symptoms can either resolve naturally, or can persist; in both cases, the
patient is subsequently discharged when appropriate.
Isolate
Conventional 
Not isolate
Isolate
x-TAG
Not isolate
Patient admitted
to hospital
Isolate
FilmArray
Not isolate
Isolate
Faecal Pathogens B
Not isolate
Go to faecal pathogen 
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FIGURE 10 Overall model structure for patients with suspected gastroenteritis comparing the different
treatment arms.
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FIGURE 11 The different pathways for isolated patients.
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FIGURE 12 The different pathways for non-isolated patients.
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In the case of isolated patients in whom no pathogen has been detected, there are three options:
1. discharge the patient because symptoms have resolved naturally
2. keep the patient in isolation because symptoms persist
3. deisolate the patient and do not provide any treatment.
Patients in whom symptoms persist undergo retesting. (These patients remain in isolation.) The second test
results either will or will not detect a pathogen. Patients in whom a pathogen is detected follow the same
care pathway as isolated patients in whom a pathogen has been detected. In the case of patients in whom
no pathogen is detected there are two options:
1. discharge the patient because symptoms have resolved
2. continue to isolate the patient and do not provide any treatment.
In the latter case, symptoms can either resolve naturally or persist; in both cases, the patient is subsequently
discharged. Among patients who have been deisolated and who have received no treatment, symptoms
can either resolve naturally or can persist; in both cases, the patient is subsequently discharged.
Non-isolated patients
For non-isolated patients in whom a pathogen has been detected, there are four options:
1. discharge the patient because symptoms have resolved
2. isolate the patient and provide treatment
3. isolate the patient and do not provide any treatment
4. do not provide any treatment.
With the final three options, symptoms can either resolve naturally, or can persist; in both cases, the
patient is subsequently discharged when appropriate.
Among non-isolated patients in whom no pathogen has been detected, symptoms can resolve naturally or
persist. Patients whose symptoms have resolved are discharged. Patients with persistent symptoms are
retested. Those patients in whom a pathogen is detected follow the same care pathway as non-isolated
patients in whom a pathogen has been detected. For patients in whom no pathogen is detected, there are
two options:
1. discharge the patient because symptoms have resolved
2. do not provide any treatment.
In the case of the latter option, symptoms can either resolve naturally or persist; in both cases, the patient
is subsequently discharged when appropriate.
Model assumptions and base-case analysis
As gastroenteritis is a self-limiting illness, most patients are treated symptomatically and there is no
significant impact on quality of life for most patients beyond the symptomatic impact while the infection
lasts. As a result of the lack of evidence with which to extrapolate benefits of multiplex testing, the model
time frame is limited to the immediate index hospitalisation (approximately 2 weeks). The model does
not take into account any sequelae or adverse events of treatment, subsequent readmission, persistent
complications or mortality. In addition, the model does not consider transition costs (moving from one test
to another or having to manage both in tandem); rather, a simple comparison of the two approaches to
testing is made.
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The base-case model is based on a hypothetical cohort of hospitalised adult patients with suspected
gastroenteritis. The analysis is conducted from a NHS and Personal Social Services perspective. All costs are
in GBP 2014/15 prices. Health outcomes were measured as QALYs gained. Results are expressed as an
incremental cost per QALY gained. As the time frame is < 1 year, no discounting of costs or outcomes is
performed. In the model, conventional testing provides the benchmark with which multiplex integrated
PCR tests are compared.
Data required for the model
No clinical data were retrieved for Faecal Pathogens B, limiting subsequent consideration to its acquisition
costs. Modelling of cost-effectiveness was possible for the xTAG GPP and FilmArray tests.
Prevalence and probabilities
Prevalence information for the model was provided from the clinical effectiveness meta-analysis review.
Table 24 below shows the prevalence of pathogens and conditional agreement probabilities when
conventional testing is the benchmark.
Prevalences for conventional testing were obtained by pooling two large, representative studies (FDA
evaluating xTAG,25 Buss et al.20 evaluating FilmArray); thus, a common prevalence matrix was applied to
both systems. The overall true pathogen detection rate, determined by conventional testing (assuming
conventional testing is correct) is 24.1%, while the positive detection rate is 22.2% for xTAG GPP and
22.9% for FilmArray testing in the first round of testing; a second confirmatory test is required to identify
false negatives. The true no-pathogen rate is 1 minus the prevalence. It is conservatively assumed that 25%
of patients with false-positive results are retested, with 75% discharged without further management,
as are all patients with true-negative results. Probabilities for positive and negative agreements for each
pathogen were drawn from the clinical effectiveness review.
To estimate the proportion of patients who followed each pathway for the different tests requires
knowledge of the proportion of patients who would be treated and not treated. These proportions were
estimated by our clinical experts, as shown in Table 25.
These proportions (see Table 25), along with the prevalences (see Table 24), were used to estimate the
proportions of patients who followed each pathway according to each pathogen (numbers are not
shown here).
The overall probabilities (conditional) for patients in whom a pathogen was detected are shown in Table 26.
When a test provides the benchmark, it is assumed that all pathogens are correctly identified and that
second testing would identify no new pathology. When a test is being compared against the benchmark,
second testing in the presence of persisting symptoms may detect missed pathology.
The proportion of patients who were isolated and not isolated in each model was based on the study by
Goldenberg et al.56 (Table 27). Following advice from our clinical experts, we have assumed that the probability
that a patient’s symptoms resolve naturally and that he or she is discharged is 0.75, and that the probability
that patients’ symptoms persist and they are discharged is 0.25. These two probabilities do not influence the
costs or QALYs within each of the different pathways. Again, on the advice of our clinical experts, among
patients in whom neither the first nor the second test detects any pathogen, the probably of receiving no
treatment and being discharged is 90%, while the probability of being isolated but receiving no pathogen-
specific treatment is 10%. Table 28 shows the probabilities for the remaining pathways.
Resource use and costs
The resource use and costs included in the economic model were those directly incurred by the NHS.
Costs for the conventional and the GPP tests, bed-days, cleaning, any other tests or investigations, blood
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TABLE 27 Common probabilities used in all models: model 1
Clinical pathway Probability value Source
Isolate 0.5113 Goldenberg et al.56
Not isolate 0.4888 Goldenberg et al.56
Symptoms resolve: discharge 0.7500 Clinical expert
Symptoms persist: discharge 0.2500 Clinical expert
Isolate/not isolate, no pathogen, symptoms persist: retest, no pathogen,
no treatment – discharge
0.9000 Clinical expert
Isolate/not isolate, no pathogen, symptoms persist: retest, no pathogen,
isolate and not treat
0.1000 Clinical expert
TABLE 25 Proportion of patients treated and not treated: model 1
Pathogen Treated and isolated Not treated and isolated Not treated and not isolated
Adenovirus – 1.00 0.00
C. difficile 0.95 0.05 0.00
Campylobacter 0.35 0.65 0.00
Cryptosporidium 0.00 1.00 0.00
E. coli O157 0.00 1.00 0.00
ETEC 0.45 0.55 0.00
Giardia 0.95 0.025 0.025
Norovirus 0.00 1.00 0.00
Rotavirus 0.00 1.00 0.00
Salmonella 0.45 0.55 0.00
Shigella 0.45 0.55 0.00
ETEC, enterotoxigenic E. coli.
TABLE 26 Probabilities used in the model in response to a positive result: model 1
Clinical pathway
Conventional testing as
benchmark, first test
xTAG FilmArray
First test Second test First test Second test
Total treated and isolated 0.5295 0.5506 0.2928 0.5428 0.2879
Not treated and isolated 0.1302 0.1317 0.1126 0.1345 0.0511
Not treated and not isolated 0.2933 0.2727 0.5239 0.2769 0.5898
Not treated and discharged 0.0470 0.0449 0.0707 0.0457 0.0712
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tests, medications and rehydration costs were all included in the analysis. All costs are presented in 2014/15
prices and any costs not in this financial year were adjusted using the Hospital and Community Health
Service pay and price index.59
Test costs
The test costs for the conventional arm were based on the study by Goldenberg et al.56 The tests included
routine culture methods, which can potentially detect Campylobacter, Salmonella, Shigella and E. coli O157;
light or fluorescent microscopy, which can detect Giardia and Cryptosporidium; enzyme immunoassays
[glutamate dehydrogenase (GDH)] or PCR for detecting C. difficile; PCR tests for detecting norovirus; and the
combined immunochromatographic tests for detecting adenovirus and rotavirus. All test costs included
consumables, labour and overheads. The costs for conventional tests are shown in Table 29.
The base model assumes an average throughput by GPP of 24 samples per day, as representative of typical
use, although some larger facilities may have considerably higher average throughput. The configurations
chosen allow flexibility to manage peak loads within facilities.
To calculate staff costs per hour associated with processing the samples, we have used the cost of a medical
laboratory assistant using Agenda for Change pay rates for 2015 band 4 mid-point (point 14: £20,844 plus
17.5% on-costs).60 This was based on working an average of 42 weeks per annum and 37.5 hours per week.
For xTAG, to run 24 samples would take an average of 5–6 hours. Using the information above, the staff
cost associated with each individual sample would be £3.43. The MAGPIX system (Luminex, Toronto, ON,
Canada) costs £25,000 and, taking into account a 10-year lifespan and using a 3.5% discount rate,61
assuming that the system is used every day for 24 samples, the cost would be £0.34 per sample. Assuming
that the annual maintenance cost is £4190, the cost of the nucleic acid extraction system is approximately
£35,000 and the Thermal cycler costs £7500 (assuming for the final two products a 5-year lifespan and
using a 3.5% discount rate), the total cost per sample would be £4.67. We have also included the cost per
well, which equates to £20, and the cost of consumables of £8.66. In total, the cost per sample for xTAG
is £37.10 (see Table 29).
For FilmArray, to run 24 samples would take an average of 3 hours (using FilmArray 2.0 with eight modules,
which is run three times). Using the information above, the staff cost associated with each individual sample
would be £2.01. The capital cost of the system is £28,000, including the costs of a further seven modules,
taking the total capital cost up to £203,000. Taking into account a 5-year lifespan and using a 3.5%
discount rate,61 assuming that the system is used every day for 24 samples, the cost would be £5.13 per
sample. The annual maintenance cost is £3400 for one module, the cost for one gastrointestinal panel kit is
£85.00 and the Cary–Blair medium cost is approximately £1. Using these costs, the total cost per sample
would be £93.53 (see Table 29).
For Faecal Pathogens B, to run 24 samples would take an average of 2–3 hours. Using the information
above, the staff cost associated with each individual sample would be £2.73. The capital cost of the system
TABLE 28 Other probabilities used in the model: model 1
Probability value Conventional xTAG FilmArray Source
Isolate, no pathogen, symptoms resolve: discharge 0.9573 0.9271 0.9673 Goldenberg et al.56
Isolate, no pathogen, symptoms persist: retest 0.0213 0.0729 0.0327 Clinical expert
Isolate, no pathogen, deisolate: not treat 0.0213 0.0000 0.0000 Clinical expert
Not isolate, no pathogen, symptoms resolve: discharge 0.8868 0.9271 0.9673 Goldenberg et al.56
Not isolate, no pathogen, symptoms resolve: retest 0.1132 0.0729 0.0327 Goldenberg et al.56
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TABLE 29 Test/per sample costs used in the economic model: model 1
Resource use Test cost (£) Reference
Conventional tests
Culture tests 11.30 Goldenberg et al.56
Light or fluorescent microscopy 10.53 Goldenberg et al.56
Enzyme immunoassay (GDH) or PCR test for screening 26.05 Goldenberg et al.56
PCR test 11.30 Clinical experta
Combined immunochromatographic tests 7.00 Goldenberg et al.56
Total cost for conventional tests 66.18 –
Total costs (£) Test cost per sample (£)
Integrated PCR tests
xTAG GPP
Capital cost (total) 25,000 0.34
Maintenance cost (per annum) 4190 0.48
Nucleic extraction system (total) 35,000 4.00
Thermal cycler (total) 7500 0.19
Test kit for 96 wells 1920 20.00
Consumables/disposables – 8.66
Staff costs (per hour) 15.55 3.43
Total costs 37.10
FilmArray
Capital cost (total) 203,000 5.13
Maintenance cost (per annum) 3400 0.39
GI panel kit 85.00 85.00
Cary–Blair medium 1.00 1.00
Staff costs (per hour) 15.55 2.01
Total costs 93.53
Faecal Pathogens B
Capital cost (total) 28,320 0.72
Maintenance cost (per annum) 3172 0.36
Step 1: tubes (per sample) 7.60 7.60
Step 2: plates (per sample) 0.80 0.80
Master mix (per sample) 1.50 1.50
Nucleic acid extraction (per sample) 3.50 3.50
Consumables/disposables 0.66 0.66
Staff costs (per hour) 15.55 2.73
Total costs 17.86
GI, gastrointestinal.
a Our clinical experts confirmed that the cost for PCR testing would be approximately the same as routine culture
test costs.
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is £28,320, and taking into account a 5-year lifespan and using a 3.5% discount rate,61 assuming that the
system is used every day for 24 samples, the cost would be £0.72 per sample. The annual maintenance
cost is £3172; the costs for tubes (step 1), plates (step 2), plus the master mix is, in total, £10.26 per
sample; and consumables and extraction come to £4.16 per sample. Using these costs, the total cost per
sample would be £17.86 (see Table 29).
After GPP testing, for confirmatory purposes we have included the cost of enzyme immunoassay (GDH)
or PCR test for screening (£26.05) when C. difficile has been detected and the cost of routine culture
(£11.30) when E. coli O157, Salmonella and Shigella have been detected.
We have not added in the cost of waste disposal associated with culture of faecal samples. The cost of
disposing of samples can be substantial; however, as confirmed by our clinical experts, this cost is common
to both arms.
In addition, we have not added any further costs for samples that are then sent to PHE for subsequent
testing. As confirmed by our clinical experts, sending these samples will not affect subsequent management
for these patients.
Unit costs for bed-days, cleaning, any other tests or investigations, blood tests, medications and rehydration
costs are presented in Table 30.
Number of bed-days before obtaining test results
It has been assumed that the results of conventional testing will come back in 3 days and the results of
GPP tests will come back more quickly: xTAG in 1 day and FilmArray in half a day. The use of bed-days
takes into account the time taken to collect a stool sample, to send the stool sample to the laboratory, to
process the test and obtain the results, to communicate the results and to decide, depending on the test
results, if any action needs to be taken.
Patients in whom a pathogen was not detected in the first instance, and who are retested because of
persisting symptoms, are assumed to consume the same number of bed-days as above before the second
set of test results is obtained.
Number of bed-days after obtaining test results
The total number of bed-days spent in hospital by patients with suspected gastroenteritis was based
on a weighted average obtained from the Admitted Patient Care spreadsheet within the Hospital
Episodes Statistics data for 2014/15.67 The primary diagnosis Healthcare Resource Group code for intestinal
infectious diseases was A00–A09. During the time period 1 April 2014 to 31 March 2015, there were
201,141 finished consultant episodes relating to intestinal infectious diseases, and mean length of stay
was 4 days (this is based on all patients regardless of age or sex). Further breakdown of codes A00–A09
enabled a calculation of the weighted average number of bed-days for the different pathogens (Table 31).
Once test results have been obtained, whether by conventional testing or by one of the GPP tests, it has
been assumed that the number of bed-days listed above will apply for the total number of bed-days
(before and after test results) for both isolated and non-isolated patients, depending on the care pathway
before the patient is discharged. However, when a pathogen was missed at the first test but identified at
the second test, the patient stay would be increased by the time delay to the second test.
A number of further assumptions were also made with regard to bed-days. First, we have assumed that
the total minimum number of bed-days for both arms would be 3 days (even though the results may
come back earlier for GPP testing). This was so that we could be consistent with what happens with
conventional care patients, as there is currently no evidence that patients would be discharged earlier.
Some patients are already discharged earlier than the 3 days (as this is an average), presumably because of
symptom resolution. Thus, the base model assumes that patients are essentially treated symptomatically
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TABLE 30 Resource use and unit costs in 2014/15 prices used in the model: model 1
Resource use Base-case value (£) Reference
Bed-days
General adult ward (cost per day) 497.39 Department of Health 201562
Adult isolation ward (cost per day) 593.89 Department of Health 2015,62
HAI Task Force63
Cleaning costs
Daily cleaning 10.11 Allen et al.64
Disposables and staff time 8.88 Allen et al.64
Spot cleaning and changing 34.80 Allen et al.64
Blood tests
Full blood count 7.00 Department of Health 201562
Routine chemistry and C-reactive protein test 4.00 Department of Health 201562
Other tests/investigations
Abdominal X-ray 161.00 Department of Health 201562
Flexible sigmoidoscopy 781.89 Department of Health 201562
Medications (cost per pack)
Vancomycin (oral) 132.47 BNF65
Metronidazole (oral) 1.21 BNF65
Fidaxomicin (Dificlir®, Astellas) (oral) 1350.00 BNF65
Erythromycin (oral) 1.61 BNF65
Ciprofloxacin (oral) 0.98 BNF65
Amoxicillin (oral) 1.61 BNF65
Rehydration methods
Dioralyte® (Sanofi-Aventis) (adult) (cost per day) 2.25 BNF65
Intravenous fluids (adult) (cost per day) 2.31 NICE 200966
Administration of rehydration methods
Oral 3.58 Allen et al.64
Intravenous fluids 14.33 Allen et al.64
BNF, British National Formulary.
TABLE 31 Hospital bed-days per pathogen: model 1
Pathogen Length of stay (days)
Campylobacter 6
C. difficile 19
E. coli 6
Parasites 5
Salmonella 6
Shigella 5
Viruses 2
Other 4
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(with simple hygiene and rehydration advice) independent of the method of testing. Second, we have
assumed that, if patients were in isolation, they might remain in isolation without moving to an open
ward/bay before being discharged. Third, for patients in whom C. difficile was detected, the number of
bed-days after the test result was split evenly between an isolation room and an open ward/bay.
Costs for bed-days were obtained from NHS Reference Costs62 (see Table 30). For stay on an adult general
ward, this cost was a weighted average based on patients with gastrointestinal infections without interventions
from the elective inpatient spreadsheet. For patients who stayed in isolated wards, an additional cost of
£96.50 was added. This cost was based on the additional cost of patients with meticillin-resistant S. aureus
infection staying in single beds in single room isolation rather than open wards.63
Daily cleaning and spot cleaning
For each day the patient spent in hospital, a cost for daily cleaning was included. This cost included time
for domestic cleaning staff, specialist cleaning agents and special cleaning equipment as reported in a
previous Health Technology Assessment publication64 looking at diarrhoea in older people who are
admitted to hospital. We also assumed that, for every second day spent in hospital, patients would have
‘an accident’ relating to their diarrhoea and spot cleaning would need to take place. This cost, again,
included time for domestic cleaning staff, specialist cleaning agents and special cleaning equipment,
as well as spot cleaning and changing of beds, laundry and disposables such as gloves and aprons.64
Unit costs for cleaning are shown in Table 30.
Blood tests and other investigations
We assumed that a full blood count will be carried out in every patient on admission, and that
approximately 30% of patients will undergo routine blood chemistry and a C-reactive protein test. Unit
costs for blood tests were obtained from the NHS Reference Costs from the Direct Access Pathology
Services spreadsheet62 (see Table 30).
We also assumed that 1% of patients in whom a pathogen was detected would undergo flexible
sigmoidoscopy, as would 10% of patients in whom no pathogen was detected. We estimated that
abdominal radiography would be performed in 10% of patients in whom C. difficile was detected and in all
patients in whom no pathogen was detected. It was assumed that 5% of patients in whom conventional
testing detected any other pathogen would undergo abdominal radiography, as would 2% of patients in the
GPP test arm, reflecting the impact of earlier microbiological diagnosis on other testing. Unit costs for the
named tests above were obtained from NHS Reference Costs62 (see Table 30).
Treatment
For most gastrointestinal infections, antimicrobial therapy is not recommended except in certain situations,
for example C. difficile infection or immunocompromise. Unit costs for drugs were obtained from the British
National Formulary (BNF)65 (see Table 30) and we have assumed that patients complete each course of tablets/
capsules prescribed either at hospital or at home. For patients in whom C. difficile infection is identified,
either metronidazole (non-severe C. difficile) or vancomycin (severe C. difficile) is administered. For patients
with severe C. difficile infection and multiple comorbidities, oral fidaxomicin (Dificlir®, Astellas) may be
considered.68 A typical course of metronidazole or vancomycin lasts for 10–14 days (and fidaxomicin lasts
10 days), and only 47% of patients complete antibiotic therapy in hospital.30 In a study of C. difficile-associated
diarrhoea in hospitalised patients in Northern Ireland, 55.2% of patients received vancomycin and 44.8%
received metronidazole.69 According to our clinical experts, approximately 4.5% of patients in hospital would
be treated with fidaxomicin. The following proportions were applied in our economic model: 52.95%
vancomycin, 42.55%metronidazole and 4.5% fidaxomicin. For C. difficile patients, two packs of vancomycin
or metronidazole are needed for a 10- to 14-day course.
Certain other pathogens are sometimes treated in the NHS; patients infected with these pathogens are
included in the isolate and treat arm of the economic model. For example, patients infected with
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Campylobacter may receive erythromycin and patients infected with Salmonella, Shigella or E. coli
(non-shiga toxin producing) may receive either ciprofloxacin or amoxicillin (on the advice of our clinical
experts we have assumed that 75% of patients would receive ciprofloxacin and 25% of patients would
receive amoxicillin); and for patients with Giardia they may receive metronidazole. Treatment is generally
not recommended for shiga toxin-producing E. coli O157.
In patients in whom Cryptosporidium is detected (this is a very rare occurrence), two drugs [paromomycin
or nitazoxanide (Alina®, Lupin Pharmaceuticals Inc., MD, USA)] can be used. However, there is no standard
approved treatment in the UK for Cryptosporidium;65 hence, we have not included any costs in the
economic model for this pathogen.
We have not included any cost of administering the drugs, as this is included in the nursing costs, which
are included in the cost of the bed-days.
Rehydration methods
Oral rehydration therapy is given only to patients who are clinically dehydrated; however, most hospitalised
patients will receive some form of rehydration. We have assumed that, for each day in hospital, 60% of
patients would receive oral rehydration and 30% of patients would receive intravenous fluids. We have
assumed that each patient receiving oral rehydration would receive 200 ml of Dioralyte® (Sanofi-Aventis)
every 4 hours; one pack of Dioralyte contains six sachets and costs £2.25.65 We have assumed that patients
receiving intravenous fluids would receive 2 l of sodium chloride 0.9% per day, at a cost of £2.31.66
The cost of nursing staff time to administer rehydration solutions must also be included. These costs were
based on the earlier study by Allen et al.,64 who calculated the time spent administering oral medication as
5 minutes and time spent administering intravenous medications as 20 minutes. The cost of a hospital-based
nurse (band 5 with qualifications) was obtained from the Unit Costs of Health and Social Care.59 The unit
costs for rehydration methods and the administering costs are shown in Table 30.
Utilities
A literature search was undertaken to identify utility values for patients with infective gastroenteritis.
Most published values are used to assess the cost-effectiveness of rotavirus vaccination for children aged
≤ 5 years.70–75 Although some of these studies differentiate utility values by severity levels, for example mild
or severe gastroenteritis or hospitalisation,70,71,76–78 none of the studies provided utility values for adults. The
most useful paper was by Minor et al.,79 who estimated health-care costs associated with food-borne illnesses
caused by known viruses, bacteria and parasites in the USA. They presented the information for different
pathogens in terms of weighted quality-adjusted life-days (QALDs) lost. The authors suggested that the use
of QALDs lost is a more helpful unit of analysis for acute illnesses than QALYs lost. The lost QALDs were
estimated by taking the average quality weight of a food-borne illness (measured by the EQ-5D index) and
the average US quality weight. They then multiplied the percentage QALD loss by the duration of the
condition. To convert to QALYs we divided the QALDs values by 365. Table 32 shows the QALY loss by the
different pathogens in our model.
Changes made to base-case model
Various changes were made to the base-case model for hospitalised adult patients (model 1) with
suspected gastroenteritis in order to carry out analyses for the different subgroups, as noted below.
Model 2: young children with suspected gastroenteritis
The model structure for young children in hospital matches the adult hospital model.
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Prevalence and probabilities
Table 33 shows the prevalence of pathogens and conditional agreement probabilities when conventional
testing is the benchmark for young children, which was estimated by our clinical experts using the hospital
prevalence for adults as a base case. The overall pathogen detection rate was 24.2% for conventional
testing, 21.4% for xTAG and 22.3% for FilmArray testing.
The proportions of young children treated in each scenario are assumed to be the same as reported in
Table 25. The overall conditional probabilities for patients in whom a pathogen is detected are shown in
Table 34.
All common probabilities, as shown in Table 27, remain the same. The other probabilities for model 2 are
shown in Table 35.
Resource use and costs
Conventional test costs and GPP costs, as shown in Table 29, remain the same.
We assumed that the number of days spent in hospital is the same for children as for adults infected with
the same pathogen (obtained from Hospital Episodes Statistics67), as hospital stay did not differ by age or
sex. The costs for bed-days were obtained from NHS Reference Costs62 based on a weighted average of
paediatric, infectious and non-infectious gastroenteritis stay, and are shown in Table 36.
TABLE 32 Mean QALY losses values used in the economic model: model 1
Pathogen Mean QALY loss 95% CI for PSA Distribution for PSA Source
Bacteria
C. difficile 0.0137 – Clinical expert
estimate (NM)
Campylobacter 0.0057 0.0035 to 0.0080 Beta Minor et al.79
Salmonella 0.0049 0.0041 to 0.0070 Beta Minor et al.79
Shigella 0.0050 0.0033 to 0.0069 Beta Minor et al.79
ETEC 0.0044 0.0032 to 0.0055 Beta Minor et al.79
E. coli O157 0.0126 0.0083 to 0.0169 Beta Minor et al.79
E. coli (STEC + non-STEC) 0.0085 0.0057 to 0.0112 Beta Minor et al.79
Parasites
Giardia 0.0123 0.0045 to 0.0201 Beta Minor et al.79
Cryptosporidium 0.0039 0.0010 to 0.0068 Beta Minor et al.79
Parasites (all) 0.0081 0.0027 to 0.0134 Beta Minor et al.79
Viruses
Adenovirus 0.0007 0.0005 to 0.0010 Beta Minor et al.79
Norovirus 0.0008 0.0006 to 0.0010 Beta Minor et al.79
Rotavirus 0.0032 0.0023 to 0.0041 Beta Minor et al.79
Viruses (all) 0.0008 0.0011 to 0.0020 Beta Minor et al.79
Other
Other (unspecified pathogen) 0.0007 0.0005 to 0.0010 Beta Minor et al.79
ETEC, enterotoxigenic E. coli; NM, Noel McCarthy; PSA, probabilistic sensitivity analysis; STEC, shiga toxin-producing E. coli.
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TABLE 34 Probabilities used in the model in response to a positive result: model 2
Clinical pathway
Conventional testing as
benchmark (first test)
xTAG FilmArray testing
First test Second test First test Second test
Total treated and isolated 0.1479 0.1579 0.0717 0.1571 0.0370
Not treated and isolated 0.1737 0.1847 0.0897 0.1837 0.0521
Not treated and not isolated 0.5932 0.5732 0.7458 0.5749 0.8146
No treatment: discharged 0.0852 0.0842 0.0928 0.0843 0.0963
TABLE 35 Other probabilities used in model 2
Clinical pathway Conventional xTAG FilmArray Source
Isolate, no pathogen, symptoms resolve: discharge 0.9573 0.9266 0.9667 Goldenberg et al.56
Isolate, no pathogen, symptoms persist: retest 0.0213 0.0734 0.0333 Clinical expert assumption
Isolate, no pathogen, deisolate: not treat 0.0213 0.0000 0.0000 Clinical expert assumption
Not isolate, no pathogen, symptoms resolve:
discharge
0.8868 0.9266 0.9667 Goldenberg et al.56
Not isolate, no pathogen, symptoms resolve: retest 0.1132 0.0734 0.0333 Goldenberg et al.56
TABLE 36 Resource use and unit costs in 2014/15 prices used in the model: model 2
Resource use Base-case value (£) Reference
Bed-days
Paediatric general ward (cost per day) 765.43 Department of Health 201562
Paediatric isolation ward (cost per day) 861.93 Department of Health 2015;62 HAI Task Force63
Medications (cost per pack)
Vancomycin (intravenous) 12.99 BNFC80
Metronidazole (oral) 1.21 BNFC80
Fidaxomicin (oral) 1350.00 BNF65
Erythromycin (oral) 1.61 BNFC80
Ciprofloxacin (oral) 1.48 BNFC80
Amoxicillin (oral) 1.37 BNFC80
Rehydration methods
Dioralyte (child) (cost per day) 2.25 BNF65
Intravenous fluids (child) (cost per day) 2.31 NICE 200966
Administration of rehydration methods
Oral 3.58 Allen et al.64
Intravenous fluids 14.33 Allen et al.64
BNFC, British National Formulary for Children.
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We have assumed that cleaning took place each day, as in the base model, and that spot cleaning took
place every day, rather than every second day as in the base model.
We have assumed that the same percentage of patients as in the base model would undergo blood tests.
We also assumed that 3% of patients in whom no pathogen was detected would undergo flexible
sigmoidoscopy (patients in whom a pathogen was detected would not undergo flexible sigmoidoscopy).
We estimated that 5% of patients in whom C. difficile was detected and all patients in whom no
pathogen was detected would undergo abdominal radiography. It was assumed that 3% of patients in the
conventional arm and 2% of patients in the GPP arm in whom any other pathogen was detected would
undergo abdominal radiography.
The proportions of patients with C. difficile, Campylobacter, Salmonella, Shigella, E. coli (non-shiga toxin
producing) or Giardia infection who received different treatments were assumed to be the same as in
the base model. The costs of the drugs were taken from the BNF for Children80 (see Table 36). Patients
infected with C. difficile require three vials of intravenous injections of vancomycin or two packs of
metronidazole for the 10- to 14-day course.
We have assumed that, for each day in hospital, 75% of young children would receive oral rehydration
and 20% of young children would receive intravenous fluids. The unit costs for the rehydration methods
were obtained from the BNF for Children80 and are shown in Table 30 along with the administration costs.
Utilities
Utilities for the different pathogens remained the same as the base model, except for rotavirus, in which
case the mean QALY loss value changed from 0.0032 to 0.0022. This figure was derived from UK-based
studies of rotavirus in children.70,72,75,78
Model 3: people in the community with suspected gastroenteritis
We have assumed that the model structure for people in the community is simplified (Figure 13).
Prevalence and probabilities
Table 37 shows the prevalence of pathogens and conditional agreement probabilities when conventional
testing is the benchmark for the community. Prevalences for conventional testing were obtained from the
Second Study of Infectious Intestinal Disease in the Community.1 The overall pathogen detection rate was
34.9% for conventional testing, 31.6% for xTAG and 32.5% for FilmArray testing. Probabilities for positive
and negative agreements for each pathogen were drawn from the clinical effectiveness review.
We have assumed that the proportion of patients treated and not treated, as shown in Table 25, would
remain the same for the community. The overall conditional probabilities for patients in whom a pathogen
is detected are shown in Table 38.
Following advice from our clinical experts, we have assumed that the probability that a patient’s symptoms
resolve naturally is 0.75 and the probability that a patient’s symptoms persist is 0.25. Other probabilities
used in the model are shown in Table 39.
Resource use and costs
Conventional test costs and GPP test costs, as shown in Table 29, remain unchanged. The community
model does not include costs incurred by the NHS, such as bed-days, cleaning, tests or investigations,
or blood tests.
For both arms, each patient is assumed to visit a GP before the testing process takes place. As this cost is
common to both arms, it has not been included. However, in the case of patients who need treatment,
the model includes the cost of 5 minutes’ GP time to review results and prescribe treatment together with
the cost of 10 minutes’ nurse time to contact the patient to explain the test result and ask the patient to
HEALTH ECONOMIC METHODS AND RESULTS
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come and collect the prescription. GP and nurse costs were obtained from the Unit Costs of Health and
Social Care for 2015.59
The proportions of patients with C. difficile, Campylobacter, Salmonella, Shigella, E. coli (non-shiga toxin
producing) or Giardia infection who received different treatments were assumed to be the same as in the
base model. However, on the advice of our clinical experts, we have assumed that 33.3% of C. difficile
Symptoms resolve 
Treat
Symptoms persist 
Pathogen
Symptoms resolve
Not treat
Patient Symptoms persist 
Symptoms resolve 
Symptoms resolve 
Treat
No pathogen Symptoms persist 
Pathogen
Symptoms resolve 
Not treat
Symptoms persist 
Symptoms persist
Symptoms resolve
No pathogen
Symptoms persist
FIGURE 13 Overall model structure for patients with suspected gastroenteritis in the community.
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patients would receive vancomycin and 66.6% would receive metronidazole. The costs of the drugs were
taken from the BNF65 (see Table 30).
We have assumed that 10% of patients in the community would receive oral rehydration. The unit costs
for the different rehydration methods were obtained from the BNF65 (no administration costs have been
included) (see Table 30).
Utilities
Utilities for the different pathogens remain the same as the base model.
Model 4: people who are immunocompromised with suspected gastroenteritis
We have assumed that the model structure for people who are immunocompromised in hospital is the
same as the non-immunocompromised adult hospital model.
Prevalence and probabilities
Table 40 shows the prevalence of pathogens and conditional agreement probabilities when conventional
testing is the benchmark for immunocompromised patients, which was estimated by our clinical experts
using the hospital prevalence for adults as a base case. The overall pathogen detection rate was 31.1% for
conventional testing, 28.7% for xTAG and 29.4% for FilmArray testing.
Our clinical experts estimated that the proportions of patients who would be treated and not treated are
as shown in Table 41.
The overall conditional probabilities for patients for whom a pathogen is detected are shown in Table 42.
All common probabilities, as shown in Table 27, remain the same. The other probabilities for model 4 are
shown in Table 43.
Resource use and costs
Conventional test costs and GPP costs, as shown in Table 29, remain the same. We have assumed that
only costs relating to the episode of diarrhoea have been included in this analysis; any additional costs
associated with the hospital stay have not been included.
We assumed that the number of days spent in hospital is the same for immunocompromised as for
non-immunocompromised adults infected with the same pathogen (obtained from Hospital Episodes
TABLE 38 Probabilities used in the model in response to a positive result: model 3
Clinical pathway
Conventional testing as
benchmark (first test)
xTAG Film Array
First test Second test First test Second test
Total treated 0.1266 0.1332 0.0651 0.1334 0.0352
Total not treated 0.8734 0.8668 0.9349 0.8666 0.9648
TABLE 39 Other probabilities used in model 3
Clinical pathway Conventional xTAG FilmArray Source
No pathogen, symptoms resolve: discharge 0.8868 0.9155 0.9615 Goldenberg et al.56
No pathogen, symptoms persist: retest 0.1132 0.0845 0.0385 Goldenberg et al.56
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Statistics67), as hospital stay did not differ by age or sex. The costs for bed-days were obtained from
NHS Reference Costs62 and remain the same as model 1.
We have assumed that cleaning will take place each day and that spot cleaning will take place every
second day, as in the base model.
TABLE 42 Probabilities used in the model in response to a positive result: model 4
Clinical pathway
Conventional testing as
benchmark (first test)
xTAG Film Array
First test Second test First test Second test
Total treated and isolated 0.5750 0.5951 0.3325 0.5895 0.3213
Not treated and isolated 0.0609 0.0628 0.0390 0.0627 0.0309
Not treated and not isolated 0.3215 0.3016 0.5617 0.3068 0.5799
No treatment: discharged 0.0425 0.0405 0.0667 0.0410 0.0679
TABLE 43 Other probabilities used in model 4
Clinical pathway Conventional xTAG FilmArray Source
Isolate, no pathogen, symptoms resolve: discharge 0.9573 0.9204 0.9645 Goldenberg et al.56
Isolate, no pathogen, symptoms persist: retest 0.0213 0.0796 0.0355 Clinical expert assumption
Isolate, no pathogen, deisolate: not treat 0.0213 0.0000 0.0000 Clinical expert assumption
Not isolate, no pathogen, symptoms resolve:
discharge
0.8868 0.9204 0.9645 Goldenberg et al.56
Not isolate, no pathogen, symptoms resolve: retest 0.1132 0.0796 0.0355 Goldenberg et al.56
TABLE 41 Proportion of patients treated and not treated: model 4
Pathogen Treated and isolated Not treated and isolated Not treated and not isolated
Adenovirus – 1.00 0.00
C. difficile 0.95 0.05 0.00
Campylobacter 0.70 0.30 0.00
Cryptosporidium 0.00 1.00 0.00
E. coli O157 0.00 1.00 0.00
ETEC 0.80 0.20 0.00
Giardia 0.95 0.025 0.025
Norovirus 0.00 1.00 0.00
Rotavirus 0.00 1.00 0.00
Salmonella 0.80 0.20 0.00
Shigella 0.80 0.20 0.00
ETEC, enterotoxigenic E. coli.
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We have assumed that every patient will undergo two full blood counts (one on admission and one after).
The same percentage (30%) of patients as in the base model will undergo routine blood chemistry and a
C-reactive protein test.
We also assumed that 20% of patients in whom a pathogen was not detected and only 1% of patients in
whom a pathogen was detected would undergo flexible sigmoidoscopy test (the latter value remains the
same as in the base model). We estimated that 10% of patients in whom C. difficile was detected and
20% of patients in whom no pathogen was detected would undergo abdominal radiography. It was
assumed that 5% of patients in the conventional arm and 2% of patients in the GPP arm in whom any
other pathogen was detected would undergo abdominal radiography.
The proportions of patients with C. difficile, Campylobacter, Salmonella, Shigella, E. coli (non-shiga toxin
producing) or Giardia infection who received different treatments were assumed to be the same as in the
base model. The costs of the drugs were taken from the BNF65 (see Table 30).
We have assumed that 60% of patients will receive oral rehydration and 30% will receive intravenous
fluids, as in the base model.
Utilities
Utilities for the different pathogens remained the same as in the base model.
Model 5: people with a recent history of foreign travel with suspected gastroenteritis
We have assumed that the model structure for people with a recent history of foreign travel with
suspected gastroenteritis is the same as for people in the community (see Figure 13).
Prevalence and probabilities
Table 44 shows the prevalence of pathogens and conditional agreement probabilities when conventional
testing is the benchmark for recent travellers and prevalences were estimated by our clinical experts using
the community prevalence for adults as a base case. The overall pathogen detection rate was 31.1% for
conventional testing, 28.0% for xTAG and 29.2% for FilmArray testing.
We have assumed that the proportion of patients treated and not treated, as shown in Table 25, will
remain the same in the case of recent travellers. The overall conditional probabilities for patients in whom
a pathogen is detected are shown in Table 45.
Following advice from our clinical experts, we have assumed that the probability that a patient’s symptoms
resolve naturally is 0.75 and the probability that symptoms persist is 0.25. Other probabilities used in the
model are shown in Table 46.
Resource use and costs
Conventional test costs and GPP test costs, as shown in Table 29, remain the same. The recent travellers
model does not include costs incurred by the NHS such as bed-days, cleaning, tests or investigations,
or blood tests.
As with the community care model, for both testing methods each patient is assumed to visit a GP before
the testing process takes place, at no net cost. Again, in the case of patients who need treatment, the
model includes the cost of 5 minutes’ GP time to review results and prescribe treatment together with the
cost of 10 minutes’ nurse time to contact the patient to explain the test result and ask the patient to come
and collect the prescription. GP and nurse costs were obtained from the Unit Costs of Health and Social
Care for 2015.59
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The proportions of patients with C. difficile, Campylobacter, Salmonella, Shigella, E. coli (non-shiga toxin
producing) or Giardia infection who received different treatments were assumed to be the same as in the
base model. The costs for the drugs were taken from the BNF65 (see Table 30).
We have assumed that 10% of recent travellers will receive oral rehydration. The unit costs for the
rehydration methods were obtained from the BNF65 (no administration costs have been included)
(see Table 30).
Utilities
Utilities for the different pathogens remained the same as in the base model.
Measuring cost-effectiveness
The models were constructed to compare the cost-effectiveness of integrated multiplex PCR tests and
conventional testing in patients with suspected infectious gastroenteritis. The models estimated the mean
total costs and total QALY losses avoided for each GPP test compared with conventional care for the initial
index episode. The analysis was undertaken from a NHS and Personal Social Services perspective, and
outcomes are reported as incremental cost-effectiveness ratios (ICERs), expressed in terms of cost per
QALY gained.
To assess the uncertainty in parameter inputs used in the decision tree model and to check if the results
obtained are robust, we present both deterministic and probabilistic results. For the deterministic analysis,
we identify the key factors driving the cost-effectiveness. For the probabilistic sensitivity analysis, to reflect
the amount and pattern of variation, the analysis was conducted by running the model with 1000
simulations and calculating the incremental costs and effects for each simulation. In each simulation, the
value for each parameter was sampled from its probability distribution. We used gamma distributions for
costs (except for test costs that we assumed were fixed) and beta distributions for utility values and
probabilities.81 For the costs and probabilities in the model, we assumed that the standard error was 0.1 of
the mean value82,83 in order to calculate the alpha and beta values that are required for the probabilistic
sensitivity analysis. These bootstrapped simulations were plotted on a cost-effectiveness plane and were
used to present results as cost-effectiveness acceptability curves (CEACs), which indicated the probability of
a GPP test being cost-effective compared with conventional testing using a willingness-to-pay threshold
varying from £0 to £60,000.
TABLE 45 Probabilities used in the model in response to a positive result: model 5
Clinical pathway
Conventional testing as
benchmark (first test)
xTAG Film Array
First test Second test First test Second test
Total treated 0.2402 0.2512 0.1389 0.2503 0.0791
Total not treated 0.7598 0.7488 0.8611 0.7497 0.9209
TABLE 46 Other probabilities used in model 5
Clinical pathway Conventional xTAG FilmArray Source
No pathogen, symptoms resolve: discharge 0.8868 0.9205 0.9636 Goldenberg et al.56
No pathogen, symptoms persist: retest 0.1132 0.0795 0.0364 Goldenberg et al.56
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Results of the cost-effectiveness modelling
The cost-effectiveness deterministic and probabilistic results for the GPP tests compared with conventional
testing are presented in this section.
Model 1 results: hospitalised adult patients with suspected gastroenteritis
Table 47 shows the results when conventional testing is the benchmark for the adult hospital model
(model 1). The deterministic model results show that both xTAG and FilmArray cost marginally less than
conventional testing (£69 and £61 cheaper per patient, respectively) with marginally fewer QALYs lost
(or more QALYs gained), and hence dominate conventional testing. The probabilistic findings are very
similar, but show huge uncertainty in the changes in cost and QALYs gained, shown by the 95% CIs.
Figures 14 and 15 show the cost-effectiveness planes when conventional testing is the benchmark for
model 1. In both figures, the bootstrap estimates are located in all four quadrants, with costs and
outcomes negatively correlated. Figures 16 and 17 show the CEACs when conventional testing provides
the benchmark. In both figures, GPP testing is of uncertain cost-effectiveness (approximately 57%
probability for xTAG and 54% probability for FilmArray) at a willingness-to-pay threshold of £20,000
per QALY. The figures also highlight that willingness to pay has no effect and as a general rule, when
estimating cost-effectiveness ratios with incremental QALYs close to zero, the ICER sign may switch.
In the base-case analysis, we assume that the minimum total bed-days required with both methods of
testing is 3 (even though the results would expect to be returned more quickly for GPP testing). In a
scenario analysis we have tested the assumption that patients undergoing GPP testing leave hospital 1 day
earlier than patients receiving conventional care, rather than after the same number of days (as in the
base-case analysis). The results of this analysis are shown in Figures 18–20.
The incremental per-patient mean costs are £63 less for xTAG and £52 less for FilmArray testing than for
conventional care when there is no difference in the overall length of stay (i.e. 3 days; see Figure 18).
If patients are discharged, on average, 1 day earlier, the cost saving per patient rises to £679 for xTAG
and to £677 for FilmArray.
TABLE 47 Cost-effectiveness results for hospitalised adult patients: model 1
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (95% CI)
(£)
Incremental QALYs
gained (95% CI)
ICER (cost
per QALY
gained)
Net
monetary
benefit
(£20,000/
QALY) (£)
Deterministic results
Conventional 3157 0.00309 – – – –
xTAG 3089 0.00292 –69 0.00018 Dominant 72
Conventional 3157 0.00309 – – – –
FilmArray 3096 0.00297 –61 0.00013 Dominant 64
Probabilistic results
Conventional 3159 0.00309 – – – –
xTAG 3095 0.00293 –63
(–929 to 791)
0.00016
(–0.00071 to 0.00106)
Dominant 67
(–802 to 947)
Conventional 3159 0.00309 – – – –
FilmArray 3107 0.00298 –52
(–883 to 793)
0.00012
(–0.00079 to 0.00104)
Dominant 54
(–806 to 909)
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FIGURE 14 Cost-effectiveness plane: xTAG vs. conventional testing (benchmark) (model 1).
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FIGURE 16 Cost-effectiveness acceptability curve: xTAG vs. conventional testing (benchmark) (model 1).
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FIGURE 19 Incremental mean QALYs (probabilistic results): model 1. (a) xTAG vs. conventional testing; and
(b) FilmArray vs. conventional testing.
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FIGURE 17 Cost-effectiveness acceptability curve: FilmArray vs. conventional testing (benchmark) (model 1).
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FIGURE 18 Incremental mean costs (probabilistic results): model 1. (a) xTAG vs. conventional testing; and
(b) FilmArray vs. conventional testing.
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Figure 19 shows the incremental mean QALYs gained when changing the length of stay for GPP testing.
However, in the model no disutility is attached to being in hospital (the value to patients is unknown);
thus, earlier discharge might result in a reduction of disutility further enhancing cost-effectiveness, if
reductions in length of stay do occur. Figure 20 shows the net monetary benefit (which brings costs and
QALYs with willingness to pay). With earlier discharge, the net monetary benefit of GPP testing increases,
but the 95% CI does not exceed zero at a threshold of £20,000 per QALY.
Figures 21 and 22 show the one-way sensitivity analysis (tornado diagrams); a number of key variables
were varied while holding others constant to understand what was influencing the net monetary benefit of
GPP tests.
Figure 21 is centred on the net monetary benefit ratio of £72 for xTAG compared with conventional
testing. The most important variable is the number of bed-days, when the speed of reporting of findings is
allowed to influence length of stay in patients without a pathogen. A variation of 50% in the number of
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Bed-days (not detect and discharge)
Probability of detect (first test)
Probability of isolation
Proportion of n = false positive
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Change in net monetary benefit (£) (WTP at £20,000)
50%
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FIGURE 21 Tornado diagram for net monetary benefit of conventional testing (benchmark) vs. xTAG: model 1.
i.v., intravenous; WTP, willingness to pay.
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bed-days for the GPP tests has a dramatic effect on net monetary benefit. For xTAG, by increasing the
number of bed-days by 50% from 3 to 4.5 days the net monetary benefit ratio falls to –£575, whereas
reducing the number of bed-days by 50% from 3 to 1.5 days increases the net monetary benefit ratio to
£719. The potential value of earlier detection and discharge (if possible) would affect the majority of
patients, and cost savings would dwarf any other influence in the model, such as assumptions about time
in isolation or changes to isolation room use. The next most important variable is the false-positive rate, as
an increase in the false-positive rate in the model gives rise to unnecessary further testing and care. Other
influences include the costs of the tests themselves, the costs of bed-days and the probability of initial
isolation. Results are similar for FilmArray and conventional testing (see Figure 22).
Model 2 results: young children with suspected gastroenteritis
Table 48 shows the results when conventional testing is the benchmark for the hospital admission model
in young children (model 2). The deterministic results show that both xTAG and FilmArray are marginally
less costly and marginally more effective (more QALYs gained), but again the probabilistic findings show
that costs and QALY savings are highly uncertain.
Figures 23 and 24 show the cost-effectiveness planes when conventional testing is the benchmark for
model 2. Like model 1, the bootstrap estimates are located in all four quadrants, with costs and outcomes
negatively correlated. Figures 25 and 26 show the CEACs when conventional testing provides the
benchmark. In both figures, GPP testing is of uncertain cost-effectiveness (approximately 58% probability
for xTAG and 57% probability for FilmArray) at a willingness-to-pay threshold of £20,000 per QALY.
As mentioned in Model 1 results: hospitalised adult patients with suspected gastroenteritis, the figures
highlight that willingness to pay has no effect and, as a general rule, when estimating cost-effectiveness
ratios with incremental QALYs close to zero, the ICER sign may switch.
In a scenario analysis, we have tested the assumption that patients undergoing GPP testing leave hospital
1 day earlier than patients receiving conventional care, rather than after the same number of days (as in
model 1). The incremental per-patient mean costs are £73 less for xTAG and £83 less for FilmArray testing
than for conventional care when there is no difference in the overall length of stay (i.e. 3 days; Figure 27).
If patients are discharged, on average, 1 day earlier, the cost saving per patient rises to £959 for xTAG and
to £969 for FilmArray.
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FIGURE 22 Tornado diagram for net monetary benefit of conventional testing (benchmark) vs. FilmArray: model 1.
i.v., intravenous; WTP, willingness to pay.
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As with model 1, the incremental mean QALYs gained varied little when changing the length of stay for
GPP testing, reflecting the fact that no disutility is attached to being in hospital. Figure 28 shows the net
monetary benefit: with earlier discharge, the net monetary benefit of GPP testing increases and for this
model with its assumptions. The 95% CI exceeds zero at a threshold of £20,000 per QALY, if GPP testing
reduces length of stay by 1 day.
Model 3 results: people in the community with suspected gastroenteritis
Table 49 shows the results when conventional testing is the benchmark for people in the community
with an episode of gastroenteritis (model 3). Use of xTAG resulted in a small net negative cost, whereas
FilmArray marginally increased costs; both tests marginally improved quality of life. The probabilistic results
showed that the differing costs were robust given the assumptions in the model. Consequently, xTAG
appears cost-effective whereas FilmArray does not.
TABLE 48 Cost-effectiveness results for hospitalised young children: model 2
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost
per QALY
gained)
Net
monetary
benefit
(£20,000 per
QALY) (£)
Deterministic results
Conventional 3300 0.00267 – – – –
xTAG 3237 0.00242 –63 0.00025 Dominant 68
Conventional 3300 0.00267 – – – –
FilmArray 3221 0.00249 –79 0.00017 Dominant 82
Probabilistic results
Conventional 3313 0.00263 – – – –
xTAG 3240 0.00239 –73
(–955 to 849)
0.00024
(–0.00049 to 0.00117)
Dominant 78
(–856 to 977)
Conventional 3313 0.00263 – – – –
FilmArray 3231 0.00246 –83
(–1094 to 858)
0.00017
(–0.00061 to 0.00114)
Dominant 86
(–869 to 1114)
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FIGURE 23 Cost-effectiveness plane: xTAG vs. conventional testing (benchmark) (model 2).
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FIGURE 26 Cost-effectiveness acceptability curve: FilmArray vs. conventional testing (benchmark) (model 2).
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FIGURE 24 Cost-effectiveness plane: FilmArray vs. conventional testing (benchmark) (model 2).
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FIGURE 25 Cost-effectiveness acceptability curve: xTAG vs. conventional testing (benchmark) (model 2).
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FIGURE 27 Incremental mean costs (£) (probabilistic results): model 2. (a) xTAG vs. conventional testing; and
(b) FilmArray vs. conventional testing.
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FIGURE 28 Net monetary benefit (willingness-to-pay threshold = 20,000/QALY) (probabilistic results): model 2.
TABLE 49 Cost-effectiveness results for people in the community: model 3
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost
per QALY
gained)
Net
monetary
benefit
(£20,000/
QALY) (£)
Deterministic results
Conventional 72 0.00139 – – – –
xTAG 40 0.00136 –32 0.00003 Dominant 32
Conventional 72 0.00139 – – – –
FilmArray 97 0.00138 25 0.00002 1,653,939 –25
Probabilistic results
Conventional 72 0.00139 – – – –
xTAG 40 0.00136 –32
(–49 to –15)
0.00003
(–0.00036 to 0.00045)
Dominant 32
(9 to 56)
Conventional 72 0.00139 – – – –
FilmArray 97 0.00137 25 (0 to 48) 0.00002
(–0.00036 to 0.00042)
1,309,346 –25
(–53 to 7)
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Figures 29 and 30 show the cost-effectiveness planes when conventional testing is the benchmark for
model 3. Bootstrapped estimates for xTAG are primarily in the southern quadrants, denoting cost saving,
whereas estimates for FilmArray are primarily in the northern quadrants, denoting increased cost. Figures 31
and 32 show the CEACs, which indicate that GPP testing probabilistically is nearly 100% cost-effective
using xTAG but approximately 6% cost-effective using FilmArray, at a willingness-to-pay threshold of
£20,000 per QALY.
Figures 33 and 34 show one-way sensitivity analyses (tornado diagrams) of key variables. Each are
varied in turn while holding others constant to understand what influences net monetary benefit, at a
willingness-to-pay threshold of £20,000 per QALY.
Net monetary benefit is centred around £32.30 for xTAG GPP when compared with conventional testing
(see Figure 33). In this community model, all of the hospital costs are removed. The most important
variables are assumptions about the costs of the conventional and GPP tests, as seen when these are
varied by 50%. The finding is similar for FilmArray (see Figure 34), which is centred on a net monetary
benefit ratio of –£24.90. Changing the cost of drugs, the cost of oral rehydration, the probability of
detection (for the first test) and the utilities had little effect on the net monetary benefit.
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FIGURE 29 Cost-effectiveness plane: xTAG vs. conventional testing (benchmark) (model 3).
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FIGURE 30 Cost-effectiveness plane: FilmArray vs. conventional testing (benchmark) (model 3).
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FIGURE 31 Cost-effectiveness acceptability curve: xTAG vs. conventional testing (benchmark) (model 3).
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FIGURE 32 Cost-effectiveness acceptability curve: FilmArray vs. conventional testing (benchmark) (model 3).
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FIGURE 33 Tornado diagram for net monetary benefit conventional testing (benchmark) vs. xTAG: model 3.
WTP, willingness to pay.
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Model 4 results: people immunocompromised with suspected gastroenteritis
Table 50 shows the results when conventional testing is the benchmark for patients who are
immunocompromised (model 4). The deterministic results show that both xTAG and FilmArray are
marginally less costly and more effective (more QALYs gained), but again the probabilistic findings show
that cost and QALY savings are highly uncertain. Figures 35 and 36 show the cost-effectiveness planes
when conventional testing is the benchmark for model 4. Like models 1 and 2, the bootstrap estimates are
located in all four quadrants, with costs and outcomes negatively correlated. Figures 37 and 38 show the
CEACs when conventional testing provides the benchmark. For both figures, GPP testing is of uncertain
cost-effectiveness (approximately 55% probability for xTAG and 57% probability for FilmArray) at a
willingness-to-pay threshold of £20,000 per QALY. As mentioned in Model 1 results: hospitalised adult
patients with suspected gastroenteritis, Figures 37 and 38 highlight that willingness to pay has no effect
and, as a general rule, when estimating cost-effectiveness ratios with incremental QALYs close to zero,
the ICER sign may switch.
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FIGURE 34 Tornado diagram for net monetary benefit conventional testing (benchmark) vs. FilmArray: model 3.
WTP, willingness to pay.
TABLE 50 Cost-effectiveness results for immunocompromised patients: model 4
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost
per QALY
gained)
Net monetary
benefit
(£20,000/
QALY) (£)
Deterministic results
Conventional 3561 0.00384 – – – –
xTAG 3486 0.00361 –76 0.00023 Dominant 80
Conventional 3561 0.00384 – – – –
FilmArray 3493 0.00367 –68 0.00017 Dominant 72
Probabilistic results
Conventional 3563 0.00384 – – – –
xTAG 3482 0.00361 –81
(–1031 to 891)
0.00023
(–0.00094 to 0.00134)
Dominant 86
(–901 to 1056)
Conventional 3563 0.00384 – – – –
FilmArray 3486 0.00367 –77
(–1024 to 871)
0.00017
(–0.00088 to 0.00129)
Dominant 80
(–883 to 1047)
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FIGURE 35 Cost-effectiveness plane: xTAG vs. conventional testing (benchmark) (model 4).
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FIGURE 36 Cost-effectiveness plane: FilmArray vs. conventional testing (benchmark) (model 4).
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FIGURE 37 Cost-effectiveness acceptability curve: xTAG vs. conventional testing (benchmark) (model 4).
HEALTH ECONOMIC METHODS AND RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
Model 5 results: people with a recent history of travel with suspected gastroenteritis
Table 51 shows the results when conventional testing is the benchmark for the recent travellers model
(model 5). The deterministic results are very similar to the adult community model (model 3); xTAG
dominates conventional testing, being cheaper (£32) and resulting in the loss of fewer QALYs. The
probabilistic analysis points to small but significant cost savings and more uncertain QALY gains. This
is shown graphically in the ICER plane (Figure 39) and CEAC (Figure 40), which find xTAG testing
probabilistically to be approximately 99% likely to be cost-effective given the assumptions in the model.
Table 51 also shows the deterministic results for FilmArray vs. conventional care. Again, the results are
similar to the community model, as shown in Model 3 results: people in the community with suspected
gastroenteritis, in that the FilmArray test is slightly more expensive and effective than conventional care,
although there is a considerable uncertainty about the QALYs gained. Probabilistic estimation is shown
graphically in the cost-effectiveness plane (Figure 41) and CEAC (Figure 42); there is an approximately
6% probability that FilmArray is cost-effective at a willingness-to-pay threshold of £20,000 per QALY.
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FIGURE 38 Cost-effectiveness acceptability curve: FilmArray vs. conventional testing (benchmark) (model 4).
TABLE 51 Cost-effectiveness results for recent travellers: model 5
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (95% CI)
(£)
Incremental QALYs
gained (95% CI)
ICER (cost
per QALY
gained)
Net
monetary
benefit
(£20,000/
QALY) (£)
Deterministic results
Conventional 73 0.00180 – – – –
xTAG 41 0.00174 –32 0.00006 Dominant 33
Conventional 73 0.00180 – – – –
FilmArray 98 0.00177 25 0.00002 1,020,674 –25
Probabilistic results
Conventional 73 0.00181 – – – –
xTAG 42 0.00175 –31
(–48 to –16)
0.00006
(–0.00044 to 0.00055)
Dominant 32
(9 to 57)
Conventional 73 0.00181 – – – –
FilmArray 98 0.00176 25
(2 to 44)
0.00004
(–0.00046 to 0.00055)
560,220 –24
(–52 to 7)
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FIGURE 39 Cost-effectiveness plane: xTAG vs. conventional testing (benchmark) (model 5).
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FIGURE 40 Cost-effectiveness acceptability curve: xTAG vs. conventional testing (benchmark) (model 5).
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FIGURE 41 Cost-effectiveness plane: FilmArray vs. conventional testing (benchmark) (model 5).
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Additional analyses
Daily throughput of tests
We varied the average daily number of samples for each of the GPP tests. For all levels of throughput, one
xTAG system is employed; for FilmArray, one system with four modules was employed for 12 samples per
day, and eight modules for 24 and 48 samples per day. Table 52 provides the deterministic cost-effectiveness
results when the number of samples is changed from 24 (base-case analysis) to 12 or 48 for model 1. There
is very little difference in the incremental costs, and the overall results show that the GPP tests dominate
conventional care.
Further additional analyses, as requested by the NICE committee, are shown in Appendix 11.
Conventional
FilmArray
1.0
0.9
0.8
0.7
0.6
0.5
Pr
o
b
ab
ili
ty
0.4
0.3
0.2
0.1
0.0
0 6 12 18 24 30 36 42 48 54
Cost (£000)/QALY
FIGURE 42 Cost-effectiveness acceptability curve: FilmArray vs. conventional testing (benchmark) (model 5).
TABLE 52 Changing the daily throughput for each GPP test
Test
Total
mean
costs (£)
Total mean
QALY loss
Incremental
costs (£)
Incremental QALYs
gained
ICER (cost
per QALY
gained)
Net monetary
benefit
(£20,000/
QALY) (£)
Deterministic results
Conventional 3300 0.00267 – – – –
xTAG 3237 0.00242 –63 0.00025 Dominant 68
Conventional 3300 0.00267 – – – –
FilmArray 3221 0.00249 –79 0.00017 Dominant 82
Deterministic results: 12 samples
Conventional 3157 0.00309 – – – –
xTAG 3094 0.00292 –64 0.00018 –359968 67
Conventional 3157 0.00309 – – – –
FilmArray 3099 0.00297 –59 0.00013 –465006 61
Deterministic results: 48 samples
Conventional 3157 0.00309 – – – –
xTAG 3086 0.00292 –71 0.00018 –399635 74
Conventional 3157 0.00309 – – – –
FilmArray 3092 0.00297 –65 0.00013 –515654 68
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Discussion
For the base-case analysis, we modelled a hypothetical cohort of hospitalised adult patients with suspected
gastroenteritis. We assumed that conventional testing provided a pragmatic benchmark with which to
compare the GPP tests. The de novo economic model was a simple decision tree analysis, as gastroenteritis is
a self-limiting illness and usually stops within 2 weeks. The analysis was conducted from a NHS and Personal
Social Services perspective. Data for the model, including prevalence information, were obtained from a
systematic clinical effectiveness review, published literature and expert opinion. Costs are reported in pounds
sterling (£) in 2014/15 prices. Results are expressed as incremental cost per QALY gained. No discounting
was performed as the time frame was < 1 year. We ran the model deterministically and probabilistically with
1000 bootstrapped iterations. We undertook various sensitivity analyses; the base-case model was adapted
to look at various subgroups: young children, people in the community, immunocompromised patients
and patients with a recent history of travel.
Methods and summary of findings
In the base model (adult hospitalised patients) and base-case assumptions, there was considerable
uncertainty about the cost-effectiveness of GPP tests (Table 53). The pattern was similar for the two other
hospital models involving young children and immunocompromised patients. These models show that
varying pathogen prevalence does not significantly affect the cost-effectiveness of testing. Important
variables are length of stay and the management of false-positive findings. In the community model,
and likewise the recent travellers model, xTAG appeared cost-effective, whereas FilmArray did not. In
community models, without the potential for hospital length-of-stay savings, cost-effectiveness is driven by
the costs of the tests themselves and assumptions made when estimating these costs. All findings are
sensitive to costs estimated for the two tests; findings would vary with different cost assumptions.
A sensitivity analysis identified the potential to reduce the number of bed-days as a key cost driver in the
adult hospital. Although earlier discharge is plausible, it is by no means certain in the present hospital
environment, in which patients are generally discharged as soon as possible and care may be symptom led
rather than diagnosis led. In the absence of evidence, earlier discharge for GPP testing was explored in
a scenario analysis, which indicated that if length of stay is reduced, then GPP testing is likely to be
cost-effective.
Strengths and limitations
Although we undertook a thorough search of cost-effectiveness studies of the use of GPP tests compared
with conventional testing for patients with suspected gastroenteritis, we could not identify any relevant
economic models that could be adapted. Consequently, a de novo decision tree model was built to
compare GPP testing with conventional care. A number of limitations apply to the economic model.
l The model provides a representation of the clinical care pathway in the NHS, although practice and
management will vary from site to site. We have compared ‘like with like’, that is, GPP tests are
compared with a complete panel of conventional tests. Clinicians in some settings may order tests
selectively and sequentially, as necessary, rather than as a complete panel of tests. As this strategy may
not alter the pathway of care for most patients, conventional testing costs would be reduced. However,
this strategy may result in a delayed diagnosis of treatable pathogens in a small minority of patients
and needs to be formally evaluated – this was beyond the scope of the current work.
l We could compare conventional testing with xTAG and FilmArray only; we could not retrieve any
clinical data for Faecal Pathogens B.
l We have assumed in the base-case model (adult hospital) that the minimum length of stay in hospital
is 3 days; in practice, some patients may be discharged earlier, but this applies to both GPP and
conventional testing.
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l The costs of the new GPP tests were based on the assumption that the machine would be running for
365 days per year, and an average of 24 samples would be run each day. We specified the capacity of
GPP tests within the model to cope with variation on a daily basis and peak demand – theoretically,
xTAG could be run twice a day in normal working hours and FilmArray units 8–10 times; thus, both
configurations could cope with higher capacity. Although the economics change marginally in
low-throughput settings, FilmArray appeared to be a comparatively expensive system.
l Assumptions made about the costs of the GPP systems relative to conventional testing are important
influences in the model.
l We have not taken into account any broader societal costs such as lost productivity or time off work as
a result of suspected gastroenteritis or length of stay in hospital. Similarly, no account has been taken
of the costs of providing alternative care for children or other dependants of adults with gastroenteritis
who are hospitalised or require care in the community. Costs may be underestimated and outcomes
overestimated, as the model has not taken into account rare instances of mortality, recurrence or
adverse events because of the lack of evidence. Thus, the model is limited to the initial index episode
and does not consider readmissions. Buchanan et al.84 stated that 10% of patients who have been
discharged on antibiotics for infectious diarrhoea from hospital before a full course of treatment has
been completed will be readmitted within 14 days of discharge.
l We have not considered the management of outbreaks, as this was excluded from the scope of work.
l We have not included costs for the treatment of Cryptosporidium, as there is no standard approved
treatment in the UK for this infection.
l We conducted a comprehensive literature search for disutility/utility values for gastroenteritis and found
that most values in the literature were based around children with rotavirus – no adult utility values
were identified for either hospital or community. Adult utilities used in the economic model for the
different pathogens are based on food-borne illnesses from the USA, which used the EQ-5D.
l In practice, each laboratory may receive a varying mix of hospital and community samples – the balance of
this mix may affect the overall cost-effectiveness of GPP testing. We have not estimated weighted analyses
based on variations in the mix of samples, as the five models presented are themselves tentative.
l Finally, modelled changes in costs and QALYs are simulations and have not been observed.
Findings should be verified through properly designed and conducted research.
TABLE 53 Summary economic model findings
Test
Incremental costs
(95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost per
QALY gained)
Probability
cost-effectivea
Net monetary
benefit (£)a
Model 1: hospitalised adult patients
xTAG –63
(–929 to 791)
0.00016
(–0.00071 to 0.00106)
Dominant 0.566 67
(–802 to 947)
FilmArray –52
(–883 to 793)
0.00012
(–0.00079 to 0.00104)
Dominant 0.544 54
(–806 to 909)
Model 2: hospitalised children
xTAG –73
(–955 to 849)
0.00024
(–0.00049 to 0.00117)
Dominant 0.583 78
(–856 to 977)
FilmArray –83
(–1094 to 858)
0.00017
(–0.00061 to 0.00114)
Dominant 0.568 86
(–869 to 1114)
Model 3: people in the community
xTAG –32 (–49 to –15) 0.00003
(–0.00036 to 0.00045)
Dominant 0.997 32 (9 to 56)
FilmArray 25 (0 to 48) 0.00002
(–0.00036 to 0.00042)
1,309,346 0.064 –25 (–53 to 7)
continued
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TABLE 53 Summary economic model findings (continued )
Test
Incremental costs
(95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost per
QALY gained)
Probability
cost-effectivea
Net monetary
benefit (£)a
Model 4: immunocompromised patients
xTAG –81
(–1031 to 891)
0.00023
(–0.00094 to 0.00134)
Dominant 0.553 86
(–901 to 1056)
FilmArray –77
(–1024 to 871)
0.00017
(–0.00088 to 0.00129)
Dominant 0.570 80
(–883 to 1047)
Model 5: recent travellers
xTAG –31 (–48 to –16) 0.00006
(–0.00044 to 0.00055)
Dominant 0.994 32 (9 to 57)
FilmArray 25 (2 to 44) 0.00004
(–0.00046 to 0.00055)
560,220 0.059 24 (–52 to 7)
a At a willingness-to-pay threshold of £20,000/QALY.
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Chapter 6 Discussion
Decision problem and objectives
The overall objective was to undertake a clinical effectiveness and cost-effectiveness analysis of the three
gastrointestinal panel tests (xTAG, FilmArray and Faecal Pathogens B). The panels simultaneously test for
common bacteria, viruses and parasites. The literature informing clinical effectiveness and cost-effectiveness
was systematically reviewed and summarised. A de novo economic model was developed to assess the
cost-effectiveness of GPP tests compared with current care in England and Wales.
Summary of methods and findings
Clinical effectiveness
We searched a number of databases including MEDLINE, EMBASE, Web of Science and The Cochrane
Library. We found 2215 unique records, of which 23 were included. Of these studies, 10 reported sufficient
data to assess agreement, by pathogen, comparing GPP assay and conventional methods using 2 × 2 tables.
In general, the methodological quality of the included studies was poor. No adequate test–treat trials or
diagnostic studies using a reference standard were retrieved, and no study conducted adequate discrepant
analysis or applied a fair umpire approach. In the absence of adequate studies, positive and negative
agreements were estimated, as recommended by FDA guidance, alternating conventional and GPP testing
as the benchmark as an aid to explore differences in findings. Using conventional methods as a benchmark,
GPP testing appears reliable and could replace current microbiological methods, although there would be
an increase in additional positive reporting. Whether or not this would result in some overtreatment is
uncertain; however, using GPP testing as the benchmark suggests that we might identify disease missed by
current methods. Potentially, the consequence might be more appropriate treatment for pathology missed
or not detected by conventional methods. Currently, the clinical importance of the additional pathogens
identified by GPP testing is uncertain.
The review has not included data from 1847 patients from three recent studies that were identified after
our deadline for considering studies for full review.45–47 These three studies consisted of a case–control
study of Ghanaian children aged < 6 years using xTAG,46 a study of 779 children aged < 18 years from the
USA using FilmArray,45 and a Belgian study of 386 mixed patients that assessed FilmArray for the detection
of shiga toxin-producing E. coli compared with an in-house culture-based PCR method.47 This final study is
the only one of the three that would have contributed 2 × 2 data for the meta-analysis; however, the study
considered only 1 out of 23 pathogens detectable with FilmArray. Full inclusion of the three studies would
therefore not have influenced or changed the conclusions of this review.
Current evidence is inadequate to compare the performance or value of different GPP systems. Direct
comparison may not necessarily be appropriate when these systems are designed with different operational
scale and throughput in mind, and provide overlapping but not identical coverage of pathogens. Further
research is needed to understand failure rates because of the various GPP systems, or importance of
multipathogen infections.
Cost-effectiveness
Given uncertainties about the performance of GPP systems and their impact on clinical care, any attempt
at economic modelling is necessarily tentative. An economic model has been developed to explore these
uncertainties. Pragmatically, as it reflects current practice, conventional testing serves as the benchmark in
the model (i.e. it is assumed to correctly identify clinically important pathology). Exploring the impact of
adopting GPP testing on clinical care requires multiple assumptions about the use of the tests and how the
tests affect the care provided. These assumptions have been variously informed by the direct evidence,
epidemiological sources and expert opinion.
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These limitations accepted, the hospital admission models indicate that use of GPP systems might be
cost-effective if they result in reduced length of stay. Community care use of GPP systems might
be cost-effective, but findings are sensitive to assumptions about the cost of GPP tests. Current evidence
precludes a robust conclusion, and so adoption should be further informed by findings from relevant and
robust research.
Strengths and limitations
Assessment of clinical evidence has depended on measures of agreement, which are not measures of test
accuracy in a conventional sense and should not be interpreted as such. For example, agreement analysis
takes no consideration of whether or not both tests can agree and be wrong. The quality of available
studies contributing to the clinical evidence review was generally poor.
Within the clinical studies identified, many pathogens were present only in very low numbers, and the
context of studies included a mixture of different patient populations (e.g. children, immunocompromised
patients, community), each with their own distribution of prevalence of pathogens.
As described, the economic model provides a representation of the clinical care pathway, and has
populated a decision tree with probabilities and values from the clinical evidence review, epidemiological
studies and clinical expert opinion. Although modelling methods permit an exploration of uncertainties,
ultimately the reliability of the model depends on the belief that modelled changes would actually occur in
clinical practice. It has not been possible to validate model findings with real-world data.
The scope of work has been limited to the management of patients in hospital and community settings
who are tested for suspected infectious gastroenteritis. The public health implications of different patterns
of testing or of special circumstances, such as infectious outbreaks, have not been considered.
Points for discussion
For the purpose of comparison within the economic model, the number of pathogens evaluated was
constrained to match the current PHE algorithm. However, the prevalence and importance of pathogens
varies over time and by context. Is the coverage within each of the panels adequate, or should this be
explicitly considered (e.g. should detection of sapovirus be specified, one of the most commonly identified
pathogens causing gastroenteritis in the community)? Sapovirus is included in the coverage of FilmArray
and the Faecal Pathogens B assay but not xTAG. Changes in prevalence and virulence of pathogens,
current coverage of GPPs and the ability of manufacturers to adapt coverage create a dynamic context for
decision-making.
Assumptions in the hospital economic models about length of stay are key to findings. What is the opinion
among committee members regarding whether length of stay is predominantly symptom driven or
pathogen detection/exclusion driven? Is there scope with earlier detection for earlier discharge, or is this
already efficiently managed in hospitals? Does the discharge destination further complicate matters given
the need for further hydration, hygiene and watchful waiting, when provision may differ between home,
care home and other institutional destinations?
The base-case model assumes an average throughput of 24 samples per day. Although we found no
evidence that our findings were strongly influenced by throughput, the largest hospital trusts in England
may currently process about 80 samples per day and the next 10–20 years may see a move towards
superlaboratories, with just 10–20 laboratories in the country, implying still greater throughput. In parallel
with these developments, GPP testing technology may further develop, making evidence requirements and
timing of adoption points for discussion.
DISCUSSION
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Chapter 7 Conclusions
The systematic review and cost-effectiveness model identify uncertainties about the adoption of GPP tests.GPP testing will generally correctly identify pathogens identified by conventional testing; however, these
tests also generate considerable additional positive results of uncertain clinical importance with potential
workplace implications for those diagnosed. Early diagnosis may change the management of patients
positively or negatively, for example possibly with earlier discharge in the case of negative findings but
possibly with unnecessary treatment in the case of positive findings when symptoms would spontaneously
resolve with watchful waiting over the following few days. The economic model reflects one pattern of care
for which patients are broadly tested in line with PHE guidance, although this practice is not universally
followed. Different practices, such as sequential testing, would give rise to different patterns of cost and
benefit. Model explorations suggest scope for GPP testing to be cost-effective, but considerable
uncertainty remains.
Recommendations for further research
Further research is needed. It may be difficult to design a study with an adequate independent reference
standard, although the clinical review suggests that such evidence may not be pivotal to an adoption
decision. A randomised controlled test–treat trial, with patients randomised to conventional or GPP testing,
recording total care received, and evaluating clinical effectiveness and cost-effectiveness outcomes, would
determine whether or not GPP systems can realise potential cost savings and improve patient utility.
Currently, there is no adequate evidence of the impact of GPP testing on the management, treatment and
outcome of patients, as no test–treat trials have been conducted. In addition, further evaluation might
consider the public health impact of different diagnostic approaches, as the results of testing are the basis
for public health surveillance of these diseases.
Current evidence should be regarded applicable to a mixed population of community and hospitalised
patients, as the studies do not adequately report outcomes by setting or subgroup. A goal for a future trial
might be to include adequate stratification of different populations (e.g. community managed patients,
community acquired and hospital managed patients, hospital acquired patients, children, travellers and
immunocompromised patients).
The NICE scope identified the PHE algorithm8 as the relevant comparator against which to consider GPP
tests. However, the PHE algorithm was published in 2013 and may need to be updated to reflect progress
in the microbiological laboratories. For instance, the new PHE guidance for the interpretation of PCR assays
for gastrointestinal pathogens states that a growing number of PHE and NHS virology laboratories use
PCR assays for the detection of gastrointestinal viral pathogens.50 The same guidance recommends PCR as a
first-line diagnostic test for the intestinal parasites G. lamblia, Cryptosporidium spp. and E. histolytica. This is
not reflected in the national standard of practice used in this review. Similarly, this review has evaluated
GPP systems according to their current specification, but it is anticipated that the coverage of these systems
will continue to evolve in response to changing pathogen prevalence, hence the evaluation problem is a
dynamic one.
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Appendix 1 Search strategy for clinical
effectiveness and cost-effectiveness review
MEDLINE and EMBASE searches
1. exp Gastroenteritis/
2. exp *Diarrhea/
3. exp *Feces/
4. exp *Gastroenteritis/
5. exp *Gastrointestinal Diseases/
6. (gastrointestin* or stool* or enteric* or feces or faeces or diarrh?ea).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Multiplex Polymerase Chain Reaction/
9. (xtag or Luminex or Filmarray or biofire).tw.
10. (“Faecal Pathogens B” or “Faecal Panel B” or ausdiagnostics).tw.
11. (multiplex* adj4 (PCR or polymerase chain reaction or assay* or panel* or test*)).tw.
12. (gastrointestinal pathogen panel or gastrointestinal infection panel).tw.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
Ovid MEDLINE: 1946 to November Week 3 2015 – 1424 downloaded.
Ovid MEDLINE In-Process & Other Non-Indexed Citations: 31 December 2015 – 138 downloaded.
Ovid EMBASE: 1980 to 2015 Week 52 – 1803 downloaded.
TABLE 54 Web of Science Core Collection search strategy: 1980 to 31 December 2015
Number Search terms
#4 #3 OR #2 OR #1
DocType=All document types; Language=All languages;
#3 TITLE: (xtag or Luminex or Filmarray or biofire or “Faecal Pathogens B” or “Faecal Panel B” or ausdiagnostics)
AND TOPIC: (gastro*)
DocType=All document types; Language=All languages;
#2 TS=(“gastrointestinal pathogen panel” or “gastrointestinal infection panel”)
DocType=All document types; Language=All languages;
#1 TITLE: (multiplex* and (PCR or polymerase chain reaction or assay* or panel* or test*)) AND TOPIC:
(gastrointestin*)
DocType=All document types; Language=All languages;
Downloaded: 98.
Auto-alerts
Weekly auto-alerts were run in Ovid MEDLINE, Ovid EMBASE and PubMed from 1 January 2016 to
31 April 2016 to check for any new studies added subsequent to the main searches.
DOI: 10.3310/hta21230 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 23
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
Search strategies for cost-effectiveness studies
Ovid MEDLINE and Ovid MEDLINE In-Process & Other Non-Indexed Citations
Ovid MEDLINE was searched from 1946 to January week 3 2016; and Ovid MEDLINE In-Process & Other
Non-Indexed Citations searched 27 January 2016.
1. exp Gastroenteritis/
2. exp *Diarrhea/
3. exp *Feces/
4. exp *Gastroenteritis/
5. exp *Gastrointestinal Diseases/
6. (gastrointestin* or stool* or enteric* or feces or faeces or diarrh?ea).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Multiplex Polymerase Chain Reaction/
9. (xtag or Luminex or Filmarray or biofire).tw.
10. (“Faecal Pathogens B” or “Faecal Panel B” or ausdiagnostics).tw.
11. (multiplex* adj4 (PCR or polymerase chain reaction or assay* or panel* or test*)).tw.
12. (gastrointestinal pathogen panel or gastrointestinal infection panel).tw.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
15. exp Economics/
16. exp “Costs and Cost Analysis”/
17. Health Status/
18. exp “Quality of Life”/
19. exp Quality-Adjusted Life Years/
20. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
21. (health state* or health status or “willingness to pay”).tw.
22. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short form or SF-36 or SF36 or
SF-6D or SF6D or SF-12 or SF12 or HUI).tw.
23. (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit* or
net-benefit* or contingent valuation).tw.
24. (quality adj2 life).tw.
25. (decision adj2 model).tw.
26. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or
(willing* adj2 pay)).tw.
27. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. 14 and 27
Downloaded: 144.
Ovid EMBASE
Searched 1974 to 27 January 2016.
1. exp Gastroenteritis/
2. exp *Diarrhea/
3. exp *Feces/
4. exp *Gastroenteritis/
5. exp *Gastrointestinal Diseases/
6. (gastrointestin* or stool* or enteric* or feces or faeces or diarrh?ea).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Multiplex Polymerase Chain Reaction/
9. (xtag or Luminex or Filmarray or biofire).tw.
10. (“Faecal Pathogens B” or “Faecal Panel B” or ausdiagnostics).tw.
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11. (multiplex* adj4 (PCR or polymerase chain reaction or assay* or panel* or test*)).tw.
12. (gastrointestinal pathogen panel or gastrointestinal infection panel).tw.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
15. exp health economics/
16. exp health status/
17. exp “quality of life”/
18. exp quality adjusted life year/
19. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
20. (health state* or health status).tw.
21. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form or SF-12 or SF12 or
SF-36 or SF36 or SF-6D or SF6D or HUI).tw.
22. (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit* or net
benefit or contingent valuation).tw.
23. (quality adj2 life).tw.
24. (decision adj2 model).tw.
25. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or
(willing* adj2 pay)).tw.
26. (resource* or quality of well-being or qwb).tw.
27. (utility* adj2 (value* or index* or health or measure* or estimate*)).tw.
28. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. 14 and 28
Downloaded: 203.
TABLE 55 Web of Science Core Collection search strategy: 1980 to 28 January 2016
Number Search terms
#6 #5 AND #4
#5 TOPIC: (cost* or economic* or QALY* or quality of life or QoL) OR TOPIC: (health state* or EQ-5D or markov)
#4 #3 OR #2 OR #1
#3 TOPIC: (xtag or Luminex or Filmarray or biofire or “Faecal Pathogens B” or “Faecal Panel B” or ausdiagnostics)
AND TOPIC: (gastro*)
#2 TOPIC: (“gastrointestinal pathogen panel”) OR TOPIC: (“gastrointestinal infection panel”)
#1 TOPIC: (multiplex* and (PCR or polymerase chain reaction or assay* or panel* or test*)) AND TOPIC:
(gastrointestin*)
Downloaded: 30.
Other searches
l Searched all sections of the Cochrane Database of Systematic Reviews (including the NHS Economic
Evaluation Database: Issue 2 of 4, April 2015) – no additional studies found.
l Cost-Effectiveness Analysis registry (https://research.tufts-nemc.org/cear4/): no additional studies found.
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Databases searched for ongoing studies
l National Institutes of Health ClinicalTrials.gov (www.clinicaltrials.gov/): 1 downloaded.
l Current Controlled Trials (www.controlled-trials.com).
l World Health Organization International Clinical Trials Registry Platform (www.who.int/ictrp/en/).
l UK Clinical Trials Gateway (www.nihr.ac.uk/research/uk-clinical-trials-gateway.htm).
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Appendix 2 Information submitted by companies
BioFire Diagnostics (FilmArray Gastrointestinal Panel)
1. FilmArray GI Panel Information Sheet.
2. FilmArray v1.5 user manual.
3. FilmArray v2.0 user manual.
4. FilmArray GI Laboratory Verification Advisory Notice.
5. Zeptometrix Panel for FilmArray GI Panel.
6. BioFire entericpathogens Final DR.
7. Selection of Publications.
8. WMMG abstract 26 May.
9. FilmArray GI Panel CE Declaration of Conformity.
10. IFU for FilmArray GI Panel.
11. FDA decision summary.
12. 510K summary.
13. Summary for 2.0 and FAIV for GI.
14. GI Panel Publications.
15. FLM1-MKT-0126 FilmArray Gastrointestinal (GI) Panel Publications Summary.
16. Request for Information.
17. The Film Array GI Panel IMPACT Study.
18. FilmArray Powerpoint Pioneering Diagnostics.
AusDiagnostics (Faecal Pathogens B)
AusDiagnostics response
Content of request for information.
1. Response to Request for Information.
2. Appendix 1: Clinical Evidence Document: Clinical Evidence Report Faecal Pathogens High-Plex Kits.
3. Appendix 2: CE conformity and IFUs.
4. Instructions for Use High-Plex Faecal Pathogens Kit.
5. Instructions for Use High-Plex Diagnostic system Cat No 9150 Easy-Plex Processor and High
Plex Analyser.
Luminex (xTAG® Gastrointestinal Pathogen Panel)
1. xTAG GPP Kit Package Insert.
2. Company Insight: Multiple Answers from a single sample.
3. Company Insight: Gastroenteritis: A serious medical and economic burden – a new approach.
4. Company Insight: Less pain with gastroenteritis.
5. NxTAG Respiratory Pathogen Panel Package Insert.
6. xTAG GPP (US) for use with MAGPIX.
7. Luminex Response to Request for information.
8. Declaration of Conformity.
9. xTAG Gastrointestinal Pathogen Panel – The state of the Art in Molecular GI Testing. Review of
Literature and Summary of Publication works.
10. GPP consumables (pdf and Excel).
11. Gastroenteritis and “doing more with less” sponsored feature in hospitalhealthcare.com.
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Appendix 3 Data extraction form
Data extraction form: clinical effectiveness of GPP for gastroenteritis.
First reviewer: Second reviewer:
Study details
Study ID (EndNote reference)
First author surname
Year of publication
Country
Study setting
Number of centres
Duration of study
Follow up (if applicable)
Funding
Aim of the study
Inclusion/exclusion criteria for patients
Inclusion criteria:
Exclusion criteria:
Participants
Item Hospital Community Total
Definition of subgroups
Total number of patients
(samples) at baseline
Number followed up
Description of study format
(number of patients and
reasons for receiving index
test, validation test
comparator test)
Baseline characteristics of
included patients
Number included in analysis
Adults (n)
Children aged < 5 years (n)
Travellers (n)
Immunocompromised
people (n)
Index test
Name of pathogen panel
test(s)
Proportion having received
index test (n/N)
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Study details
Method of batching
Pathogens tested:
Adenovirus 40/41 (x/F/B)
Astrovirus (F/B)
C. difficile toxin A/B (x/F/B)
Campylobacter (x/F/B)
Cryptosporidium (x/F/B)
Cyclospora cayetanensis (F)
E. coli O157 (x/F/B)
EAEC (F)
E. histolytica (x/F/B)
EPEC (F)
ETEC (x/F)
Giardia (x/F/B)
Norovirus (x/F/B)
Plesiomonas shigelloides (F)
Rotavirus (x/F/B)
Salmonella (x/F/B)
Sapovirus (F/B
Shigella (x/F/B)
STEC (x/F/B)
Vibrio (parahaemolyticus,
vulnificus and cholerae) (F)
V. cholerae (x/F)
Y. enterocolitica (x/F)
Conventional method (comparator)
Did all patients receive at
least one conventional test?
Did all patients receive all
available conventional tests?
Methods and proportion
having received each test:
Adenovirus 40/41
Astrovirus
C. difficile toxin A/B
Campylobacter
Cryptosporidium
E. coli O157
Giardia
Norovirus
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Study details
P. shigelloides
Rotavirus
Salmonella
Sapovirus
Shigella
V. cholerae
Other (not specified in
PHE algorithm, please
specify)
Validation method (reference standard/fair umpire)
Define patients who received
validation method (e.g. GPP
+/conventional– discordant
only)
Place where validation
method was undertaken
(same laboratory as index
test?)
Validation method
(judgement biased/unbiased):
Adenovirus 40/41 (x/F/B)
Astrovirus (F/B)
C. difficile toxin A/B (x/F/B)
Campylobacter (x/F/B)
Cryptosporidium (x/F/B)
C. cayetanensis (F)
E. coli O157 (x/F/B)
EAEC (F)
E. histolytica (x/F/B)
EPEC (F)
ETEC (x/F)
Giardia (x/F/B)
Norovirus (x/F/B)
P. shigelloides (F)
Rotavirus (x/F/B)
Salmonella (x/F/B)
Sapovirus (F/B)
Shigella (x/F/B)
STEC (x/F/B)
Vibrio (parahaemolyticus,
vulnificus and cholerae) (F)
V. cholerae (x/F)
Y. enterocolitica (x/F)
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Study details
Outcomes
Specify measure(s) of test
agreement reported (e.g. test
accuracy, kappa,
concordance, agreement)
Record 3 × 2 table by
pathogen reported in the
following format:
Conventional
method +
Conventional
method –
Conventional
not tested
Describe
conventional
method
Describe
validation
method
GPP+ a (verified +/–) b (verified +/–) # (verified +/–)
GPP– c (verified +/–) d (verified +/–) # (verified +/–)
–, negative; +, positive.
Adenovirus 40/41 (x/F/B)
Astrovirus (F/B)
C. difficile toxin A/B (x/F/B)
Campylobacter (x/F/B)
Cryptosporidium (x/F/B)
C. cayetanensis (F)
E. coli O157 (x/F/B)
EAEC (F)
E. histolytica (x/F/B)
EPEC (F)
ETEC (x/F)
Giardia (x/F/B)
Norovirus (x/F/B)
P. shigelloides (F)
Rotavirus (x/F/B)
Salmonella (x/F/B)
Sapovirus (F/B)
Shigella (x/F/B)
STEC (x/F/B)
Vibrio (parahaemolyticus,
vulnificus and cholerae) (F)
V. cholerae (x/F)
Y. enterocolitica (x/F)
Overall 2 × 2 table results
Patients with infections with
index test (n)
Patients with one pathogen (n)
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Study details
Patients with coinfections (n)
With two pathogens (n)
With three or more
pathogens (n)
Patients with infections with
comparator (n)
Patients with infections
following validation (n)
Change in treatment/
management by test
outcome
Time spent in isolation
Patients isolated
Patients removed from
isolation (n)
Patients not removed
from isolation
Patients taken off/change
in antibiotic treatment (n)
Test failure rates
Turnaround time
Costs
Morbidity
Mortality
HRQoL
Other outcomes
Authors’ conclusion
Reviewer’s notes
B, Faecal Pathogens B assay; EAEC, enteroaggregative E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli;
F, FilmArray GI Panel; HRQoL, health-related quality of life; STEC, shiga toxin-producing E. coli; x, xTAG assay.
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Appendix 4 Quality Assessment of Diagnostic
Accuracy Studies-2 quality appraisal tool and
guidance notes
See hard copy 
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Guidance notes for study assessment using tailored Quality
Assessment of Diagnostic Accuracy Studies-2
Risk of bias should be classed as low for each domain only if all questions could be answered with ‘yes’.
If one or more signalling question is answered with ‘no’, the risk of bias should be classed as ‘high’ and,
equally, if at least one question is answered with ‘unclear’, the risk of bias should be judged ‘unclear’.
Domain 1: patient selection
The study setting is primarily the microbiology laboratory, which is why samples are more frequently
collected into the study than patients. Consecutive or random samples should be included in the study,
patients should not have received prior testing and only one sample per episode should be considered in
the study.
A. Risk of bias
Was a consecutive or random sample of patients enrolled?
This question should be answered with ‘yes’ only if the study clearly states that samples or patients were
recruited consecutively or randomly (either retrospectively or prospectively).
Was a case–control design avoided?
This question can be answered with ‘yes’ if the study design is a prospective cohort. If the study is a
case–control study this question should be answered with ‘no’.
Did the study avoid inappropriate exclusions?
If the study excludes > 10% of participants with or without specifying reasons, the exclusions should be
considered as inappropriate and the question answered with ‘no’. This cut-off point has been determined
pragmatically. The exclusion of samples that do not conform with the shape of the container is not classed
as inappropriate exclusions as these would not be eligible patients for testing.
Was only one sample per episode included in the study?
If the sample size is equal to the number of patients enrolled in the study, this question can be answered
with ‘yes’. If the study included only samples and did not specify whether or not there was one sample per
episode per patient, the question should be answered with ‘unclear’. If the study included more samples
than patients, the question should be answered with ‘no’ unless the study clearly states that only one
sample was included per episode or specifies 1 month between samples (marking different episodes).
B. Concerns regarding applicability
If the setting is a microbiology laboratory and samples are from patients with diarrhoea, concerns
regarding applicability are ‘low’. If there is uncertainty about the samples originating from patients with
diarrhoea or samples from only test-negative (by conventional test) patients are included in the study,
the study population is questionable and the concern of applicability should be classed as ‘unclear’ and
‘high’, respectively.
For studies undertaken in (developing) countries (including countries in Africa, Asia and South America)
that are expected to have considerably different prevalences of pathogens, applicability of study results
should be of ‘high’ concern.
If the study included a mixed population in terms of setting and subpopulations of interest (i.e. travellers,
immunocompromised patients, children aged ≤ 5 years), the study population can be regarded as
applicable to the population in which the test is likely to be undertaken (general clinical laboratory receiving
samples from community, outpatient, accident and emergency and hospitalised patients). If the population
DOI: 10.3310/hta21230 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 23
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
is travellers or immunocompromised patients only, the study population is not applicable to the population
in which the test is likely to be undertaken in, thus applicability concerns should be rated as ‘high’.
Domain 2: index test
The main sources of bias introduced by conducting and interpreting an index test are blinding and defining
the threshold. The index test in this assessment is a laboratory testing kit that is analysed by computer
software and results reported as ‘yes’ or ‘no’ following a pre-specified threshold to judge (1) elevated
relative fluorescence (xTAG) and (2) fluorescent images of the DNA melt curve analysis of the PCR reactions
(FilmArray). Blinding of personnel to the results of the comparator or the verification method is a ‘no
bias’ issue.
A. Risk of bias
Were the index test results interpreted without knowledge of the results of
the comparator and verification method?
This question can be answered with ‘yes’, as the test is completely objective.
Was a threshold explicitly pre-specified?
This question can be answered with ‘yes’, as the threshold is pre-specified within the GPP test and if the
test or its interpretation has not been changed.
Add: did all samples receive the index test?
Answer the question with ‘yes’ if the study did not specify any selective testing with the GPP test.
Add: was the index test undertaken as recommended by the manufacturer?
At least one study reported deviation from manufacturer’s protocol because it used stool in Cary–Blair
medium and not raw sample. However, the 510(k)Substantial Equivalence Determination Decision
Summary40 submitted to the FDA added a claim for human stool in Cary–Blair medium. Therefore, stool
samples in Cary–Blair is not a deviation from the recommended protocol. This question can be answered
with ‘yes’ if the study clearly states that the protocol followed the manufacturer’s recommendations; it is
‘unclear’ if nothing is specified (or we shall assume that it was undertaken according to protocol) or if the
GPP assay was undertaken by Luminex and BioFire, retrospectively. This question should be answered
with ‘no’ if the recommended time period for GPP testing (within 3 days) was not adhered to or if the
specimens were not frozen for longer time periods between sampling and testing with GPP (testing within
2–3 days or immediate freezing at –70 °C).
B. Concerns about applicability
If the GPP test is used per manufacturer’s recommendations, the concern of applicability of the index test
is ‘low’.
Add Domain 3: comparator
The main sources of bias introduced by conducting and interpreting the comparator are blinding, defining
the threshold and performing culture on frozen samples.
Blinding would be of concern if the comparator (conventional test) was undertaken following the GPP test.
In that case, risk of bias should be judged as ‘high’. Blinding to the results of the verification method is of
no concern, as only discordant (if any) results were verified, which means that verification took place after
the comparator test.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
Laboratories follow criteria for how to interpret conventional methods, which vary between tests and can
be subjective (e.g. culture for bacteria and serotyping). Therefore, thresholds will vary between laboratories
and individuals even with criteria specified in clinical practice. The levels of concern for the various types of
tests vary as, for instance, a subjective threshold for the quantitative measure of PCRs can be pre-specified
or a testing kit will report a yes/no outcome. It is of importance that studies clearly describe or reference
criteria that have been used.
If not all samples were tested for all pathogens (physician chooses tests) using the comparator methods
specified, the results will be highly biased, as this decision is unlikely to be independent of previous
assessments and patient selection, and this question should therefore be answered with ‘no’.
Undertaking bacterial culture on previously frozen samples reduces accuracy and results in increased
discrepancies. Therefore, studies that used culture of frozen samples should be classed as having a
‘high’ risk of bias.
A. Risk of bias
Were the comparator results interpreted without knowledge of the results
of the index test and verification method?
If the comparator (mostly conventional tests) is undertaken following the GPP test, the risk of bias should
be judged as ‘high’ unless the tests are undertaken in different laboratories.
Was a threshold explicitly pre-specified?
Conventional microbiological methods in standard clinical laboratories follow criteria in the interpretation
of tests (in the UK these need to meet UK standards), which vary between tests. For PCR it can be
quantitative (the number of cycles after which a positive result must be detectable at a given level), for
others it is qualitative and defined by meeting a set of conditions (e.g. that something is growing under
particular growth conditions AND that it has a defined appearance on staining and viewing down a
microscope AND causes a particular biochemical reaction); these can be subjective.
For the assessment of threshold used in the studies, we would expect that studies report or reference the
criteria used for interpretation of results in order to answer this question with ‘yes’. Otherwise, this
question needs to be answered with ‘no’.
Add: was culture performed on fresh (not previously frozen) samples?
This question should be answered with ‘no’ only if the study clearly states that culture was undertaken
from frozen samples.
B. Concerns about applicability
Concerns about the applicability of the study to the research question are high if the comparator methods
are not consistent with the methods specified in the PHE algorithm. ‘High’ concern about applicability
should, therefore, be chosen if the conventional methods include multiplexing assays, PCR and sequencing,
culture confirmed by serotyping or sequencing. Concerns about applicability are also ‘high’ on study level if
the study included fewer pathogens than included in the PHE algorithm and if the clinician requested the
pathogens that should be tested for with the conventional test.
The definition for this study is the following:
The PHE algorithm8 consists of primary testing for Salmonella, Campylobacter, Shigella, E. coli O157,
Cryptosporidium and C. difficile with additional tests for children aged < 5 years for rotavirus, adenovirus
40/41 and norovirus. Secondary testing in hospitalised adults is recommended for norovirus and parasites
including Giardia, whereas people in the community should not be tested for norovirus and children aged
< 5 years should also be tested for astro- and sapovirus. Furthermore, our assessment included travellers as
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a subgroup of interest for whom additional tests for Vibrio and Plesiomonas species are considered if
returning from areas other than Western Europe, North America, Australia or New Zealand. Physicians
following this algorithm use local tests that vary across the UK and may or may not request all tests
detailed in the PHE algorithm, depending on symptoms and suspicion following patient assessment. In
order to compare GPP testing to microbiology techniques, as outlined in the PHE syndromic algorithm for
routine testing, a clear definition of the comparator is needed.
For the purpose of this review, no differentiation is being made between primary and secondary testing or
differences in terms of population testing (children, adults, travellers) and seasonality (including norovirus
testing only in winter months). For a sufficiently equivalent comparator, all pathogens mentioned in the
syndromic PHE pathway8 for any of the populations of interest are considered. A pragmatic judgement was
required regarding whether or not the number of tested pathogens in the studies is sufficiently similar to
the PHE algorithm8 [i.e. at least 75% (≥ 11 of previously specified pathogens) included in study].
In terms of tests, the following was assumed – testing is classed as sufficiently equivalent to the PHE
algorithm8 if the comparator in the studies includes:
l culture or PCR for bacteria
l PCR or enzyme immunoassay (EIA) for viruses
l microscopy or EIA for parasites
l PCR and/or EIA for C. difficile.
Domain 4: reference standard
As there is no independent and reliable reference standard, we would at least expect an independent
and unbiased umpire test to be used in the studies to assess discordant results between index test and
conventional methods [e.g. exposure, treatment effect (pathogen-specific treatment) or self-reported
symptoms, previous antibiotic treatment, over-the-counter medicine].
Verification of discordant results by retesting, by optimising index test and conventional methods or by
undertaking individual PCRs with primers different from primers used in the GPP assay is still biased, as
PCR assays are not sufficiently different from GPP tests (i.e. index test), which are also based on PCR
methodology that identifies all nucleic acids and does not differentiate between viable organisms,
colonisation and dead organisms.
Blinding is of concern for the verification method, as it is undertaken following GPP and conventional testing.
A. Risk of bias
Is the reference standard likely to correctly classify the target condition?
Answer this question with ‘no’ if conventional methods were used as reference standard or if GPP was
used as reference standard. Answer the question with ‘no’ if the verification method or the fair umpire
was biased and insufficiently independent of either the conventional methods or the index test. This
question can only be answered with ‘yes’ if a fair umpire (unbiased and independent) was used to solve
discordant test results.
Were the reference standard results interpreted without knowledge of the
results of the index test?
This question should be answered with ‘no’ if no blinding was clearly stated for the interpretation of the
verification methods if they were undertaken after the index test.
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Add: was the reference standard independent and unbiased?
This question can only be answered with ‘yes’ if a fair umpire test based on exposure or treatment was
used to assess discordant results. Otherwise the question should be answered with ‘no’ and risk of bias
classed as ‘high’.
B. Concerns about applicability
This question assesses whether or not the target condition identified by the reference standard matches
the target condition of interest in the review. The target condition for this assessment is the pathogen
causing symptoms of diarrhoea. If the reference standard detects pathogen DNA/ribonucleic acid at levels
that are unlikely to be cause for symptoms or detect dead organisms, then the applicability concern is
high. Therefore, the concerns about the applicability of the reference standard are ‘high’ if discrepant
results were investigated with PCR-based methods and the comparator methods for at least some
pathogens were conventional non-PCR microbiology tests.
Domain 5: flow and timing
A. Risk of bias
Was there an appropriate interval between index test(s) and
reference standard?
As there is no disease progression or treatment effect if both tests are undertaken on the same sample,
this question can be answered with ‘yes’ if it is clear that both tests were performed on the same sample.
If the tests were undertaken on different samples the risk of bias should be regarded as ‘high’, as
gastroenteritis is an acute condition that often resolves in a few days.
Did all discordant samples receive a reference standard?
If the study did not undertake verification of discordant results or only a proportion of discordant samples
were verified, this question should be answered with ‘no’.
Did all patients receive the same reference standard?
Methods are different for different pathogens. This is not classed as differential verification as the GPP
test is assessed on the pathogen level. If any of the pathogens in the study was verified with different
methods, this question should be answered with ‘no’. This question should be answered with ‘yes’ if the
verification method was the same for all patients for individual pathogens. For any pathogen samples that
were still discrepant following initial verification, and some had to be followed up by additional, different
testing, this question should be answered with ‘no’.
Add: did all samples receive the comparator methods for all pathogens
considered in the study?
This question should only be answered with ‘yes’ if the study clearly states that all samples received the
comparator methods for all pathogens considered in the study. This question needs to be answered with
‘no’ if the study reports that physicians requested the number of conventional tests for each sample
(resulting in different totals in the 2 × 2 table across pathogens) and risk of bias should be classed
as ‘high’.
Were all patients included in the analysis?
If inhibited or undetermined results were excluded from the analysis, this question should be answered
with ‘no’.
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Appendix 5 List of excluded full texts and
abstracts with reasons
TABLE 56 List of full papers excluded with reason
Study reference Reason for exclusion
Abbasi P, Kargar M, Doosti A, Mardaneh J, Ghorbani-Dalini S, Dehyadegari MA.
Characterization of shiga-toxin producing E. coli (STEC) and enteropathogenic E. coli
(EPEC) using multiplex real-time PCR assays for stx1, stx2, eaeA. Iranian J Microbiol
2014;6:169–74
Not index test
Al-Talib H, Latif B, Mohd-Zain Z. Pentaplex PCR assay for detection of hemorrhagic bacteria
from stool samples. J Clin Microbiol 2014;52:3244–9
Not index test
Antikainen J, Kantele A, Pakkanen SH, Laaveri T, Riutta J, Vaara M, et al. A quantitative
polymerase chain reaction assay for rapid detection of 9 pathogens directly from stools of
travellers with diarrhea. Clin Gastroenterol Hepatol 2013;11:1300–7.e3
Not index test
Antonishyn NA, Crozier NA, McDonald RR, Levett PN, Horsman GB, et al. Rapid detection
of norovirus based on an automated extraction protocol and a real-time multiplexed
single-step RT-PCR. J Clin Virol 2006;37:156–61
Not index test
Assis FEA, Wolf S, Surek M, De Toni F, Souza EM, Pedrosa FO, et al. Impact of aeromonas
and diarrheagenic Escherichia coli screening in patients with diarrhea in Parana, Southern
Brazil. J Infect Dev Ctries 2014;8:1609–14
Not index test
Barra-Carrasco J, Hernandez-Rocha C, Miranda-Cardenas C, Alvarez-Lobos M, Guzman
Duran AM, Paredes-Sabja D. Diagnostic accuracy of a multiplex real-time PCR to predict
Clostridium difficile ribotype 027. Anaerobe 2013;22:115–17
Letter to editor
Bonkoungou IJ, Lienemann T, Martikainen O, Dembele R, Sanou I, Traore AS, et al.
Diarrhoeagenic Escherichia coli detected by 16-plex PCR in children with and without
diarrhoea in Burkina Faso. Clin Microbiol Infect 2012;18:901–6
Not index test
Bonkoungou IJ, Lienemann T, Martikainen O, Dembele R, Sanou I, Traore AS, et al.
Comparison of multiplex PCR with serogrouping and PCR-RFLP of fliC gene for the
detection of enteropathogenic Escherichia coli (EPEC). Braz J Infect Dis 2011;15:365–9
Not index test
Bouzari S, Jafari A, Zarepour M. Distribution of virulence related genes among
enteroaggregative Escherichia coli isolates: using multiplex PCR and hybridization.
Infect Genet Evolut 2005;5:79–83
Not index test
Bruijnesteijn van Coppenraet LES, Dullaert-de Boer M, Ruijs GJHM, van der Reijden WA,
van der Zanden AGM, Weel JFL, et al. Case–control comparison of bacterial and protozoan
microorganisms associated with gastroenteritis: application of molecular detection.
Clin Microbiol Infect 2015;21:592.e9–92.e19
Not index test
Bubba L, Pellegrinelli L, Pariani E, Primache V, Amendola A, Binda S. A novel multiplex
one-step real-time RT-PCR assay for the simultaneous identification of enterovirus and
parechovirus in clinical fecal samples. J Prev Med Hyg 2015;56:E57–60
Not index test
Bueris V, Sircili MP, Taddei CR, dos Santos MF, Franzolin MR, Martinez MB, et al. Detection
of diarrheagenic Escherichia coli from children with and without diarrhea in Salvador,
Bahia, Brazil. Memorias do Instituto Oswaldo Cruz 2007;102:839–44
Not index test
Catanzaro M, Cirone J. Real-time polymerase chain reaction testing for Clostridium difficile
reduces isolation time and improves patient management in a small community hospital.
Am J Infect Control 2012;40:663–6
Not index test
Chavada R, Maley M. Evaluation of a commercial multiplex PCR for rapid detection of
multi drug resistant Gram negative infections. Open Microbiol J 2015;9:125–35
Not stool samples
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TABLE 56 List of full papers excluded with reason (continued )
Study reference Reason for exclusion
Chen Y, Li Z, Han D, Cui D, Chen X, Zheng S, et al. Viral agents associated with
acute diarrhea among outpatient children in southeastern China. Pediatr Infect Dis J
2013;32:e285–90
Not index test
Chiu CH, Ou JT. Rapid identification of Salmonella serovars in feces by specific detection of
virulence genes, invA and spvC, by an enrichment broth culture-multiplex PCR combination
assay. J Clin Microbiol 1996;34:2619–22
Not index test
de Boer RF, Ott A, Kesztyus B, Kooistra-Smid AM. Improved detection of five major
gastrointestinal pathogens by use of a molecular screening approach. J Clin Microbiol
2010;48:4140–6
Not index test
de Boer RF, Wijma JJ, Schuurman T, Moedt J, Dijk-Alberts BG, Ott A, et al. Evaluation of a
rapid molecular screening approach for the detection of toxigenic Clostridium difficile in
general and subsequent identification of the tcdC DELTA117 mutation in human stools.
J Microbiol Methods 2010;83:59–65
Not index test
Di Cristanziano V, Timmen-Wego M, Lubke N, Kaiser R, Pfister H, Di Cave D, et al.
Application of Luminex Gastrointestinal Pathogen Panel to human stool samples from
Côte d’Ivoire. J Infect Dev Ctries 2015;9:884–9
Diarrhoeal patients < 80% of
study population [3/34 (9%)]
Dunbar SA. Molecular revolution entering GI diagnostic testing. MLO Med Lab Obs
2013;45:28
Review
Dung TT, Phat VV, Nga TV, My PV, Duy PT, Campbell JI, et al. The validation and utility of
a quantitative one-step multiplex RT real-time PCR targeting rotavirus A and norovirus.
J Virol Methods 2013;187:138–43
Not index test
El Metwally HAR, Ibrahim HAH, El-Athamna MN, Amer MA. Multiplex PCR for detection of
diarrheagenic Escherichia coli in Egyptian children. J Med Sci 2007;7:255–62
Not index test
Freedman SB, Lee BE, Louie M, Pang XL, Ali S, Chuck A, et al. Alberta Provincial Pediatric
EnTeric Infection TEam (APPETITE): epidemiology, emerging organisms, and economics.
BMC Pediatr 2015;15:89
No outcomes
Frickmann H, Warnke P, Frey C, Schmidt S, Janke C, Erkens K, et al. Surveillance of food-
and smear-transmitted pathogens in European soldiers with diarrhea on deployment in the
tropics: experience from the European Union Training Mission (EUTM) Mali. BioMed Res Int
2015;2015:573904
Not index test
Garcia C, Chincha O, Leon M, Iglesias D, Barletta F, Mercado E, et al. High frequency of
diarrheagenic Escherichia coli in human immunodeficiency virus (HIV) patients with and
without diarrhea in Lima, Peru. Am J Trop Med Hyg 2010;82:1118–20
Not index test
Goldenberg SD, Bacelar M, Brazier P, Bisnauthsing K, Edgeworth JD. A cost benefit analysis
of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious
gastroenteritis in hospitalised patients. J Infect 2015;70:504–11
Not test accuracy
Hagen RM, Adlkofer J, Acqua S, Sarpong N, Priesnitz S, Adu-Sarkodie Y, et al. Multiplex/
realtime PCR in the laboratory diagnosis and for the epidemiological screening of
pathogens causing diarrhea in early childhood in Ghana. Trop Med Int Health 2009;14:58
Not index test
Hegde A, Ballal M, Shenoy S. Detection of diarrheagenic Escherichia coli by multiplex PCR.
Indian J Med Microbiol 2012;30:279–84
Not index test
Heyworth MF. Diagnostic testing for Giardia infections. Trans R Soc Trop Med Hyg
2014;108:123–5
Review
Hopkins MJ, Booth JA, Cunliffe NA, Hart IJ. Validation of a real-time multiplex PCR
protocol for diagnosis of viral gastroenteritis. Clin Microbiol Infect 2012;18:198–9
Not index test
Hussein EM. Molecular identification of Cyclospora spp. using multiplex PCR from
diarrheic children compared to others conventional methods. J Egyptian Soc Parasitol
2007;37:585–98
Not index test
Jasuja J, Veit J, Fofana HKM, Nimmesgern A, Saye R, Doumbia MN, et al. Stool-based
polymerase chain reaction for the diagnosis of multiple pathogens in Mali: a case–control
study. Trop Med Int Health 2015;20:142
Not index test
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TABLE 56 List of full papers excluded with reason (continued )
Study reference Reason for exclusion
Jex AR, Stanley KK, Lo W, Littman R, Verweij JJ, Campbell BE, et al. Detection of diarrhoeal
pathogens in human faeces using an automated, robotic platform. Mol Cell Probes
2012;26:11–15
Not index test
Kim S, Frye JG, Hu J, Fedorka-Cray PJ, Gautom R, Boyle DS. Multiplex PCR-based method
for identification of common clinical serotypes of Salmonella enterica subsp. enterica.
J Clin Microbiol 2006;44:3608–15
Not index test
Li W, Zhang N, Gong P, Cao L, Li J, Su L, et al. A novel multiplex PCR coupled with
Luminex assay for the simultaneous detection of Cryptosporidium spp., Cryptosporidium
parvum and Giardia duodenalis. Vet Parasitol 2010;173:11–18
Not index test
Liu J, Gratz J, Maro A, Kumburu H, Kibiki G, Taniuchi M, et al. Simultaneous detection of
six diarrhea-causing bacterial pathogens with an in-house PCR-luminex assay. J Clin
Microbiol 2012;50:98–103
Not index test
Liu J, Kabir F, Manneh J, Lertsethtakarn P, Begum S, Gratz J, et al. Development and
assessment of molecular diagnostic tests for 15 enteropathogens causing childhood
diarrhoea: a multicentre study. Lancet Infect Dis 2014;14:716–24
Not index test
Liu J, Kibiki G, Maro V, Maro A, Kumburu H, Swai N, et al. Multiplex reverse transcription
PCR Luminex assay for detection and quantitation of viral agents of gastroenteritis.
J Clin Virol 2011;50:308–13
Not index test
Maas L, Dorigo-Zetsma JW, de Groot CJ, Bouter S, Plotz FB, van Ewijk BE. Detection of
intestinal protozoa in paediatric patients with gastrointestinal symptoms by multiplex
real-time PCR. Clin Microbiol Infect 2014;20:545–50
Not index test
Malecki M, Schildgen V, Kamm M, Mattner F, Schildgen O. Rapid screening method for
multiple gastro-enteric pathogens also detects novel EHEC O104:H4. Int J Med Microbiol
2011;301:38
Letter to Editor
Navidad JF, Griswold DJ, Gradus MS, Bhattacharyya S. Evaluation of Luminex xTAG
gastrointestinal pathogen analyte-specific reagents for high-throughput, simultaneous
detection of bacteria, viruses, and parasites of clinical and public health importance.
J Clin Microbiol 2013;51:3018–24
Not index test (not xTAG
commercialised kit)
Nazeer JT, El Sayed Khalifa K, von Thien H, El-Sibaei MM, Abdel-Hamid MY, Tawfik RA,
et al. Use of multiplex real-time PCR for detection of common diarrhea causing protozoan
parasites in Egypt. Parasitol Res 2013;112:595–601
Not index test
Pavlinac PB, Onchiri FM, John-Stewart GC, Naulikha JM, Donna DM, Odundo EA, et al.
Accuracy of the integrated management of childhood illness (IMCI) algorithm in identifying
culture-confirmed diarrheal pathogens requiring antibiotic therapy. Am J Trop Med Hyg
2014;1:574–5
Not index test
Qin X, Klein EJ, Galanakis E, Thomas AA, Stapp JR, Rich S, et al. Real-time PCR assay for
detection and differentiation of shiga toxin-producing Escherichia coli from clinical
samples. J Clin Microbiol 2015;53:2148–53
Not index test
Siah SP, Merif J, Kaur K, Nair J, Huntington PG, Karagiannis T, et al. Improved detection of
gastrointestinal pathogens using generalised sample processing and amplification panels.
Pathology 2014;46:53–9
Not index test
Sjoling A, Sadeghipoorjahromi L, Novak D, Tobias J. Detection of major diarrheagenic
bacterial pathogens by multiplex PCR panels. Microbiol Res 2015;172:34–40
Not index test
So CW, Kim DS, Yu ST, Cho JH, Kim JD. Acute viral gastroenteritis in children hospitalized
in Iksan, Korea during December 2010–June 2011. Korean J Pediatr 2013;56:383–8
Not index test
Stark D, Al-Qassab SE, Barratt JL, Stanley K, Roberts T, Marriott D, et al. Evaluation of
multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba
fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples. J Clin
Microbiol 2011;49:257–62
Not index test
Taniuchi M, Verweij JJ, Noor Z, Sobuz SU, Lieshout L, Petri WA Jr, et al. High throughput
multiplex PCR and probe-based detection with Luminex beads for seven intestinal
parasites. Am J Trop Med Hyg 2011;84:332–7
Not index test
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TABLE 56 List of full papers excluded with reason (continued )
Study reference Reason for exclusion
ten Hove R, Schuurman T, Kooistra M, Moller L, van Lieshout L, Verweij JJ. Detection of
diarrhoea-causing protozoa in general practice patients in The Netherlands by multiplex
real-time PCR. Clin Microbiol Infect 2007;13:1001–7
Not index test
Tobias J, Kassem E, Rubinstein U, Bialik A, Vutukuru SR, Navaro A, et al. Involvement of
main diarrheagenic Escherichia coli, with emphasis on enteroaggregative E. coli, in severe
non-epidemic pediatric diarrhea in a high-income country. BMC Infect Dis 2015;15:79
Not index test
Tobias J, Vutukuru SR. Simple and rapid multiplex PCR for identification of the main
human diarrheagenic Escherichia coli. Microbiol Res 2012;167:564–70
Not index test
Van Lint P, De Witte E, De Henau H, De Muynck A, Verstraeten L, Van Herendael B, et al.
Evaluation of a real-time multiplex PCR for the simultaneous detection of Campylobacter
jejuni, Salmonella spp., Shigella spp./EIEC, and Yersinia enterocolitica in fecal samples.
Eur J Clin Microbiol Infect Dis 2015;34:535–42
Not index test
Van Lint P, Rossen JW, Vermeiren S, Ver Elst K, Weekx S, Van Schaeren J, et al. Detection
of Giardia lamblia, Cryptosporidium spp. and Entamoeba histolytica in clinical stool samples
by using multiplex real-time PCR after automated DNA isolation. Acta Clin Belg
2013;68:188–92
Not index test
Verweij JJ, van Lieshout L. Intestinal parasitic infections in an industrialized country; a new
focus on children with better DNA-based diagnostics. Parasitology 2011;138:1492–8
Review
Wang J, Xu Z, Niu P, Zhang C, Zhang J, Guan L, et al. A two-tube multiplex reverse
transcription PCR assay for simultaneous detection of viral and bacterial pathogens of
infectious diarrhea. BioMed Res Int 2014;2014:648520
Not index test
Wiemer D, Loderstaedt U, von Wulffen H, Priesnitz S, Fischer M, Tannich E, et al. Real-time
multiplex PCR for simultaneous detection of Campylobacter jejuni, Salmonella, Shigella and
Yersinia species in fecal samples. Int J Med Microbiol 2011;301:577–84
Not index test
TABLE 57 List of abstracts mentioning index tests excluded with reason
Study reference Reason for exclusion
Ciardo D, Dubuis O, Burki D, Noppen C, Viollier EH. Infectious gastroenteritis:
comparison of conventional and molecular methods for detection of pathogens.
Clin Microbiol Infect 2012;18:501–2
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Halligan E, Bible J, Cliff P, Wilson A, Carlton-Carew L, Goldenberg S, et al.
An evaluation of the Luminex xTAG gastrointestinal pathogen panel at a
London teaching hospital 2011: the comparative performance of a rapid
molecular multiplex assay and current standard laboratory investigations of
infectious gastroenteritis. Clin Microbiol Infect 2012;18:403
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Mansuy JM, Plachot C, Mengelle C, Grouteau E, Claudet I, Kamar N, et al.
Use of a multiplex molecular assay for the detection of pathogens in stools from
diarrhoeic patients. Clin Microbiol Infect 2012;18:502
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Marimon JM, Montes M, Gomariz M, Cilla G, Perez-Trallero E. Diagnosis of
gastroenteric infections: comparison of traditional methods with the new
molecular technologies. Clin Microbiol Infect 2012;18:503
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
McMillen T, Chen J, Sun J, Nie S, Fan F, Babady N, et al. Evaluation of cepheid
norovirus assay for detection of noroviruses genogroup I and II in stool.
J Mol Diagnos 2014;16:730
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Vocale C, Landini MP, Sambri V. First Italian experience in clinical practice of the
gastrointestinal pathogen panel using a unique multiplexing technology at a
Bologna hospital. Clin Microbiol Infect 2012;18:501
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
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TABLE 57 List of abstracts mentioning index tests excluded with reason (continued )
Study reference Reason for exclusion
Becker S, Chatigre JK, Coulibaly JT, Herrmann M, N’Goran E, Utzinger J, et al.
Luminex xTAG GPP multiplex PCR assay for the diagnosis of gastrointestinal
pathogens: preliminary findings from a case–control study in Côte d’Ivoire.
Int J Med Microbiol 2013;303:25–6
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Chapin K, McVeigh L, Ponraj V, Flores-Cortez E, Dickenson R. Comparison of
the BioFire FilmArray gastrointestinal panel, the BD MAX enteric bacterial panel
and the luminex xTAG gastrointestinal pathogen panel to traditional laboratory
methods. J Mol Diagn 2014;16:738
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Chapin KC, Dickenson RA, Andrea SB, Huang R. Multiplex assay evaluation of
Luminex xTAG analyte-specific reagents for diagnosis of gastrointestinal
pathogens. J Mol Diagn 2012;14:681
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Eibach D, Krumkamp R, Hahn A, Sarpong N, Adu-Sarkodie Y, Leva A, et al.
Application of the Luminex xTAG gastrointestinal pathogen panel for the
detection of gastrointestinal pathogens in a rural African setting. Trop Med Int
Health 2015;20:117
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Herding E, Hansen G. Clinical utility of the luminex xTAG GPP assay in a
characterized culture negative high-risk population cohort suggests enhanced
detection of infectious GI associated illness compared to conventional culture
testing and hospital ordering. J Mol Diagn 2014;16:743
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Kahlau P, Malecki M, Schildgen V, Mattner F, Schildgen O. ProGastro SSCS vs
Luminex GPP: a first experience in comparing two multiplex assays for
gastrointestinal pathogens. J Mol Diagn 2012;14:672
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Lee SD, Elshimali Y, Lobos J, Scarsella A. Validation of luminex xTAG
gastrointestinal pathogen panel with stool specimens in S.T.A.R. buffer.
J Mol Diagn 2014;16:737–8
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Macpherson M, Rutherford C, Jayaratne P, Dale SE. Development of a real-time,
reverse transcriptase (RT) multiplex PCR assay for the detection of rotavirus and
adenovirus in faecal specimens. Can J Infect Dis Med Microbiol 2013;24:33B–4B
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Manji R, Ginocchio CC. Clinical performance assessment of the luminex xTAG
investigational assay for the detection of enteric pathogens directly from clinical
specimens. J Mol Diagn 2013;15:894
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Morrison S, Shennan M, Zhang H. Evaluation of the xTAG stool sample
pretreatment pack using the xTAG gastrointestinal pathogen panel. Clin
Microbiol Infect 2012;18:782–3
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Ohrmalm C, Yaghoubian S, Leyva L, Zhang H, Blomberg J. Evaluation of a
multiplex nucleic acid test for the detection of gastrointestinal pathogens in
faecal samples. Clin Microbiol Infect 2011;17:S553
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Pichon M, Bal A, Morfin F, Casalegno JS, Billaud G, Lina B, et al. Evaluation of a
multiplex gastrointestinal panel. Which test for a pediatric population? J Clin
Virol 2015;70:S32–3
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Rogatcheva M, Vaughn M, Wallace R, Crisp R, Alger G, Gardner J, et al.
Detection of bacterial, viral, and protozoan pathogens using the FilmArray
gastrointestinal (GI) system. J Mol Diagn 2012;14:669
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Sefers S, Chappell J. Evaluation of the luminex xTAG gastrointestinal pathogen
panel and analyte-specific reagents for the detection of enteropathogens in
stool. J Mol Diagn 2013;15:886
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Sinclair WB, Lopansri BK, Merica CB, Panahi R, Wood JS, Owen M, et al. BioFire
FilmArray 2.0 throughput performance. J Mol Diagn 2015;17:846
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Twining N, Spirtovic S, Costello M, Michalov M, Mazur L. Performance of
luminex xTAG gastrointestinal pathogen panel LDT assay. J Mol Diagn
2013;15:881
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
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TABLE 57 List of abstracts mentioning index tests excluded with reason (continued )
Study reference Reason for exclusion
Wessels E, Rusman L, Van Bussel M, Claas ECJ. Prospective application of the
Luminex xTAG-GPP multiplex PCR in diagnosing infectious gastroenteritis.
Clin Microbiol Infect 2012;18:503–4
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
Yaghoubian S, Himsworth D, Dey C, Lan L, Bussel MV, Claas EC. Clinical
performance of xTAG GPP multiplexed gastrointestinal panel for the
simultaneous detection and identification of viral, bacterial and parasitic
pathogens in stool specimens. J Mol Diagn 2010;12:881
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
York V, Petterson J, Ward PM, Green N, She RC. The value of a multiplexed
gastrointestinal pathogen panel in two distinct patient populations. J Mol Diagn
2014;16:731
Abstract, insufficient detail on validation
method, comparator and/or test
accuracy outcomes per pathogen tested
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Appendix 6 Ongoing trial
TABLE 58 Ongoing trial
Criterion Details
Title Implementation of a Molecular Diagnostic for Paediatric Acute Gastroenteritis: The FilmArray GI Panel
IMPACT Study (IMPACT)
Population Children (aged < 18 years) presenting to the emergency department or on-site urgent care centre
with symptoms of gastroenteritis (e.g. diarrhoea, vomiting, nausea, etc.) with symptoms for at least
24 hours but < 14 days
Primary outcomes Number of additional health-care encounters experienced related to the initial gastrointestinal episode
Secondary
outcomes
Health-care cost analysis following implementation of the FilmArray Gastrointestinal Panel
Intervention FilmArray Gastrointestinal Panel
Study design Non-randomised efficacy study
Source https://clinicaltrials.gov/ct2/show/NCT02248285
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Appendix 7 Tables of 2 × 2 data by pathogen
and gastrointestinal pathogen panel test
The 2 × 2 data in the tables in this appendix are reported in the format shown in Table 59.
xTAG
Viruses
TABLE 59 2 × 2 data format
Conventional test + Conventional test –
GPP+ a (+/+) b (–/+)
GPP– c (+/–) d (–/–)
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 60 Adenovirus
Study a b c d Total
Claas et al. 201321 4 4 16 628 652
Deng et al. 201523 3 0 2 285 290
Duong et al. 201624 23 5 2 449 479
FDA 201225 4 13 1 1154 1172
Gu et al. 201526 3 2 20 110 135
Halligan et al. 201427 6 2 0 181 189
Mengelle et al. 201329 0 2 5 396 403
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 61 Norovirus
Study a b c d Total
Claas et al. 201321 (G1) 9 0 0 642 651
Claas et al. 201321 (G2) 62 14 5 570 651
Deng et al. 201523 (G1) 8 0 0 282 290
Deng et al. 201523 (G2) 37 3 2 248 290
Duong et al. 201624 (G1) 15 5 2 457 479
Duong et al. 201624 (G2) 85 4 3 387 479
Gu et al. 201526 29 9 2 159 199
Halligan et al. 201427 66 79 14 1284 1443
Mengelle et al. 201329 0 17 1 250 268
Pankhurst et al. 201430 183 16 16 624 839
FDA 201225 74 98 4 1023 1199
Coste et al. 201322 0 14 0 40 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 62 Rotavirus
Study a b c d Total
Claas et al. 201321 18 1 0 633 652
Deng et al. 201523 61 6 1 222 290
Duong et al. 201624 117 4 9 349 479
Gu et al. 201526 1 0 0 109 110
Halligan et al. 201427 13 6 0 158 177
Mengelle et al. 201329 61 9 2 332 404
FDA 201225 2 2 0 1162 1166
Coste et al. 201322 2 0 0 52 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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Bacteria
TABLE 63 Clostridium difficile
Study a b c d Total
Claas et al. 201321 30 11 1 343 385
Gu et al. 201526 44 8 4 107 163
Halligan et al. 201427 121 10 6 1175 1312
Mengelle et al. 201329 5 8 0 331 344
Pankhurst et al. 201430 195 19 4 621 839
FDA 201225 107 105 7 922 1141
Coste et al. 201322 1 0 0 53 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 64 Campylobacter
Study a b c d Total
Claas et al. 201321 111 15 3 382 511
Deng et al. 201523 20 16 0 254 290
Duong et al. 201624 (PCR) 59 3 6 411 479
Duong et al. 201624 (culture) 27 35 3 414 479
Gu et al. 201526 0 0 0 112 112
Halligan et al. 201427 23 37 0 1336 1396
Mengelle et al. 201329 1 12 0 368 381
Pankhurst et al. 201430 110 11 7 711 839
FDA 201225 3 21 0 1155 1179
Coste et al. 201322 2 12 0 40 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 65 Escherichia coli O157
Study a b c d Total
Claas et al. 201321 15 5 1 407 428
Deng et al. 201523 1 2 0 287 290
aGu et al. 201526 0 1 0 111 112
Halligan et al. 201427 3 2 0 1391 1396
Mengelle et al. 201329 0 1 0 265 266
FDA 201225 2 9 0 1158 1169
a Study did not separate out E. coli O157 or enteroaggregative, enteropathogenic, enterotoxigenic or shiga toxin-
producing E. coli.
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 66 Enterotoxigenic E. coli
Study a b c d Total
Claas et al. 201321 0 7 0 68 75
Deng et al. 201523 1 4 0 285 290
Mengelle et al. 201329 0 0 0 266 266
FDA 201225 2 4 6 1156 1168
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 67 Salmonella
Study a b c d Total
Claas et al. 201321 62 6 13 408 489
Deng et al. 201523 25 6 5 254 290
Duong et al. 201624 (PCR) 84 128 9 258 479
Duong et al. 201624 (culture) 38 172 2 267 479
Gu et al. 201526 1 3 0 108 112
Halligan et al. 201427 11 36 0 1349 1396
Mengelle et al. 201329 7 14 2 356 379
Pankhurst et al. 201430 15 9 18 797 839
FDA 201225 10 18 0 1143 1171
Coste et al. 201322 0 1 0 53 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 68 Shigella
Study a b c d Total
Claas et al. 201321 40 13 0 452 505
Deng et al. 201523 3 1 0 286 290
Duong et al. 201624 (PCR) 86 6 4 383 479
Duong et al. 201624 (culture) 40 51 0 388 479
Gu et al. 201526 1 0 0 111 112
Halligan et al. 201427 3 11 0 1382 1396
Mengelle et al. 201329 1 0 0 378 379
FDA 201225 2 17 0 1154 1173
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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Parasites
TABLE 72 Cryptosporidium
Study a b c d Total
Claas et al. 201321 32 7 3 833 868
Gu et al. 201526 0 0 0 35 35
Halligan et al. 201427 1 6 0 229 236
Mengelle et al. 201329 0 1 0 117 118
FDA 201225 12 53 1 1131 1197
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 69 Shiga toxin-producing E. coli
Study a b c d Total
Claas et al. 201321 8 1 0 162 171
Mengelle et al. 201329 5 2 0 258 265
FDA 201225 1 16 0 1153 1170
Coste et al. 201322 0 2 1 51 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 70 Vibrio cholerae
Study a b c d Total
Claas et al. 201321 0 0 1 194 195
Deng et al. 201523 0 0 0 290 290
FDA 201225 0 1 0 1166 1167
Mengelle et al. 201329 0 0 0 379 379
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 71 Yersinia enterocolitica
Study a b c d Total
Claas et al. 201321 0 0 0 366 366
Deng et al. 201523 1 0 0 289 290
Gu et al. 201526 0 0 0 38 38
Mengelle et al. 201329 0 0 0 379 379
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 73 Entamoeba histolytica
Study a b c d Total
Claas et al. 201321 6 6 0 845 857
Deng et al. 201523 0 1 0 289 290
Halligan et al. 201427 0 9 1 226 236
FDA 201225 0 19 0 1149 1168
Mengelle et al. 201329 0 0 0 285 285
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 74 Giardia
Study a b c d Total
Claas et al. 201321 26 13 0 829 868
Deng et al. 201523 0 0 0 290 290
Gu et al. 201526 0 0 0 35 35
Halligan et al. 201427 1 17 0 218 236
Mengelle et al. 201329 0 0 0 118 118
FDA 201225 4 39 0 1132 1175
Coste et al. 201322 1 0 0 53 54
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
FilmArray
Viruses
TABLE 75 Adenovirus
Study a b c d Total
Buss et al. 201520 42 13 2 1499 1556
Gu et al. 201526 3 2 20 110 135
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 76 Astrovirus
Study a b c d Total
Buss et al. 201520 7 1 0 1548 1556
Gu et al. 201526 4 0 6 189 199
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 77 Norovirus
Study a b c d Total
Buss et al. 201520 52 18 3 1483 1556
Gu et al. 201526 28 0 3 168 199
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 78 Rotavirus
Study a b c d Total
Buss et al. 201520 6 12 0 1538 1556
Gu et al. 201526 1 0 0 109 110
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 79 Sapovirus
Study a b c d Total
Buss et al. 201520 46 13 0 1497 1556
Gu et al. 201526 5 0 2 192 199
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Bacteria
TABLE 80 Clostridium difficile
Study a b c d Total
Buss et al. 201520 163 41 2 1350 1556
Gu et al. 201526 39 5 9 110 163
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 81 Campylobacter
Study a b c d Total
Buss et al. 201520 34 24 1 1497 1556
Gu et al. 201526 0 0 0 112 112
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 82 Shigella
Study a b c d Total
Buss et al. 201520 47 2 2 1505 1556
Gu et al. 201526 1 0 0 111 112
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 83 Shiga toxin-producing E. coli
Study a b c d Total
Buss et al. 201520 33 5 0 1518 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 84 Vibrio (parahaemolyticus, vulnificus and cholerae)
Study a b c d Total
Buss et al. 201520 0 2 0 1554 1556
Gu et al. 201526 0 1 0 111 112
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 85 Vibrio cholerae
Study a b c d Total
Buss et al. 201520 0 1 0 1555 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 86 Yersinia enterocolitica
Study a b c d Total
Buss et al. 201520 1 0 0 1555 1556
Gu et al. 201526 0 0 0 38 38
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 87 Escherichia coli O157
Study a b c d Total
Buss et al. 201520 3 1 0 34 38
aGu et al. 201526 0 4 0 108 112
a Study did not separate out E. coli O157, enteroaggregative E. coli, enteropathogenic E. coli, enterotoxigenic E. coli and
Shiga toxin-producing E. coli.
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 88 Enteroaggregative E. coli
Study a b c d Total
Buss et al. 201520 82 27 1 1446 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 89 Enteropathogenic E. coli
Study a b c d Total
Buss et al. 201520 314 34 3 1167 1518
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 90 Enterotoxigenic E. coli
Study a b c d Total
Buss et al. 201520 22 9 0 1525 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 91 Plesiomonas shigelloides
Study a b c d Total
Buss et al. 201520 3 15 0 1538 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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TABLE 92 Salmonella
Study a b c d Total
Buss et al. 201520 31 6 0 1519 1556
Gu et al. 201526 1 0 0 111 112
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Parasites
TABLE 93 Entamoeba histolytica
Study a b c d Total
Buss et al. 201520 0 0 0 1556 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 94 Cryptosporidium
Study a b c d Total
Buss et al. 201520 18 6 0 1532 1556
Gu et al. 201526 0 0 0 35 35
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 95 Cyclospora cayetanensis
Study a b c d Total
Buss et al. 201520 19 0 0 1537 1556
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
TABLE 96 Giardia
Study a b c d Total
Buss et al. 201520 20 7 0 1529 1556
Gu et al. 201526 0 0 0 35 35
Reproduced from Freeman et al. 2017.49 © 2017 Freeman et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
Appendix 8 Meta-analytic outcomes of test
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FIGURE 43 Negative agreement: xTAG vs. conventional testing (benchmark). ETEC, enterotoxigenic E. coli;
STEC, shiga toxin-producing E. coli; RE, random-effects estimate. Reproduced from Freeman et al. 2017.49
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FIGURE 43 Negative agreement: xTAG vs. conventional testing (benchmark). ETEC, enterotoxigenic E. coli;
STEC, shiga toxin-producing E. coli; RE, random-effects estimate. Reproduced from Freeman et al. 2017.49
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FIGURE 44 Negative agreement: conventional testing vs. xTAG (benchmark). ETEC, enterotoxigenic E. coli;
STEC, shiga toxin-producing E. coli; RE, random-effects estimate. Reproduced from Freeman et al. 2017.49
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FIGURE 44 Negative agreement: conventional testing vs. xTAG (benchmark). ETEC, enterotoxigenic E. coli;
STEC, shiga toxin-producing E. coli; RE, random-effects estimate. Reproduced from Freeman et al. 2017.49
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FIGURE 45 Negative agreement: FilmArray vs. conventional testing (benchmark). EAEC, enteroaggregative E. coli;
EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; STEC, shiga toxin-producing E. coli; RE, random-effects
estimate; p.v.c., parahaemolyticus, vulnificus and cholerae.
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FIGURE 46 Negative agreement: conventional testing vs. FilmArray (benchmark). EAEC, enteroaggregative E. coli;
EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; STEC, shiga toxin-producing E. coli; RE, random-effects
estimate; p.v.c., parahaemolyticus, vulnificus and cholerae.
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Appendix 9 Excluded gastrointestinal pathogen
panel economic studies with reason
TABLE 97 Excluded GPP economic studies with reason
Author (year) Title Journal details Comments Reason for exclusion
Bignardi and
Settle (2015)53
Can the Luminex xTAG
gastrointestinal pathogen
panel really save money?
Journal of Infection
71:498–9
The author provides
some comments on
why they think xTAG
GPP will not actually
save the NHS any
money
Letter to editor commenting
on Goldenberg et al.56
paper. Not an economic
evaluationa
Binnicker
(2015)54
Multiplex molecular
panels for diagnosis of
gastrointestinal infection:
performance, result
interpretation, and
cost-effectiveness
Journal of Clinical
Microbiology
53:3723–8
The paper looks at
how xTAG GPP and
FilmArray work and
some of the trials the
two interventions are
in
Not an economic
evaluationa
Freedman et al.
(2015)55
Alberta Provincial Pediatric
EnTeric Infection TEam
(APPETITE): epidemiology,
emerging organisms, and
economics
BMC Pediatrics
15:89
The paper proposes
using xTAG GPP
instead of current
methods
A protocol. Not an
economic evaluationa
Halligan et al.
(2014)27
Multiplex molecular testing
for management of infectious
gastroenteritis in a hospital
setting: a comparative
diagnostic and clinical utility
study
Clinical Microbiology
and Infection
20:460–7
The paper provides
some useful cost
information as
provided in the
Goldenberg et al.
study56
Clinical paper linking to
Goldenberg et al.56 paper.
Not an economic
evaluationa
a Not looking at incremental costs and incremental benefits.
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Appendix 10 Quality assessment of economic
evaluation studies
TABLE 98 The CHEERS quality assessment checklist for economic evaluation studies
Assessment Goldenberg et al.56
Title Y
Abstract Y
Introduction
Background and objectives Y
Methods
Target population and subgroups Y
Setting and location Y
Study perspective Y
Comparators Y
Time horizon Y
Discount rate N/A
Choice of health outcomes Y
Measurement of effectiveness N
Measurement and valuation of preference-based outcomes N
Estimating resources and costs Y
Currency, price date and conversion P
Choice of model N/A
Assumptions P
Analytical methods P
Results
Study parameters Y
Incremental costs and outcomes Y
Characterising uncertainty Y
Discussion
Study findings Y
Limitations Y
Generalisability N
Other
Source of funding Y
Conflicts of interest Y
N, No; N/A, not applicable; P, partial; Y, yes.
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TABLE 99 Philips’ quality assessment checklist for studies that included an economic model
Philips’ criteria Goldenberg et al.56
Structure
1. Is there a clear statement of the decision problem? Y
2. Is the objective of the model specified and consistent with the stated decision problem? Y
3. Is the primary decision-maker specified? Y
4. Is the perspective of the model stated clearly? Y
5. Are the model inputs consistent with the stated perspective? Y
6. Has the scope of the model been stated and justified? N
7. Are the outcomes of the model consistent with the perspective, scope and overall objective of
the model?
P
8. Is the structure of the model consistent with a coherent theory of the health condition under
evaluation?
P
9. Are the sources of the data used to develop the structure of the model specified? Y
10. Are the causal relationships described by the model structure justified appropriately? N
11. Are the structural assumptions transparent and justified? N
12. Are the structural assumptions reasonable given the overall objective, perspective and scope
of the model?
UNC
13. Is there a clear definition of the options under evaluation? Y
14. Have all feasible and practical options been evaluated? UNC
15. Is there justification for the exclusion of feasible options? UNC
16. Is the chosen model type appropriate given the decision problem and specified causal
relationships within the model?
P
17. Is the time horizon of the model sufficient to reflect all important differences between the
options?
Y
18. Are the time horizon of the model and the duration of treatment described and justified? UNC
19. Do the disease states (state transition model) or the pathways (decision tree model) reflect the
underlying biological process of the disease in question and the impact of interventions?
Y
20. Is the cycle length defined and justified in terms of the natural history of disease? N/A
Data
21. Are the data identification methods transparent and appropriate given the objectives of the
model?
P
22. When choices have been made between data sources, are these justified appropriately? UNC
23. Has particular attention been paid to identifying data for the important parameters of the
model?
UNC
24. Has the quality of the data been assessed appropriately? N
25. When expert opinion has been used, are the methods described and justified? UNC
26. Is the data modelling methodology based on justifiable statistical and epidemiological
techniques?
UNC
27. Is the choice of baseline data described and justified? P
28. Are transition probabilities calculated appropriately? N/A
29. Has a half-cycle correction been applied to both costs and outcomes? N/A
30. If not, has the omission been justified? N/A
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TABLE 99 Philips’ quality assessment checklist for studies that included an economic model (continued )
Philips’ criteria Goldenberg et al.56
31. If relative treatment effects have been derived from trial data, have they been synthesised
using appropriate techniques?
N/A
32. Have the methods and assumptions used to extrapolate short-term results to final outcomes
been documented and justified?
N/A
33. Have alternative extrapolation assumptions been explored through sensitivity analysis? N/A
34. Have assumptions regarding the continuing effect of treatment once treatment is complete
been documented and justified?
N/A
35. Have alternative assumptions regarding the continuing effect of treatment been explored
through sensitivity analysis?
N/A
36. Are the costs incorporated into the model justified? Y
37. Has the source for all costs been described? Y
38. Have discount rates been described and justified given the target decision-maker? N/A
39. Are the utilities incorporated into the model appropriate? N/A
40. Is the source of utility weights referenced? N/A
41. Are the methods of derivation for the utility weights justified? N/A
42. Have all data incorporated into the model been described and referenced in sufficient detail? P
43. Has the use of mutually inconsistent data been justified (i.e. are assumptions and choices
appropriate)?
UNC
44. Is the process of data incorporation transparent? UNC
45. If data have been incorporated as distributions, has the choice of distributions for each
parameter been described and justified?
N/A
46. If data have been incorporated as distributions, is it clear that second order uncertainty is
reflected?
N/A
47. Have the four principal types of uncertainty been addressed? N/A
48. If not, has the omission of particular forms of uncertainty been justified? N/A
49. Have methodological uncertainties been addressed by running alternative versions of the
model with different methodological assumptions?
N
50. Is there evidence that structural uncertainties have been addressed via sensitivity analysis? N
51. Has heterogeneity been dealt with by running the model separately for different subgroups? N
52. Are the methods of assessment of parameter uncertainty appropriate? N/A
53. If data are incorporated as point estimates, are the ranges used for sensitivity analysis stated
clearly and justified?
P
54. Is there evidence that the mathematical logic of the model has been tested thoroughly before
use?
N
55. Are any counterintuitive results from the model explained and justified? N
56. If the model has been calibrated against independent data, have any differences been
explained and justified?
N
57. Have the results been compared with those of previous models and any differences in results
explained?
N
N, no; N/A, not applicable; P, partial; UNC, unclear; Y, yes.
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Appendix 11 Additional economic analyses as
requested by the National Institute for Health and
Care Excellence Committee
A t the request of the committee, we have changed the assumptions outlined in this appendix.
Comparator cost fixed at £20 for each of the models
For each of the models, we have changed the comparator cost from £66.18 (base-case analysis) to £20.
Most results have stayed in the same direction as the base-case results presented in the report. However, for
models 3 and 5, when comparing xTAG with conventional care, xTAG no longer dominates conventional
care – xTAG is now slightly more expensive, although it is still slightly more effective (Table 100).
TABLE 100 Comparator cost fixed at £20 (probabilistic results)
Test
Incremental costs
(95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost per
QALY gained)
Probability
cost-effectivea
Net monetary
benefit (£)a
(95% CI)
Model 1: hospitalised adult patients
xTAG –26 (–872 to 837) 0.00018
(–0.00072 to 0.00111)
Dominant 0.548 30 (–852 to 891)
FilmArray –24 (–878 to 838) 0.00013
(–0.00076 to 0.00104)
Dominant 0.543 27 (–852 to 894)
Model 2: hospitalised children
xTAG –16 (–1009 to 959) 0.00024
(–0.00061 to 0.00112)
Dominant 0.545 21 (–965 to 1021)
FilmArray –43 (–942 to 885) 0.00016
(–0.00068 to 0.00106)
Dominant 0.571 47 (–890 to 957)
Model 3: people in the community
xTAG 18 (8 to 26) 0.00003
(–0.00032 to 0.00045)
518,112 0.379 –17 (–32 to –1)
FilmArray 74 (52 to 91) 0.00002
(–0.00037 to 0.00040)
3,264,373 0.069 –74 (–97 to –46)
Model 4: immunocompromised patients
xTAG –25 (–916 to 912) 0.00023
(–0.00086 to 0.00139)
Dominant 0.544 29 (–932 to 935)
FilmArray –30 (–981 to 899) 0.00019
(–0.00088 to 0.00136)
Dominant 0.539 34 (–916 to 1009)
Model 5: recent travellers
xTAG 18 (11 to 26) 0.00005
(–0.00048 to 0.00055)
356,931 0.432 –17 (–35 to –1)
FilmArray 75 (58 to 90) 0.00002
(–0.00049 to 0.00056)
4,203,556 0.112 –75 (–99 to –51)
a At a willingness-to-pay threshold of £20,000/QALY.
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Threshold analysis
Taking into account the change in direction and magnitude for models 3 and 5 when comparing xTAG
with conventional care, we have computed a threshold analysis to see at which comparator cost the ICER
result changes from being dominant to not dominant. For model 3 using the probabilistic results, the
switching point is when the conventional cost is £36.60, and for model 5 using the probabilistic results,
the switching point is when the conventional cost is £36.80 (Table 101).
This threshold analysis is better reflected in Figures 47 and 48, which show that the 95% CI fluctuates
around zero at a threshold of £20,000 per QALY when the price of conventional testing is changed.
TABLE 101 Threshold analysis changing comparator cost for xTAG (probabilistic results)
Test
Incremental costs
(95% CI) (£)
Incremental QALYs
gained (95% CI)
ICER (cost per
QALY gained)
Probability
cost-effectivea
Net monetary
benefit (£)a
(95% CI)
Model 3: people in the community
£20 18 (8 to 26) 0.00003
(–0.00032 to 0.00045)
518,112 0.379 –17 (–32 to –1)
£36.60 0 (–11 to 11) 0.00003
(–0.00036 to 0.00042)
1857 0.530 0 (–17 to 19)
Base case –32 (–49 to –15) 0.00003
(–0.00036 to 0.00045)
Dominant 0.997 32 (9 to 56)
Model 5: recent travellers
£20 18 (11 to 26) 0.00005
(–0.00048 to 0.00055)
356,931 0.432 –17 (–35 to –1)
£36.80 0 (–10 to 9) 0.00006
(–0.00043 to 0.00054)
90 0.588 1 (–16 to 19)
Base case –31 (–48 to –16) 0.00006
(–0.00044 to 0.00055)
Dominant 0.994 32 (9 to 57)
a At a willingness-to-pay threshold of £20,000/QALY.
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FIGURE 47 Net monetary benefit (willingness-to-pay threshold £20,000/QALY) (probabilistic results): xTAG vs.
conventional care (model 3).
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Tornado diagram
We have not presented ICERs for the most influential parameters, as seen in Figures 21, 22, 33 and 34, as
most results are dominant and it does not make sense to present ICERs. Instead, we have tabulated the
net monetary benefit ratios for the most influential parameters at a threshold of £20,000 per QALY
(Table 102).
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FIGURE 48 Net monetary benefit (willingness-to-pay threshold £20,000/QALY) (probabilistic results): for xTAG vs.
conventional care (model 5).
TABLE 102 Net monetary benefit ratios for the most influential parameters
Parameters
xTAG vs. conventional care (£)
FilmArray vs. conventional
care (£)
Increase by
50%
Decrease by
50%
Increase by
50%
Decrease by
50%
Hospital model (model 1)
Base-case net monetary benefit ratio 72.10 63.77
Cost of adult bed-day: general 88.53 55.67 67.99 59.54
Cost of adult bed-day: isolation 74.23 69.98 100.86 26.67
Cost of conventional test 106.86 37.35 98.52 29.01
Cost of xTAG or FilmArray test 52.50 91.71 15.82 111.71
Bed-days for GPP testing (not detect and
symptoms resolve)
–575.08 719.28 –605.26 732.80
Probability of detect (first test) 101.25 42.95 77.89 49.64
Probability of isolates 50.35 93.85 49.89 77.64
Proportion of n = false positive 20.80 123.41 43.07 84.47
Community model (model 3)
Base-case net monetary benefit ratio 32.30 –24.90
Cost of conventional test 67.82 –3.23 10.63 –60.43
Cost of xTAG or FilmArray test 12.67 51.92 –72.94 23.14
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Weighted analyses
For this analysis we have looked at what happens to the incremental costs and benefits when we have a
50% weighting for models 1 (adult hospital) and 3 (adult community). For the weighted analysis, GPP
testing no longer dominates conventional care, as although it is slightly cheaper, it is slightly less effective
(Table 103).
TABLE 103 Weighted analysis for models 1 and 3 (probabilistic results)
Test
Incremental costs
(95% CI) (£)
Incremental QALYs
gained (95% CI) ICER (cost per QALY gained)
Probability
cost-effectivea
xTAG –48 (–785 to 658) –0.00010
(–0.00088 to 0.00059)
490,232 0.689
FilmArray –13 (–746 to 643) –0.00007
(–0.00088 to 0.00064)
195,303 0.444
a At a willingness-to-pay threshold of £20,000 per QALY.
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